<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Megestrol acetate for treatment of anorexia‐cachexia syndrome - Ruiz Garcia, V - 2013 | Cochrane Library</title> <meta content="Megestrol acetate for treatment of anorexia‐cachexia syndrome - Ruiz Garcia, V - 2013 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004310.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Megestrol acetate for treatment of anorexia‐cachexia syndrome - Ruiz Garcia, V - 2013 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004310.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD004310.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Megestrol acetate for treatment of anorexia‐cachexia syndrome" name="citation_title"/> <meta content="Vicente Ruiz Garcia" name="citation_author"/> <meta content="La Fe University Hospital" name="citation_author_institution"/> <meta content="vicenteruizgarcia@gmail.com" name="citation_author_email"/> <meta content="Eduardo López‐Briz" name="citation_author"/> <meta content="La Fe University Hospital" name="citation_author_institution"/> <meta content="Rafael Carbonell Sanchis" name="citation_author"/> <meta content="Sagunt Hospital" name="citation_author_institution"/> <meta content="Jose Luis Gonzalvez Perales" name="citation_author"/> <meta content="National Health Service" name="citation_author_institution"/> <meta content="Sylvia Bort‐Martí" name="citation_author"/> <meta content="HIPRA" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="3" name="citation_issue"/> <meta content="10.1002/14651858.CD004310.pub3" name="citation_doi"/> <meta content="2013" name="citation_date"/> <meta content="2013/03/28" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004310.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004310.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004310.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Acquired Immunodeficiency Syndrome [complications]; Anorexia [*drug therapy, etiology]; Appetite Stimulants [adverse effects, *therapeutic use]; Cachexia [*drug therapy, etiology]; Megestrol Acetate [adverse effects, *therapeutic use]; Neoplasms [complications]; Randomized Controlled Trials as Topic; Syndrome" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004310.pub3&amp;doi=10.1002/14651858.CD004310.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004310.pub3&amp;doi=10.1002/14651858.CD004310.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004310.pub3&amp;doi=10.1002/14651858.CD004310.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004310.pub3&amp;doi=10.1002/14651858.CD004310.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004310.pub3&amp;doi=10.1002/14651858.CD004310.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004310.pub3&amp;doi=10.1002/14651858.CD004310.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004310.pub3&amp;doi=10.1002/14651858.CD004310.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004310.pub3&amp;doi=10.1002/14651858.CD004310.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004310.pub3&amp;doi=10.1002/14651858.CD004310.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004310.pub3&amp;doi=10.1002/14651858.CD004310.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004310.pub3&amp;doi=10.1002/14651858.CD004310.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004310.pub3&amp;doi=10.1002/14651858.CD004310.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004310.pub3&amp;doi=10.1002/14651858.CD004310.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004310.pub3&amp;doi=10.1002/14651858.CD004310.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004310.pub3&amp;doi=10.1002/14651858.CD004310.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004310.pub3&amp;doi=10.1002/14651858.CD004310.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004310.pub3&amp;doi=10.1002/14651858.CD004310.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004310.pub3&amp;doi=10.1002/14651858.CD004310.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004310.pub3&amp;doi=10.1002/14651858.CD004310.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004310.pub3&amp;doi=10.1002/14651858.CD004310.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004310.pub3&amp;doi=10.1002/14651858.CD004310.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004310.pub3&amp;doi=10.1002/14651858.CD004310.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004310.pub3&amp;doi=10.1002/14651858.CD004310.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="afU96cMv";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD004310\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD004310\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004310\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004310\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD004310.pub3",title:"Megestrol acetate for treatment of anorexia\\u2010cachexia syndrome",firstPublishedDate:"Mar 28, 2013 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Pain, Palliative and Supportive Care Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=afU96cMv&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004310.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD004310.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD004310.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD004310.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004310.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD004310.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD004310.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD004310.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD004310.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD004310.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>8125 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD004310.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004310.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004310.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004310.pub3/full#CD004310-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004310.pub3/full#CD004310-sec-0096"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004310.pub3/full#CD004310-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004310.pub3/full#CD004310-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004310.pub3/full#CD004310-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004310.pub3/full#CD004310-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004310.pub3/full#CD004310-sec-0052"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004310.pub3/full#CD004310-sec-0090"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004310.pub3/appendices#CD004310-sec-0103"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/table_n/CD004310StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/table_n/CD004310StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004310.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004310.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004310.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD004310.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD004310.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD004310.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2019 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Megestrol acetate for treatment of anorexia‐cachexia syndrome</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004310.pub3/information#CD004310-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Vicente Ruiz Garcia</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004310.pub3/information#CD004310-cr-0003">Eduardo López‐Briz</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004310.pub3/information#CD004310-cr-0004">Rafael Carbonell Sanchis</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004310.pub3/information#CD004310-cr-0005">Jose Luis Gonzalvez Perales</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004310.pub3/information#CD004310-cr-0006">Sylvia Bort‐Martí</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/information/en#CD004310-sec-0115">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 28 March 2013 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD004310.pub3">https://doi.org/10.1002/14651858.CD004310.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD004310-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004310-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD004310-abs-0005">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD004310-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD004310-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD004310-abs-0001" lang="en"> <section id="CD004310-sec-0001"> <h3 class="title" id="CD004310-sec-0001">Background</h3> <p>This is an updated version of a previously published review in <i>The Cochrane Library</i> (2005, Issue 2) on 'Megestrol acetate for the treatment of anorexia‐cachexia syndrome'. Megestrol acetate (MA) is currently used to improve appetite and to increase weight in cancer‐associated anorexia. In 1993, MA was approved by the US Food and Drug Administration for the treatment of anorexia, cachexia or unexplained weight loss in patients with AIDS. The mechanism by which MA increases appetite is unknown and its effectiveness for anorexia and cachexia in neoplastic and AIDS (acquired immunodeficiency syndrome) patients is under investigation. </p> </section> <section id="CD004310-sec-0002"> <h3 class="title" id="CD004310-sec-0002">Objectives</h3> <p>To evaluate the efficacy, effectiveness and safety of MA in palliating anorexia‐cachexia syndrome in patients with cancer, AIDS and other underlying pathologies. </p> </section> <section id="CD004310-sec-0003"> <h3 class="title" id="CD004310-sec-0003">Search methods</h3> <p>We sought studies through an extensive search of electronic databases, journals, reference lists, contact with investigators and other search strategies outlined in the methods. The most recent search for this update was carried out in May 2012. </p> </section> <section id="CD004310-sec-0004"> <h3 class="title" id="CD004310-sec-0004">Selection criteria</h3> <p>Studies were included in the review if they assessed MA compared to placebo or other drug treatments in randomised controlled trials of patients with a clinical diagnosis of anorexia‐cachexia syndrome related to cancer, AIDS or any other underlying pathology. </p> </section> <section id="CD004310-sec-0005"> <h3 class="title" id="CD004310-sec-0005">Data collection and analysis</h3> <p>Two independent review authors conducted data extraction and evaluated methodological quality. We performed quantitative analyses using appetite and quality of life as a dichotomous variable, and analysed weight gain as continuous and dichotomous variables. </p> </section> <section id="CD004310-sec-0006"> <h3 class="title" id="CD004310-sec-0006">Main results</h3> <p>We included 35 trials in this update, the same number but not the same trials as in the previous version of the review. The trials comprised 3963 patients for effectiveness and 3180 for safety. Sixteen trials compared MA at different doses with placebo, seven trials compared different doses of MA with other drug treatments and 10 trials compared different doses of MA. Meta‐analysis showed a benefit of MA compared with placebo, particularly with regard to appetite improvement and weight gain in cancer, AIDS and other underlying conditions, and lack of benefit in the same patients when MA was compared to other drugs. There was insufficient information to define the optimal dose of MA, but higher doses were more related to weight improvement than lower doses. Quality of life improvement in patients was seen only when comparing MA versus placebo but not other drugs in both subcategories: cancer and AIDS. Oedema, thromboembolic phenomena and deaths were more frequent in the patients treated with MA. More than 40 side effects were studied. </p> </section> <section id="CD004310-sec-0007"> <h3 class="title" id="CD004310-sec-0007">Authors' conclusions</h3> <p>This review shows that MA improves appetite and is associated with slight weight gain in cancer, AIDS and in patients with other underlying pathology. Despite the fact that these patients are receiving palliative care they should be informed of the risks involved in taking MA. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD004310-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004310-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD004310-abs-0006">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD004310-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD004310-abs-0004">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD004310-abs-0003" lang="en"> <h3>Megestrol acetate for treatment of anorexia‐cachexia syndrome</h3> <p><b>Anorexia‐cachexia syndrome (ACS)</b> is a common clinical problem characterised by loss of appetite and weight loss. It is common in patients who suffer from advanced cancer, AIDS and some other conditions. At present, there is no cure for ACS. </p> <p><b>Megestrol acetate (MA)</b> is classified as a female hormone and is taken by mouth. It is currently used to improve appetite and to increase weight in ACS. </p> <p>This updated review shows that:</p> <p>‐ MA improves appetite and has a small effect on weight gain;</p> <p>‐ MA does not improve quality of life;</p> <p>‐ side effects are more frequent in patients treated with MA.</p> <p>This review shows that MA is associated with an increased risk of blood clots (which may result in swelling, pain or redness of one extremity and not the other, sudden difficulty in breathing, severe headache or vision changes), fluid retention (resulting in swelling of the feet or hands) and death. </p> <p>In patients who take MA, approximately one in four will have an increase in their appetite, one in 12 will have an increase in their weight and one in 23 will die. </p> <p>Limited data are available regarding the safety of using MA, especially in the long term.  </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD004310-sec-0096" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD004310-sec-0096"></div> <h3 class="title" id="CD004310-sec-0097">Implications for practice</h3> <section id="CD004310-sec-0097"> <p>The new trials identified and included in the present review update have not led to significant changes to the conclusions of the previous review (megestrol acetate (MA) improves appetite and slightly increases weight, without clinical relevance), except for adverse events. MA may be prescribed in patients with cancer to increase appetite and improve weight gain. Currently, there is no evidence to recommend MA to improve quality of life. This update has followed The Cochrane Collaboration guidelines for an unbiased review. Quality is difficult to define, since it depends on the design, conduct and analysis of a trial, its clinical relevance or the quality of reporting. Studies of low methodological quality can alter the interpretation of the benefit of an intervention. In this update, we assessed 58% of the trials as high quality for some outcomes such as improvement of weight. </p> <p>Many concerns remain unresolved. Health‐related quality of life is an important goal in health care and cancer clinical trials, and is the cornerstone for delivery of good palliative medicine. The increasing recognition of patient autonomy means that subjective measures will become more important and, in the current climate of evidence‐based medicine, such measures must be valid and reliable. </p> <p>Despite MA being approved US Food and Drug Administration for use in AIDS patients, this drug failed to show weight improvement and weight gain when compared with other drugs. MA compared with placebo was effective in AIDS patients in one trial. </p> <p>In summary, MA could be prescribed to improve appetite in the context of palliative medicine, but it should be emphasised that this drug will probably not lead to full weight loss recovery or improve quality of life, and it is related to adverse events, including an increased risk of death. </p> </section> <h3 class="title" id="CD004310-sec-0098">Implications for research</h3> <section id="CD004310-sec-0098"> <p>This update of the review shows that there is still a need for high‐quality trials focused on the evaluation of the effectiveness of MA. Trials with long‐term follow‐up are needed to rule out an increase in mortality. Even though the US Food and Drug Administration has approved MA for use in AIDS patients, more research is needed in this respect. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD004310-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD004310-sec-0022"></div> <div class="table" id="CD004310-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Megestrol acetate for cachexia anorexia syndrome</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Megestrol acetate for cachexia anorexia syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> cachexia anorexia syndrome<br/> <b>Settings:</b> cancer patients, AIDS patients and patients with other underlying conditions<br/> <b>Intervention:</b> megestrol acetate </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Megestrol acetate </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Appetite improvement compared with placebo</b><br/> Subjective sense of appetite, responses to follow‐up questionnaire<br/> Follow‐up: mean 4 to 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 2.19</b> <br/> (1.41 to 3.4) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>699<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NNTB = 4 (95% CI 2 to 11)</p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>214 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>469 per 1000</b><br/> (302 to 728) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Weight improvement compared with placebo</b><br/> % of patients that improved their weight in kg<br/> Follow‐up: mean 4 to 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.51</b> <br/> (1.08 to 2.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1106<br/> (10 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>3,4,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>NNTB = 12 (95% CI 6 to 69)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>246 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>329 per 1000</b><br/> (260 to 408) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>233 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>312 per 1000</b><br/> (247 to 387) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Appetite improvement compared to other drugs</b><br/> Questionnaire of appetite rating<br/> Follow‐up: median 8 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.03</b> <br/> (0.64 to 1.67) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>475<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>6,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>NNTB = NS</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>325 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>335 per 1000</b><br/> (208 to 543) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>325 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>335 per 1000</b><br/> (208 to 543) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Weight improvement compared to other drugs</b><br/> % of patients that improved their weight in kg<br/> Follow‐up: mean 8 to 15 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.66</b> <br/> (1.09 to 2.52) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1131<br/> (7 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>3,8,9,10</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>NNTB = 22 (95% CI 9 to 159)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>72 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>119 per 1000</b><br/> (78 to 180) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>57 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>95 per 1000</b><br/> (62 to 144) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Deaths</b><br/> Follow‐up: mean 2 to 15 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 1.42</b> <br/> (1.04 to 1.94) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>1307<br/> (10 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>11,12,13,14</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>NNTH = 23 (95% CI 10 to 200)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>102 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>146 per 1000</b><br/> (107 to 200) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>48 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>69 per 1000</b><br/> (50 to 94) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Thromboembolic phenomena including thrombophlebitis</b><br/> Follow‐up: mean 4 to 16 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.84</b> <br/> (1.07 to 3.18) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1544<br/> (11 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>13,15,16</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>NNTH = 55 (95% CI 22 to 385)<br/> NNTH = 11 (95% CI 4 to 77)<br/> NNTH = 2 (95% CI 1 to 15) <sup>17</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>191 per 1000</b><br/> (113 to 323) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>500 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>955 per 1000</b><br/> (565 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Oedema</b><br/> Follow‐up: mean 2 to 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.36</b> <br/> (1.07 to 1.72) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2182<br/> (12 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>18,19</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>NNTH = 28 (95% CI 4 to 143)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>104 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>141 per 1000</b><br/> (111 to 179) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>109 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>148 per 1000</b><br/> (117 to 187) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval;<b>NNTB:</b> number needed to treat for an additional beneficial outcome; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Adequate sequence generation was low risk only in <a href="./references#CD004310-bbs2-0006" title="FeliuJ , Gonzalez‐BaronM . Usefulness of megestrol acetate in cancer cachexia and anorexia. A placebo controlled study. American Journal of Clinical Oncology1992;15:436‐40. Gonzalez BaronM , FeliuJ , ZamoraP , ArtalA , GarridoP , ChaconI . Usefulness of megestrol acetate on cancer cachexia: a double blind randomized study. Annals of Oncology1990;1:29‐31. ">Feliu 1992</a>. Allocation concealment was unclear in all studies. In three out of five studies appetite was rated as high risk of bias because it could be sensitive to lack of blinding.<br/> <sup>2</sup> The two different subcategories (cancer and AIDS patients) showed similar effects. Heterogeneity was moderate (I<sup>2</sup> = 59%) and is due to the study of <a href="./references#CD004310-bbs2-0026" title="SchmollE , WilkeH , TholeR , PreusserP ,  WildfangI ,  SchmollHJ . Megestrol acetate in cancer cachexia. Seminars in Oncology1991;18(1 Suppl 2):32‐4. [CN‐00072963] ">Schmoll 1991</a>. Heterogeneity without this study became low (I<sup>2</sup> = 39%). The confidence intervals of the studies overlap.<br/> <sup>3</sup> Doses of MA were very different (960 mg, 800 mg, 480 and 160 mg) compared with placebo.<br/> <sup>4</sup> Eight out of 10 studies were rated as unclear for adequate sequence generation; only one study was rated as low risk for allocation concealment. All studies were rated as low risk of bias for blinding. <a href="./references#CD004310-bbs2-0026" title="SchmollE , WilkeH , TholeR , PreusserP ,  WildfangI ,  SchmollHJ . Megestrol acetate in cancer cachexia. Seminars in Oncology1991;18(1 Suppl 2):32‐4. [CN‐00072963] ">Schmoll 1991</a>, <a href="./references#CD004310-bbs2-0027" title="SchmollE . Risks and benefits of various therapies for cancer anorexia. Oncology1992;49:43‐5. ">Schmoll 1992</a> and <a href="./references#CD004310-bbs2-0033" title="VonRoennJH , ArmstrongD . Megestrol acetate in patients with AIDS‐related cachexia. Annals of Internal Medicine1994;121:393‐9. ">Von Roenn 1994</a> were rated low risk because lack of blinding is not related to weight. Only one study was rated as high risk of bias for incomplete outcome data. All trials were rated unclear with respect to freedom from 'other bias'.<br/> <sup>5</sup> The effect is quite similar and CI values overlap for most of the studies. However, two studies (Feliu and Schmoll) showed greater effects and the CI was quite wide. The study of <a href="./references#CD004310-bbs2-0036" title="YehSS , LovittS , SchusterMW . Usage of megestrol acetate in the treatment of anorexia‐cachexia syndrome in the elderly. Journal of Nutrition, Health and Aging2009;13:448‐54. YehSS , WuSY . Improvement in quality of life measures and stimulation of weight gain after treatment with megestrol acetate oral suspension in geriatric cachexia: results of a double‐blind, placebo‐controlled study. Journal of the American Geriatrics Society2000;48(5):485‐92. YehSS , WuSY , LevineDM , ParkerTS , OlsonJS , StevensMR , et al. The correlation of cytokine levels with body weight after megestrol acetate treatment in geriatric patients. Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2001;56:M48‐54. ">Yeh 2000</a> showed different results in patients with geriatric cachexia to patients with neoplasia and AIDS. Heterogeneity was moderate (I<sup>2</sup> = 53%).<br/> <sup>6</sup> The only study found was rated as unclear risk of bias for adequate sequence generation and allocation concealment. It was not a blinded study and was rated as high risk of bias for the blinding item.<br/> <sup>7</sup> We pooled the results of two comparisons: MA versus dexamethasone and fluoxymesterone.<br/> <sup>8</sup> All studies except <a href="./references#CD004310-bbs2-0023" title="MwamburiDM , GerriorJ , WilsonIB , ChangH , ScullyE , SabooriS , et al. Comparing megestrol acetate therapy with oxandrolone therapy for HIV‐related weight loss: similar results in 2 months. Clinical Infectious Diseases2004;38:895‐902. ">Mwamburi 2004</a> were rated as unclear risk of bias for adequate sequence generation and allocation concealment study.<br/> <sup>9</sup> Heterogeneity was moderate (I<sup>2</sup> = 51%) but heterogeneity between subgroups was high. The effect seemed to be different in cancer and AIDS patients. The CI values overlapped for most of the studies. Cancer patients showed a better response for weight.<br/> <sup>10</sup> The CI interval (9 to 159) is too wide to establish a true effect.<br/> <sup>11</sup> Only one study out of seven was rated as low risk of bias for adequate sequence generation and allocation concealment.<br/> <sup>12</sup> Although the I<sup>2</sup> in both subgroups was 0% and the overall I<sup>2</sup> was low (6.4%), patients with cancer, AIDS and other pathologies were quite different. Moreover the comparator included placebo and other drugs.<br/> <sup>13</sup> Different doses of MA in each subgroup.<br/> <sup>14</sup> The CI interval for the NNT (10 to 200) is too wide to establish a true effect.<br/> <sup>15</sup> Adequate sequence generation was rated as low risk in three out of 10 trials and allocation concealment was rated low risk only in two out of 10.<br/> <sup>16</sup> Although the I<sup>2</sup> in both subgroups was 0% and the overall I<sup>2</sup> was low (0%), patients with cancer, AIDS and other pathologies were quite different. Moreover the comparator included placebo and other drugs.<br/> <sup>17</sup> The first NNTH was calculated with data of this Systematic Review. The second NNTH was calculated with an expected value of 0.10% and the last was calculated with an expected rate of 50%.<br/> <sup>18</sup> Only three out of 11 trials were rated as low risk for adequate sequence generation. Only two out of 11 trials were rated as low risk for allocation concealment.<br/> <sup>19</sup> Although the I<sup>2</sup> in both subgroups was 0% and the overall I<sup>2</sup> was low (0%), patients with cancer, AIDS and other pathologies such as COPD were quite different. Moreover the comparator included placebo and other drugs. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD004310-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD004310-sec-0023"></div> <section id="CD004310-sec-0024"> <h3 class="title" id="CD004310-sec-0024">Description of the condition</h3> <p>This review is an update of a previously published review in <i>The Cochrane Library</i> (2005, Issue 2) on megestrol acetate for anorexia‐cachexia syndrome. Anorexia‐cachexia syndrome is a common clinical problem that substantially impacts upon the quality of life and survival of affected patients. It is characterised by loss of appetite, weight loss and tissue wasting, accompanied by a decrease in muscle mass and adipose tissue, impoverishing quality of life and often preceding the patient's death (<a href="./references#CD004310-bbs2-0164" title="NelsonKA , WalshD , SheehanFA . The cancer anorexia‐cachexia syndrome. Journal of Clinical Oncology1994;12:213‐25. ">Nelson 1994</a>; <a href="./references#CD004310-bbs2-0168" title="SplinterTA . Cachexia and cancer: a clinician's view. Annals of Oncology1992;3(3):25‐7. ">Splinter 1992</a>). </p> <p>More than two‐thirds of patients dying from advanced cancer suffer from anorexia‐cachexia syndrome (<a href="./references#CD004310-bbs2-0147" title="ArgilésJM , MeijsingSH , Pallares‐TrujilloJ . Cancer cachexia. A therapeutic approach. Medical Research Review (US)2001;21:83‐101. ">Argilés 2001</a>). Anorexia‐cachexia syndrome is also described in other pathologies such as in acquired immune deficiency syndrome (AIDS), anorexia nervosa, degenerative illnesses of the central nervous system and terminally ill patients (<a href="./references#CD004310-bbs2-0174" title="VonRoennJH , KnopfK . Anorexia/cachexia in patients with HIV: lessons for the oncologist. Oncology1996;10(7):1049‐56. ">Von Roenn 1996</a>). Incidence is variable and difficult to determine but in general the syndrome may occur in 15% to 40% of patients with cancer, and in more than 80% of patients with advanced illness (<a href="./references#CD004310-bbs2-0151" title="BrueraE . Clinical management of anorexia and cachexia in patients with advanced cancer. Oncology1992;49(2):35‐42. ">Bruera 1992</a>). </p> <p>The mechanism that causes cachexia is poorly understood, but inflammatory cytokines probably have a role, such as tumour necrosis factor‐alpha (which is also nicknamed 'cachexin' or 'cachectin'), angiotensin II and glucocorticoids, interferon gamma and interleukin 6, as well as the tumour‐secreted proteolysis‐inducing factor (<a href="./references#CD004310-bbs2-0172" title="TisdaleM . Mechanisms of cancer cachexia. Physiological Reviews 209;89:381‐410. ">Tisdale 2009</a>). Ghrelin levels are also high in patients who have cancer‐induced cachexia (<a href="./references#CD004310-bbs2-0176" title="WolfI , SadetzkiS , KanetyH , KundelY , ParienteC , EpsteinN , et al. Adiponectin, ghrelin and leptin in cancer cachexia in breast and colon cancer patients. Cancer2006;106:966‐73. ">Wolf 2006</a>).  </p> <p>An international consensus statement defines cachexia as weight loss greater than 5%, or weight loss greater than 2% in individuals already showing depletion according to current body weight and height (body mass index (BMI) &lt; 20 kg/m<sup>2</sup>) or skeletal muscle mass (sarcopaenia) (<a href="./references#CD004310-bbs2-0154" title="FearonK , StrasserF , AnkerSD , BosaeusI , BrueraE , FainsingerRL , et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncology2011;12:489‐95. ">Fearon 2011</a>). </p> </section> <section id="CD004310-sec-0025"> <h3 class="title" id="CD004310-sec-0025">Description of the intervention</h3> <p>Early intervention and attention to nutritional status are essential in patients with anorexia‐cachexia syndrome. Pharmacological interventions for neoplastic cachexia include drugs that stimulate the appetite: megestrol acetate (MA) and dronabinol; cytokine inhibitors (such as cyproheptadine, thalidomide, pentoxifylline and an eicosapentaenoic acid (EPA)); and anabolic agents such as nandrolone decanoate, oxandrolone and corticosteroids (<a href="./references#CD004310-bbs2-0148" title="BalogDL , EpsteinME , Amidio‐GrotonMI . HIV wasting syndrome: treatment update. Annals of Pharmacotherapy1998;32(4):446‐58. ">Balog 1998</a>). EPA seems to suppress well‐characterised mediators of cancer‐associated wasting, including interleukin‐6, an inflammatory cytokine. It also acts over the proteolysis‐inducing factor, another well‐described mediator (<a href="./references#CD004310-bbs2-0149" title="BarberMD , RossJA , VossAC , TisdaleMJ ,  FearonKC . The effect of an oral nutritional supplement enriched with fish oil on weight‐loss in patients with pancreatic cancer. British Journal of Cancer1999;81:80‐6. ">Barber 1999</a>; <a href="./references#CD004310-bbs2-0175" title="WigmoreSJ , FearonKCH , MaingayJP , RossJA . Down‐regulation of the acute‐phase response in patients with pancreatic cancer cachexia receiving oral eicosapentaenoic acid is mediated via suppression of interleukin‐6. Clinical Science1997;92:215‐21. ">Wigmore 1997</a>). </p> <p>MA is a synthetic progestogen agent. It was first synthesised in England in 1963. Developed as an oral contraceptive, the agent was first tested in the treatment of breast cancer in 1967 and, later on, for the treatment of endometrial cancer. MA is currently used to improve appetite and to increase weight in cancer‐associated anorexia. From September 1993, MA was approved by the Food and Drug Administration (FDA) in the USA for the treatment of anorexia, cachexia or unexplained weight loss in patients with AIDS. In addition, there are recent reports of the drug being used to improve the quality of life of elderly patients with cachexia. A possible role in anorexia nervosa has also been proposed (<a href="./references#CD004310-bbs2-0036" title="YehSS , LovittS , SchusterMW . Usage of megestrol acetate in the treatment of anorexia‐cachexia syndrome in the elderly. Journal of Nutrition, Health and Aging2009;13:448‐54. YehSS , WuSY . Improvement in quality of life measures and stimulation of weight gain after treatment with megestrol acetate oral suspension in geriatric cachexia: results of a double‐blind, placebo‐controlled study. Journal of the American Geriatrics Society2000;48(5):485‐92. YehSS , WuSY , LevineDM , ParkerTS , OlsonJS , StevensMR , et al. The correlation of cytokine levels with body weight after megestrol acetate treatment in geriatric patients. Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2001;56:M48‐54. ">Yeh 2000</a>). </p> <p>MA is only available as a tablet of 20 to 40 mg or liquid form (200 mg or 625 mg/5ml MA). A great variability in dosage is observed in the scientific literature, ranging from 100 mg to 1600 mg per day (<a href="./references#CD004310-bbs2-0029" title="TchekmedyianNS , HickmanM . Megestrol acetate in cancer anorexia and weight loss. Cancer1992;69:1268‐74. ">Tchekmedyian 1992</a>; <a href="./references#CD004310-bbs2-0033" title="VonRoennJH , ArmstrongD . Megestrol acetate in patients with AIDS‐related cachexia. Annals of Internal Medicine1994;121:393‐9. ">Von Roenn 1994</a>). The liquid form is usually dosed at 800 mg per day and the oral form at four tablets per day. The recommended duration of treatment is six weeks or more. MA is considered a relatively non toxic drug with a low incidence of adverse effects, such as fluid retention, venous thrombosis, diarrhoea, rash, impotence, pruritus, increased blood sugar level and headache (<a href="./references#CD004310-bbs2-0161" title="LoprinziC , EllisonNM , GoldbergRM , MichalakJC ,  BurchPA . Alleviation of cancer anorexia and cachexia: studies of the Mayo Clinic and the North Central Cancer Treatment Group. Seminars in Oncology1990;17(6 Suppl 9):8‐12. ">Loprinzi 1990a</a>; <a href="./references#CD004310-bbs2-0032" title="SeguiMA , VadellC , Gimenez‐ArnauJM , MoralesS , CireraL , BestitI , et al. Double‐blind randomized trial for the treatment of cancer related cachexia: comparison of placebo vs two different doses of megestrol acetate [Abstract 99]. Proceedings of the American Society of Clinical Oncology1996;15:529. VadellC , SeguiMA . Anticachectic efficacy of megestrol acetate at different doses and versus placebo in patients with neoplastic cachexia. American Journal of Clinical Oncology1998;21:347‐51. ">Vadell 1998</a>; <a href="./references#CD004310-bbs2-0033" title="VonRoennJH , ArmstrongD . Megestrol acetate in patients with AIDS‐related cachexia. Annals of Internal Medicine1994;121:393‐9. ">Von Roenn 1994</a>). The recommended adult initial dosage of MA oral suspension in HIV patients is 800 mg/day (20 ml/day); clinically effective dosages are expected to range from 312.5 to 625 mg daily. In patients with neoplastic disease the most common dosages used range from 480 to 600 mg daily. </p> </section> <section id="CD004310-sec-0026"> <h3 class="title" id="CD004310-sec-0026">How the intervention might work</h3> <p>Although the mechanism by which MA increases appetite is unknown, most hypotheses point to action on cytokines, which inhibit the action of tumour necrosis factor on fatty tissue and its products. Currently, interest is especially focused on its effectiveness in the treatment of anorexia and cachexia in neoplastic and AIDS patients. Studies at the Mayo Clinic and The North Central Cancer Treatment Group Study have reported and reviewed multiple placebo‐controlled, randomised, double‐blind clinical trials of MA and other drugs for the improvement of anorexia‐cachexia syndrome in all types of cancer (<a href="./references#CD004310-bbs2-0014" title="JatoiA , RowlandK , LoprinziCL , SloanJA , DakhilSR , MacDonaldN , et al. An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer‐associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort. Journal of Clinical Oncology2004;22:2469‐76. ">Jatoi 2004</a>; <a href="./references#CD004310-bbs2-0161" title="LoprinziC , EllisonNM , GoldbergRM , MichalakJC ,  BurchPA . Alleviation of cancer anorexia and cachexia: studies of the Mayo Clinic and the North Central Cancer Treatment Group. Seminars in Oncology1990;17(6 Suppl 9):8‐12. ">Loprinzi 1990a</a>). </p> </section> <section id="CD004310-sec-0027"> <h3 class="title" id="CD004310-sec-0027">Why it is important to do this review</h3> <p>This is an update of a previous systematic review. In this update we identified new trials and found that more diseases have begun to be treated with MA. We focused on the adverse events of MA as main outcomes. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD004310-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD004310-sec-0028"></div> <p> <ol id="CD004310-list-0001"> <li> <p>To evaluate the effectiveness and safety of MA in palliating anorexia‐cachexia syndrome in subgroups of patients with cancer, AIDS and other underlying pathologies. </p> </li> </ol> </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD004310-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD004310-sec-0029"></div> <section id="CD004310-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD004310-sec-0031"> <h4 class="title">Types of studies</h4> <p>Randomised controlled trials (RCTs) which may be double‐blind, single‐blind or unblinded.</p> <p>In the previous version of the review we included some cross‐over studies. However, in the current update we decided not to include these studies, because the time between the two phases is too short to be certain whether any adverse event or outcome, such as weight or appetite, is due to MA or placebo. Moreover, treating with MA or placebo in the first phase could result in groups in the second phase not having the same basal characteristics. Finally, due to the fact that these patients are very frail and have high mortality, the number of patients in such studies could be too low. </p> </section> <section id="CD004310-sec-0032"> <h4 class="title">Types of participants</h4> <p>Patients with a clinical diagnosis of anorexia‐cachexia related to cancer, AIDS or another underlying pathology (independent of gender, age or race) were included. We decided to include only trials with patients who clearly had some previous weight loss or definition of cachexia‐anorexia syndrome. </p> </section> <section id="CD004310-sec-0033"> <h4 class="title">Types of interventions</h4> <p>The review focuses on the following treatment comparisons:</p> <p> <ul id="CD004310-list-0002"> <li> <p>MA at any dose versus placebo;</p> </li> <li> <p>MA at any dose versus other active drug treatments (stimulants of appetite such as dronabinol, cytokine inhibitors such as cyproheptadine, eicosapentaenoic acid (EPA) and anabolic agents such as nandrolone decanoate and corticosteroids); </p> </li> <li> <p>MA at different doses.</p> </li> </ul> </p> </section> <section id="CD004310-sec-0034"> <h4 class="title">Types of outcome measures</h4> <p>We assessed the following outcome measures.</p> <section id="CD004310-sec-0035"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD004310-list-0003"> <li> <p>Weight gain, measured as a dichotomous variable (number of patients who gained weight) and as a continuous variable in kg (difference between baseline and the end of treatment). </p> </li> <li> <p>Improvement in quality of life by means of a validated instrument, or with scales of functional scores (e.g. Karnofsky Index and performance status) that measure the well‐being status of the patient. The quality of life measures will depend on the instrument used, e.g. patient assessments using a Likert‐type scale based on patients' statements and self report questionnaires, or the use of the Spitzer Index of quality of life, completed by the clinician. </p> </li> <li> <p>Adverse effects: we analysed these as the number of patients who suffered an event described as a side effect by the authors of each study. </p> </li> </ul> </p> </section> <section id="CD004310-sec-0036"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD004310-list-0004"> <li> <p>Appetite increase, expressed as a dichotomous variable (number of patients who experienced appetite increase) or a continuous variable. </p> </li> <li> <p>Measurements of the mid‐arm circumference and triceps skin fold thickness by anthropometry, as a percentage of the differences in the total body muscle and fat mass. </p> </li> <li> <p>Deaths.</p> </li> </ul> </p> <p>Study withdrawals and drop‐outs were analysed as:</p> <p> <ul id="CD004310-list-0005"> <li> <p>total number of drop‐outs and withdrawals;</p> </li> <li> <p>number of withdrawals due to lack of effectiveness of treatment;</p> </li> <li> <p>number of withdrawals due to adverse effects.</p> </li> </ul> </p> </section> </section> </section> <section id="CD004310-sec-0037"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD004310-sec-0038"> <h4 class="title">Electronic searches</h4> <p>We searched the following electronic databases to identify relevant studies:</p> <p> <ul id="CD004310-list-0006"> <li> <p>Cochrane Pain, Palliative and Supportive Care Group Trials Register (2011, Issue 3) (see <a href="./appendices#CD004310-sec-0104">Appendix 1</a>); </p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL) (<i>The Cochrane Library</i> 2011, Issue 3); </p> </li> <li> <p>MEDLINE from 1966 to May 2012 (see <a href="./appendices#CD004310-sec-0105">Appendix 2</a>); </p> </li> <li> <p>EMBASE from 1980 to May 2012 (see <a href="./appendices#CD004310-sec-0106">Appendix 3</a>). </p> </li> </ul> </p> <p>We combined the general strategy for identifying RCTs in MEDLINE with a strategy designed to retrieve trials of MA for cachexia. For the identification of studies to include in or consider for this review, we developed detailed search strategies for each database searched. </p> </section> <section id="CD004310-sec-0039"> <h4 class="title">Searching other resources</h4> <p>We checked lists of references from systematic reviews of MA and from the included studies to identify further trials. </p> <p>Studies were not excluded on the basis of language or publication status (published, unpublished, in press and in progress). </p> <p>We sought additional data from published trials by contacting authors. We consulted the information made available by the main researchers/sponsors. </p> <p>We also reviewed information on the clinical trial meta‐register database (<a href="http://www.controlled-trials.com/mrct/" target="_blank">http://www.controlled‐trials.com/mrct/</a>). </p> </section> </section> <section id="CD004310-sec-0040"> <h3 class="title" id="CD004310-sec-0040">Data collection and analysis</h3> <section id="CD004310-sec-0041"> <h4 class="title">Selection of studies</h4> <p>Two review authors independently reviewed the titles and abstracts of studies identified in the search to assess which studies might potentially meet the inclusion criteria. Where there was doubt, we acquired the full article for further inspection. We then obtained potential studies identified by this process and two authors independently screened them to see if they met the review criteria. We created an Excel spreadsheet. We did not need to resolve any disagreements through discussion. </p> </section> <section id="CD004310-sec-0042"> <h4 class="title">Data extraction and management</h4> <p>Two authors independently extracted data using a data collection form (in Excel). We checked any disagreements in the data collection and we reviewed the studies again only if there was a mismatch between them. We collected, when possible, data for intention‐to‐treat populations as raw numbers, summary measures with standard deviations, confidence intervals and P values of outcomes reported and compiled these into the Excel spreadsheet. </p> </section> <section id="CD004310-sec-0043"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>According to the recommendations in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i>, we assessed the risk of bias by creating a summary of 'Risk of bias' table (<a href="./references#CD004310-bbs2-0156" title="HigginsJPT , GreenS . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. Chichester, UK: Wiley‐Blackwell, 2011:649. ">Higgins 2011</a>). </p> <p>The main criteria used to measure the risk of bias included: blinding of participants, allocation concealment, random sequence generation, incomplete outcome data, selective reporting of outcomes and other bias (early stopping of trials or imbalance in the baseline of people in the groups). We explicitly judged the risk of bias in each study on the basis of the following criteria: low risk of bias, high risk of bias, unclear risk of bias (either lack of information or uncertainty over the potential bias). These criteria were included in the tables. Disagreements were resolved by discussion between the two review authors. If needed, a third review author was available for discussion in case of unresolved disagreements. </p> <p>We also evaluated the methodological quality of the studies using a validated scale called the Oxford Quality Scale (<a href="./references#CD004310-bbs2-0157" title="JadadA , MooreRA , Carroll D ,  JenkinsonC ,  ReynoldsDJ ,  GavaghanDJ ,  etal . Assessing the quality of reports on randomized clinical trials: is blinding necessary?. Controlled Clinical Trials1996;170:1‐12. ">Jadad 1996</a>), according to the following domains: concealment of allocation, double‐blinding, intention‐to‐treat analysis and loss to follow‐up. We also assessed each study using the zero to five‐point scale described by <a href="./references#CD004310-bbs2-0157" title="JadadA , MooreRA , Carroll D ,  JenkinsonC ,  ReynoldsDJ ,  GavaghanDJ ,  etal . Assessing the quality of reports on randomized clinical trials: is blinding necessary?. Controlled Clinical Trials1996;170:1‐12. ">Jadad 1996</a>, as summarised below. </p> <p> <ol id="CD004310-list-0007"> <li> <p>Was the study described as randomised? (1 = yes; 0 = no).</p> </li> <li> <p>Was the study described as double‐blind? (1 = yes; 0 = no).</p> </li> <li> <p>Were withdrawals and drop‐outs described? (1 = yes; 0 = no).</p> </li> <li> <p>Was the method of randomisation well‐described and appropriate? (1 = yes; 0 = no); deduct one point if inappropriate. </p> </li> <li> <p>Was the double‐blinding well‐described and appropriate? (1= yes; 0 = no); deduct one point if inappropriate. </p> </li> </ol> </p> </section> <section id="CD004310-sec-0044"> <h4 class="title">Measures of treatment effect</h4> <p>We use the risk ratio (RR) because it is more intuitive (<a href="./references#CD004310-bbs2-0150" title="BoisselJP , CucheratM , LiW , ChatellierG , GueyffierF , BuyseM , et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use. Therapie1999;54:405‐11. ">Boissel 1999</a>) than the odds ratio and because odds ratios tend to be interpreted as RR by clinicians (<a href="./references#CD004310-bbs2-0156" title="HigginsJPT , GreenS . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. Chichester, UK: Wiley‐Blackwell, 2011:649. ">Higgins 2011</a>). We used the risk difference to quantify the number needed to treat for an additional beneficial outcome (NNTB) (<a href="./references#CD004310-bbs2-0160" title="LaupacisA , SackettDL , RobertsRS . An assessment of clinically useful measures of the consequences of treatment. New England Journal of Medicine1988;318:1728‐33. ">Laupacis 1988</a>). For continuous data we used mean differences (MD) when the results were measured in the same way in different studies. We used standardised mean differences (SMD) when the results obtained were conceptually the same but used different measurement scales. We recorded the central estimate (mean) and standard deviation. Where these were not directly stated we calculated them from the standard error. </p> </section> <section id="CD004310-sec-0045"> <h4 class="title">Unit of analysis issues</h4> <p>Most of the studies used a simple parallel‐group design, in which participants are individually randomised to one of two intervention groups. Unit of analysis was not an issue in this review. </p> </section> <section id="CD004310-sec-0046"> <h4 class="title">Dealing with missing data</h4> <p>We carried out an intention‐to‐treat analysis. Everyone allocated to the intervention was counted whether they completed the follow‐up or not. We have assumed that those who dropped out had no change in their outcome. This rule is conservative concerning response to treatment, because it assumes that those discontinuing the studies would not have responded. It is not conservative concerning adverse effects, but we felt that assuming that all those leaving early would have developed side effects would overestimate risk. </p> <p>When published data were missing, incomplete or inconsistent with RCT protocols or meeting abstracts, we asked for further information from the authors/manufacturers. We have only excluded abstracts of studies that are interim reports of studies that have not yet finished recruiting. </p> </section> <section id="CD004310-sec-0047"> <h4 class="title">Assessment of heterogeneity</h4> <p>We explored heterogeneity between the trials using the Chi<sup>2</sup> test for heterogeneity with a 10% level of significance, and the I<sup>2</sup> statistic. We complied with the recommendations in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i>, which determine that an I<sup>2</sup> value of 0% to 40% might not be important; 30% to 60% may represent moderate heterogeneity; 50% to 90% may represent substantial heterogeneity; and 75% to 100% considerable heterogeneity (<a href="./references#CD004310-bbs2-0153" title="DeeksJ , HigginsJ , AltmanD . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. The Cochrane Collaboration, 2008. Available from: www.cochrane‐handbook.org. ">Deeks 2008</a>). </p> </section> <section id="CD004310-sec-0048"> <h4 class="title">Assessment of reporting biases</h4> <p>We planned to explore reporting bias using funnel plots if we had a meta‐analysis of 10 or more studies. The items in the assessment biases were: 1) Allocation 2) Blinding 3) Incomplete outcome data 4) Selective reporting 5) Other potential source of bias </p> </section> <section id="CD004310-sec-0049"> <h4 class="title">Data synthesis</h4> <p>We explored the need to analyse the results according to a fixed or random‐effects analysis (<a href="./references#CD004310-bbs2-0159" title="LairdNM , WangF . Estimating rates of change in randomized clinical trials. Controlled Clinical Trials1990;11:405‐19. ">Laird 1990</a>). In the event of significant heterogeneity we may have made a decision not to present combined result (<a href="./references#CD004310-bbs2-0167" title="SchulzKF , AltmanDG . Statistical Methods for Data Synthesis. Cochrane Workshop Report. Oxford: UK Cochrane Centre, 1993. ">Schulz 1993</a>). We calculated the number needed to treat for an additional beneficial outcome (NNT or NNTB) and the number needed for an additional harmful outcome (NNTH). We used the mean difference to calculate the benefit (absolute change expressed as both a percentage and in its original units) for continuous outcomes such as Karnofsky Index score or weight gain. </p> <p>For dichotomous variables, we computed treatment effects as risk ratios (RR) with 95% confidence intervals (CI). For continuous variables such as weight gain or appetite gain we calculated differences in means and their 95% CI (mean difference (MD)) and for quality of life (including different scales), we calculated differences in means and their 95% CI (standardised mean difference (SMD)). Only validated scales with a normal distribution were included in the analysis. We determined validity of the scale from the psychometric properties of the instrument as described in the trial by the review authors. </p> <p>We used a random‐effects model in the analysis. We analysed statistical heterogeneity between studies with the Chi<sup>2</sup> test, using P &lt; 0.1 as a cut‐off value to represent the presence of significant heterogeneity. When a high level of heterogeneity was detected, we made attempts to identify the sources of the heterogeneity and performed subsequent meta‐analysis using a random‐effects model. </p> <p>We used the 'Grades of Recommendation, Assessment, Development and Evaluation' approach developed by the GRADE Working Group for grading the quality of evidence. The GRADE approach specifies four levels of quality. The highest quality rating is for randomised trial evidence. Review authors can, however, downgrade randomised trial evidence to moderate, low or even very low‐quality evidence, depending on the presence of five specific factors (<a href="./references#CD004310-bbs2-0156" title="HigginsJPT , GreenS . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. Chichester, UK: Wiley‐Blackwell, 2011:649. ">Higgins 2011</a>, chapter 11). </p> <p>We used GRADE software to provide an overall grading of the quality of the evidence by outcome. </p> </section> <section id="CD004310-sec-0050"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>If heterogeneity was detected we planned to carry out subgroup analysis (<a href="./references#CD004310-bbs2-0177" title="YusufS , WittesJ , ProbstfieldJ , TyrolerHA . Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA1991;266:93‐8. ">Yusuf 1991</a>) and/or a meta‐regression in order to explain it (<a href="./references#CD004310-bbs2-0171" title="ThompsonSG , SharpSJ . Explaining heterogeneity in meta‐analysis: a comparison of methods. Statistics in Medicine1999;18:2693‐708. ">Thompson 1999</a>). </p> <p>Subgroup analyses were planned for:</p> <p> <ul id="CD004310-list-0008"> <li> <p>patients with AIDS;</p> </li> <li> <p>patients with cancer;</p> </li> <li> <p>patients with other underlying disease (elderly, chronic obstructive pulmonary disease (COPD), cardiac heart failure); </p> </li> <li> <p>high doses of MA (=&gt; 800 mg/d) versus low doses of MA (&lt; 800 mg/d);</p> </li> <li> <p>duration of trial, size and methodological quality.</p> </li> </ul> </p> </section> <section id="CD004310-sec-0051"> <h4 class="title">Sensitivity analysis</h4> <p>In order to explore the impact of specific factors on the meta‐analysis results, we undertook sensitivity analyses with: </p> <p> <ul id="CD004310-list-0009"> <li> <p>studies of high methodological quality, defined as studies with appropriate concealment of allocation, appropriate blinding and analysis by intention‐to‐treat (ITT); </p> </li> <li> <p>studies where patients received more than six weeks of treatment.</p> </li> </ul> </p> <p>We carried out the statistical analyses using the statistical package in Review Manager 5.1.6 (<a href="./references#CD004310-bbs2-0166" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011. ">RevMan 2011</a>). </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD004310-sec-0052" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD004310-sec-0052"></div> <section id="CD004310-sec-0053"> <h3 class="title">Description of studies</h3> <section id="CD004310-sec-0054"> <h4 class="title">Results of the search</h4> <p>Searching the electronic databases identified:</p> <p> <ul id="CD004310-list-0010"> <li> <p>385 references in MEDLINE;</p> </li> <li> <p>401 references in EMBASE; and</p> </li> <li> <p>164 references in the Cochrane Central Register of Controlled Trials (CENTRAL).</p> </li> </ul> </p> <p>We located an additional reference through Google and one more through a researcher who was involved in one trial that was never published. </p> <p>We updated the first search to May 2012 (see <a href="./appendices#CD004310-sec-0105">Appendix 2</a>; <a href="./appendices#CD004310-sec-0106">Appendix 3</a>; <a href="./appendices#CD004310-sec-0104">Appendix 1</a>) and one trial was added (<a href="./references#CD004310-bbs2-0021" title="MadedduC , DessìM , PanzoneF , SerpeR , AntoniG , CauMC , et al. Randomized phase III clinical trial of a combined treatment with carnitine + celecoxib ± megestrol acetate for patients with cancer‐related anorexia/cachexia syndrome. Clinical Nutrition2012;31:176‐82. ">Madeddu 2012</a>). </p> <p>A flowchart of included studies, according to the PRISMA recommendations, is shown in <a href="#CD004310-fig-0001">Figure 1</a> </p> <div class="figure" id="CD004310-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD004310-fig-0001" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD004310-sec-0055"> <h4 class="title">Included studies</h4> <p>We included most of the trials that were in the previous version of the review: <a href="./references#CD004310-bbs2-0001" title="BatterhamM , GarsiaR . Randomised prospective medium term comparison of megestrol acetate, nandrolone decanoate and dietary therapy alone for HIV associated weight loss [abstract]. Australasian Society for HIV Medicine1997;9:91. BatterhamMJ , GarsiaR . A comparison of megestrol acetate, nandrolone decanoate and dietary counselling for HIV associated weight loss. International Journal of Andrology2001;24(4):232‐40. ">Batterham 2001</a>; <a href="./references#CD004310-bbs2-0002" title="BellerE , TattersallM . Improved quality of life with megestrol acetate in patients with endocrine‐insensitive advanced cancer: a randomised placebo‐controlled trial. Annals of Oncology1997;8:277‐83. ">Beller 1997</a>; <a href="./references#CD004310-bbs2-0004" title="DeConnoF , MartiniC . Megestrol acetate for anorexia in patients with far‐advanced cancer: a double‐blind controlled clinical trial. European Journal of Cancer1998;34:1705‐9. ">De Conno 1998</a>; <a href="./references#CD004310-bbs2-0005" title="EubanksV , KoppersmithN . Effects of megestrol acetate on weight gain, body composition, and pulmonary function in patients with cystic fibrosis. Journal of Pediatrics2002;140:439‐44. ">Eubanks 2002</a>; <a href="./references#CD004310-bbs2-0006" title="FeliuJ , Gonzalez‐BaronM . Usefulness of megestrol acetate in cancer cachexia and anorexia. A placebo controlled study. American Journal of Clinical Oncology1992;15:436‐40. Gonzalez BaronM , FeliuJ , ZamoraP , ArtalA , GarridoP , ChaconI . Usefulness of megestrol acetate on cancer cachexia: a double blind randomized study. Annals of Oncology1990;1:29‐31. ">Feliu 1992</a>; <a href="./references#CD004310-bbs2-0007" title="FietkauR , RieplM . Supportive treatment with megestrol acetate during radio (chemo) therapy. A randomised trial. Strahlentherapie und Onkologie1996;172:162‐8. FietkauR , RieplM , KettnerH , HinkeA , SauerR . Supportive use of megestrol acetate in patients with head and neck cancer during radio(chemo)therapy. European Journal of Cancer1997;33:75‐9. [CN‐00137738] ">Fietkau 1996</a>; <a href="./references#CD004310-bbs2-0008" title="GambardellaA , PesceL , BologninoP , LombardiG , BarbieriM , RinaldiC . Megestrol acetate prevents cachexia in elderly cancer patient. Annals of Oncology1998;9(Suppl 3):72. [CN‐00305911] GambardellaA , PesceL , LammardoAM , LombardiG , BarbagalloM , TirelliP , et al. New factors involvement in elderly cancer patients with anorexia/cachexia syndrome role of megestrol acetate. Annals of Oncology2000;9 Suppl 2:22. ">Gambardella 1998</a>; <a href="./references#CD004310-bbs2-0009" title="GebbiaV , TestaA . Prospective randomised trial of two dose levels of megestrol acetate in the management of anorexia‐cachexia syndrome in patients with metastatic cancer. British Journal of Cancer1996;73:1576‐80. ">Gebbia 1996</a>; <a href="./references#CD004310-bbs2-0011" title="HeckmayrM , GatzemeierU . Treatment of cancer weight loss in patients with advanced lung cancer. Oncology1992;49(Suppl 2):32‐4. ">Heckmayr 1992</a>; <a href="./references#CD004310-bbs2-0013" title="JatoiA , WindschitlHE . Dronabinol versus megestrol acetate versus combination for cancer‐associated anorexia: A North Central Cancer Treatment Group Study. Journal of Clinical Oncology2002;20:567‐73. ">Jatoi 2002</a>; <a href="./references#CD004310-bbs2-0014" title="JatoiA , RowlandK , LoprinziCL , SloanJA , DakhilSR , MacDonaldN , et al. An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer‐associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort. Journal of Clinical Oncology2004;22:2469‐76. ">Jatoi 2004</a>; <a href="./references#CD004310-bbs2-0016" title="LoprinziCL , EllisonNM . Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. Journal of the National Cancer Institute1990;82:1127‐32. ">Loprinzi 1990b</a>; <a href="./references#CD004310-bbs2-0017" title="LoprinziCL , BernathAM . Phase III evaluation of 4 doses of megestrol acetate for patients with cancer anorexia and/or cachexia. Oncology1994;51:2‐7. LoprinziCL , MichalakJC , SchaidDJ , MailliardJA , AthmannLM , GoldbergRM , et al. Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia. Journal of Clinical Oncology1993;11:762‐7. [CN‐00092689] ">Loprinzi 1994</a>; <a href="./references#CD004310-bbs2-0018" title="LoprinziCL , KuglerJ , SloanJ , MailliardJ , KrookJ , WilwerdingM , et al. Phase III randomized comparison of megestrol acetate, dexamethasone, and fluoxymesterone for the treatment of cancer anorexia/cachexia [Meeting abstract no 167]. ASCO Annual Meeting. 1997. LoprinziCL , KuglerJW . Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. Journal of Clinical Oncology1999;17:3299‐306. ">Loprinzi 1999a</a>; <a href="./references#CD004310-bbs2-0022" title="McMillanDC , SimpsonJM . Effect of megestrol acetate on weight loss, body composition and blood screen of gastrointestinal cancer patients. Clinical Nutrition1994;13:85‐9. ">McMillan 1994</a>; <a href="./references#CD004310-bbs2-0024" title="OsterMH , EndersSR . Megestrol acetate in patients with AIDS and cachexia. Annals of Internal Medicine1994;121:400‐8. ">Oster 1994</a>; <a href="./references#CD004310-bbs2-0025" title="Sancho‐CuestaJF . Megestrol acetate and weight loss in advanced cancer [Abstract no: 1141]. European Journal of Cancer1993;29A:S204. ">Sancho‐Cuesta 1993</a>; <a href="./references#CD004310-bbs2-0027" title="SchmollE . Risks and benefits of various therapies for cancer anorexia. Oncology1992;49:43‐5. ">Schmoll 1992</a>; <a href="./references#CD004310-bbs2-0029" title="TchekmedyianNS , HickmanM . Megestrol acetate in cancer anorexia and weight loss. Cancer1992;69:1268‐74. ">Tchekmedyian 1992</a>; <a href="./references#CD004310-bbs2-0031" title="UlutinHC , ArpaciF , PakY . Megestrol acetate for cachexia and anorexia in advanced non‐small cell lung cancer: a randomized study comparing two different doses. Tumori2002;88:277‐80. ">Ulutin 2002</a>; <a href="./references#CD004310-bbs2-0032" title="SeguiMA , VadellC , Gimenez‐ArnauJM , MoralesS , CireraL , BestitI , et al. Double‐blind randomized trial for the treatment of cancer related cachexia: comparison of placebo vs two different doses of megestrol acetate [Abstract 99]. Proceedings of the American Society of Clinical Oncology1996;15:529. VadellC , SeguiMA . Anticachectic efficacy of megestrol acetate at different doses and versus placebo in patients with neoplastic cachexia. American Journal of Clinical Oncology1998;21:347‐51. ">Vadell 1998</a>; <a href="./references#CD004310-bbs2-0033" title="VonRoennJH , ArmstrongD . Megestrol acetate in patients with AIDS‐related cachexia. Annals of Internal Medicine1994;121:393‐9. ">Von Roenn 1994</a>; <a href="./references#CD004310-bbs2-0035" title="WeisbergJ , WangerJ . Megestrol acetate stimulates weight gain and ventilation in underweight COPD patients. Chest2002;121(4):1070‐8. ">Weisberg 2002</a>; <a href="./references#CD004310-bbs2-0036" title="YehSS , LovittS , SchusterMW . Usage of megestrol acetate in the treatment of anorexia‐cachexia syndrome in the elderly. Journal of Nutrition, Health and Aging2009;13:448‐54. YehSS , WuSY . Improvement in quality of life measures and stimulation of weight gain after treatment with megestrol acetate oral suspension in geriatric cachexia: results of a double‐blind, placebo‐controlled study. Journal of the American Geriatrics Society2000;48(5):485‐92. YehSS , WuSY , LevineDM , ParkerTS , OlsonJS , StevensMR , et al. The correlation of cytokine levels with body weight after megestrol acetate treatment in geriatric patients. Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2001;56:M48‐54. ">Yeh 2000</a> and included the following new trials: <a href="./references#CD004310-bbs2-0003" title="Casado HerráezA . Phase II randomized study of two dose levels of megestrol acetate versus placebo for the treatment of anorexia and cachexia in patients with locoregional advanced or metastatic cancer [Estudio de fase II randomizado de dos niveles posológicos de acetato de Megestrol versus placebo para el tratamiento de la anorexia y la caquexia en pacientes con cáncer locoregional avanzado o metastásico. (Tesis de Doctorado ‐ Universidad Complutense Madrid)]. Available from http://eprints.ucm.es/8119/1/T30450.pdf 2008 (accessed 24 December 2011). ">Casado 2008</a>; <a href="./references#CD004310-bbs2-0010" title="GiacosaA , FrascioF , SukkarSG , CostantiniM , BaraccoG , CapelliM . Changes of nutritional and psychological status after megestrol acetate treatment of cancer cachexia. Rivista Italiana Di Nutrizione Parenterale Ed Enterale.1997;15:20‐3. ">Giacosa 1997</a>; <a href="./references#CD004310-bbs2-0012" title="HerrejonA , CatalanP , PalopJ , InchaurragaI , BlanquerR , LopezA . Effect of 8‐week 320 mg megestrol acetate daily administration in severe COPD and weight loss [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181:A4484. HerrejonA , PalopJ , InchaurragaI , LopezA , BañulsC , HernandezA , et al. Low doses of megestrol acetate increase weight and improve nutrition status in patients with severe chronic obstructive pulmonary disease and weight loss. Medicina Clinica2011;137:193‐8. ">Herrejon 2011</a>; <a href="./references#CD004310-bbs2-0015" title="LesserGJ , CaseD , SharpS , ChoksiJ , MillerA , AtkinsJ , et al. A phase III randomized study comparing the effects of oxandrolone (Ox) and megestrol acetate (Meg) on weight (wt), lean body mass (LBM) and quality of life (QOL) in solid tumor patients (pts) receiving chemotherapy (chemo). Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I2006;24(18S (June 20 Suppl)):18546. ">Lesser 2006</a>; <a href="./references#CD004310-bbs2-0021" title="MadedduC , DessìM , PanzoneF , SerpeR , AntoniG , CauMC , et al. Randomized phase III clinical trial of a combined treatment with carnitine + celecoxib ± megestrol acetate for patients with cancer‐related anorexia/cachexia syndrome. Clinical Nutrition2012;31:176‐82. ">Madeddu 2012</a>; <a href="./references#CD004310-bbs2-0020" title="MacbethFR , GrgeorA , Cott . A randomised study of megestrol acetate (MA) and prednisolone (P) for anorexia and weight loss in patients with lung cancer. Lung Cancer1994;1 Suppl 1:88. ">Macbeth 1994</a>; <a href="./references#CD004310-bbs2-0023" title="MwamburiDM , GerriorJ , WilsonIB , ChangH , ScullyE , SabooriS , et al. Comparing megestrol acetate therapy with oxandrolone therapy for HIV‐related weight loss: similar results in 2 months. Clinical Infectious Diseases2004;38:895‐902. ">Mwamburi 2004</a>; <a href="./references#CD004310-bbs2-0026" title="SchmollE , WilkeH , TholeR , PreusserP ,  WildfangI ,  SchmollHJ . Megestrol acetate in cancer cachexia. Seminars in Oncology1991;18(1 Suppl 2):32‐4. [CN‐00072963] ">Schmoll 1991</a>; <a href="./references#CD004310-bbs2-0028" title="SummerbellCD , YouleM , McDonaldV , CatalanJ , GazzardBG . Megestrol acetate vs cyproheptadine in the treatment of weight loss associated with HIV infection. International Journal of STD and AIDS1992;3:278‐80. ">Summerbell 1992</a>;<a href="./references#CD004310-bbs2-0030" title="TimponeJG , WrightDJ . The safety and pharmacokinetics of single‐agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome. AIDS Research and Human Retroviruses1997;13:305‐15. ">Timpone 1997</a>; <a href="./references#CD004310-bbs2-0034" title="CillaDD , GutierrezJL , KristensenA , KramerLD . The safety of megestrol acetate concentrated suspension (MA‐CS) and megestrol acetate oral suspension (MA‐OS) in a pilot study in patients with HIV‐associated unintended weight loss (UWL) [Abstract]. Blood2006;108:43. WankeC , GutierrezJ , KristensenA , MacEarchern , L . Safety and efficacy of two preparations of megestrol acetate in HIV‐infected individuals with weight loss in Africa, India, and the United States. Journal of Applied Research2007;7:206‐16. ">Wanke 2007</a>. Ultimately we included 35 trials, representing 3963 patients studied for effectiveness and 3240 for safety. We could not use the data from the included trials <a href="./references#CD004310-bbs2-0015" title="LesserGJ , CaseD , SharpS , ChoksiJ , MillerA , AtkinsJ , et al. A phase III randomized study comparing the effects of oxandrolone (Ox) and megestrol acetate (Meg) on weight (wt), lean body mass (LBM) and quality of life (QOL) in solid tumor patients (pts) receiving chemotherapy (chemo). Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I2006;24(18S (June 20 Suppl)):18546. ">Lesser 2006</a> and <a href="./references#CD004310-bbs2-0008" title="GambardellaA , PesceL , BologninoP , LombardiG , BarbieriM , RinaldiC . Megestrol acetate prevents cachexia in elderly cancer patient. Annals of Oncology1998;9(Suppl 3):72. [CN‐00305911] GambardellaA , PesceL , LammardoAM , LombardiG , BarbagalloM , TirelliP , et al. New factors involvement in elderly cancer patients with anorexia/cachexia syndrome role of megestrol acetate. Annals of Oncology2000;9 Suppl 2:22. ">Gambardella 1998</a>. See <a href="./references#CD004310-sec-0121" title="">Characteristics of included studies</a> table. </p> <p>Many of these citations were replicated across the three databases.</p> <p>The designs of the 35 trials were as follows:</p> <section id="CD004310-sec-0056"> <h5 class="title">MA at different doses compared with placebo</h5> <p>Seventeen trials compared MA at different doses with placebo: <a href="./references#CD004310-bbs2-0002" title="BellerE , TattersallM . Improved quality of life with megestrol acetate in patients with endocrine‐insensitive advanced cancer: a randomised placebo‐controlled trial. Annals of Oncology1997;8:277‐83. ">Beller 1997</a>; <a href="./references#CD004310-bbs2-0003" title="Casado HerráezA . Phase II randomized study of two dose levels of megestrol acetate versus placebo for the treatment of anorexia and cachexia in patients with locoregional advanced or metastatic cancer [Estudio de fase II randomizado de dos niveles posológicos de acetato de Megestrol versus placebo para el tratamiento de la anorexia y la caquexia en pacientes con cáncer locoregional avanzado o metastásico. (Tesis de Doctorado ‐ Universidad Complutense Madrid)]. Available from http://eprints.ucm.es/8119/1/T30450.pdf 2008 (accessed 24 December 2011). ">Casado 2008</a>; <a href="./references#CD004310-bbs2-0004" title="DeConnoF , MartiniC . Megestrol acetate for anorexia in patients with far‐advanced cancer: a double‐blind controlled clinical trial. European Journal of Cancer1998;34:1705‐9. ">De Conno 1998</a>; <a href="./references#CD004310-bbs2-0005" title="EubanksV , KoppersmithN . Effects of megestrol acetate on weight gain, body composition, and pulmonary function in patients with cystic fibrosis. Journal of Pediatrics2002;140:439‐44. ">Eubanks 2002</a>; <a href="./references#CD004310-bbs2-0006" title="FeliuJ , Gonzalez‐BaronM . Usefulness of megestrol acetate in cancer cachexia and anorexia. A placebo controlled study. American Journal of Clinical Oncology1992;15:436‐40. Gonzalez BaronM , FeliuJ , ZamoraP , ArtalA , GarridoP , ChaconI . Usefulness of megestrol acetate on cancer cachexia: a double blind randomized study. Annals of Oncology1990;1:29‐31. ">Feliu 1992</a>; <a href="./references#CD004310-bbs2-0007" title="FietkauR , RieplM . Supportive treatment with megestrol acetate during radio (chemo) therapy. A randomised trial. Strahlentherapie und Onkologie1996;172:162‐8. FietkauR , RieplM , KettnerH , HinkeA , SauerR . Supportive use of megestrol acetate in patients with head and neck cancer during radio(chemo)therapy. European Journal of Cancer1997;33:75‐9. [CN‐00137738] ">Fietkau 1996</a>; <a href="./references#CD004310-bbs2-0012" title="HerrejonA , CatalanP , PalopJ , InchaurragaI , BlanquerR , LopezA . Effect of 8‐week 320 mg megestrol acetate daily administration in severe COPD and weight loss [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181:A4484. HerrejonA , PalopJ , InchaurragaI , LopezA , BañulsC , HernandezA , et al. Low doses of megestrol acetate increase weight and improve nutrition status in patients with severe chronic obstructive pulmonary disease and weight loss. Medicina Clinica2011;137:193‐8. ">Herrejon 2011</a>; <a href="./references#CD004310-bbs2-0016" title="LoprinziCL , EllisonNM . Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. Journal of the National Cancer Institute1990;82:1127‐32. ">Loprinzi 1990b</a>; <a href="./references#CD004310-bbs2-0022" title="McMillanDC , SimpsonJM . Effect of megestrol acetate on weight loss, body composition and blood screen of gastrointestinal cancer patients. Clinical Nutrition1994;13:85‐9. ">McMillan 1994</a>; <a href="./references#CD004310-bbs2-0024" title="OsterMH , EndersSR . Megestrol acetate in patients with AIDS and cachexia. Annals of Internal Medicine1994;121:400‐8. ">Oster 1994</a>; <a href="./references#CD004310-bbs2-0026" title="SchmollE , WilkeH , TholeR , PreusserP ,  WildfangI ,  SchmollHJ . Megestrol acetate in cancer cachexia. Seminars in Oncology1991;18(1 Suppl 2):32‐4. [CN‐00072963] ">Schmoll 1991</a>; <a href="./references#CD004310-bbs2-0027" title="SchmollE . Risks and benefits of various therapies for cancer anorexia. Oncology1992;49:43‐5. ">Schmoll 1992</a>; <a href="./references#CD004310-bbs2-0029" title="TchekmedyianNS , HickmanM . Megestrol acetate in cancer anorexia and weight loss. Cancer1992;69:1268‐74. ">Tchekmedyian 1992</a>; <a href="./references#CD004310-bbs2-0032" title="SeguiMA , VadellC , Gimenez‐ArnauJM , MoralesS , CireraL , BestitI , et al. Double‐blind randomized trial for the treatment of cancer related cachexia: comparison of placebo vs two different doses of megestrol acetate [Abstract 99]. Proceedings of the American Society of Clinical Oncology1996;15:529. VadellC , SeguiMA . Anticachectic efficacy of megestrol acetate at different doses and versus placebo in patients with neoplastic cachexia. American Journal of Clinical Oncology1998;21:347‐51. ">Vadell 1998</a>; <a href="./references#CD004310-bbs2-0033" title="VonRoennJH , ArmstrongD . Megestrol acetate in patients with AIDS‐related cachexia. Annals of Internal Medicine1994;121:393‐9. ">Von Roenn 1994</a>; <a href="./references#CD004310-bbs2-0035" title="WeisbergJ , WangerJ . Megestrol acetate stimulates weight gain and ventilation in underweight COPD patients. Chest2002;121(4):1070‐8. ">Weisberg 2002</a>; <a href="./references#CD004310-bbs2-0036" title="YehSS , LovittS , SchusterMW . Usage of megestrol acetate in the treatment of anorexia‐cachexia syndrome in the elderly. Journal of Nutrition, Health and Aging2009;13:448‐54. YehSS , WuSY . Improvement in quality of life measures and stimulation of weight gain after treatment with megestrol acetate oral suspension in geriatric cachexia: results of a double‐blind, placebo‐controlled study. Journal of the American Geriatrics Society2000;48(5):485‐92. YehSS , WuSY , LevineDM , ParkerTS , OlsonJS , StevensMR , et al. The correlation of cytokine levels with body weight after megestrol acetate treatment in geriatric patients. Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2001;56:M48‐54. ">Yeh 2000</a>. In <a href="./references#CD004310-bbs2-0021" title="MadedduC , DessìM , PanzoneF , SerpeR , AntoniG , CauMC , et al. Randomized phase III clinical trial of a combined treatment with carnitine + celecoxib ± megestrol acetate for patients with cancer‐related anorexia/cachexia syndrome. Clinical Nutrition2012;31:176‐82. ">Madeddu 2012</a> one arm was carnitine plus celecoxib and the second arm was carnitine plus celecoxib plus MA 300 mg/day. In this trial only few safety data were available for the meta‐analysis and we decided include it in this comparison. </p> </section> <section id="CD004310-sec-0057"> <h5 class="title">MA at different doses compared with other treatment drugs</h5> <p>Seven trials compared different doses of MA with other drug treatments. MA was compared with dronabinol in two studies (<a href="./references#CD004310-bbs2-0013" title="JatoiA , WindschitlHE . Dronabinol versus megestrol acetate versus combination for cancer‐associated anorexia: A North Central Cancer Treatment Group Study. Journal of Clinical Oncology2002;20:567‐73. ">Jatoi 2002</a>; <a href="./references#CD004310-bbs2-0030" title="TimponeJG , WrightDJ . The safety and pharmacokinetics of single‐agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome. AIDS Research and Human Retroviruses1997;13:305‐15. ">Timpone 1997</a>); dexamethasone and fluoxymesterone in one study (<a href="./references#CD004310-bbs2-0162" title="LoprinziCL , KuglerJW , SloanJA . Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. Journal of Clinical Oncology1999;17:3299‐306. ">Loprinzi 1999</a>); nandrolone decanoate in one study (<a href="./references#CD004310-bbs2-0001" title="BatterhamM , GarsiaR . Randomised prospective medium term comparison of megestrol acetate, nandrolone decanoate and dietary therapy alone for HIV associated weight loss [abstract]. Australasian Society for HIV Medicine1997;9:91. BatterhamMJ , GarsiaR . A comparison of megestrol acetate, nandrolone decanoate and dietary counselling for HIV associated weight loss. International Journal of Andrology2001;24(4):232‐40. ">Batterham 2001</a>); cyproheptadine in one study (<a href="./references#CD004310-bbs2-0028" title="SummerbellCD , YouleM , McDonaldV , CatalanJ , GazzardBG . Megestrol acetate vs cyproheptadine in the treatment of weight loss associated with HIV infection. International Journal of STD and AIDS1992;3:278‐80. ">Summerbell 1992</a>); oxandrolone in two studies (<a href="./references#CD004310-bbs2-0015" title="LesserGJ , CaseD , SharpS , ChoksiJ , MillerA , AtkinsJ , et al. A phase III randomized study comparing the effects of oxandrolone (Ox) and megestrol acetate (Meg) on weight (wt), lean body mass (LBM) and quality of life (QOL) in solid tumor patients (pts) receiving chemotherapy (chemo). Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I2006;24(18S (June 20 Suppl)):18546. ">Lesser 2006</a>; <a href="./references#CD004310-bbs2-0023" title="MwamburiDM , GerriorJ , WilsonIB , ChangH , ScullyE , SabooriS , et al. Comparing megestrol acetate therapy with oxandrolone therapy for HIV‐related weight loss: similar results in 2 months. Clinical Infectious Diseases2004;38:895‐902. ">Mwamburi 2004</a>); prednisolone in one study (<a href="./references#CD004310-bbs2-0020" title="MacbethFR , GrgeorA , Cott . A randomised study of megestrol acetate (MA) and prednisolone (P) for anorexia and weight loss in patients with lung cancer. Lung Cancer1994;1 Suppl 1:88. ">Macbeth 1994</a>) and eicosapentaenoic acid (EPA) in one study (<a href="./references#CD004310-bbs2-0014" title="JatoiA , RowlandK , LoprinziCL , SloanJA , DakhilSR , MacDonaldN , et al. An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer‐associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort. Journal of Clinical Oncology2004;22:2469‐76. ">Jatoi 2004</a>). </p> </section> <section id="CD004310-sec-0058"> <h5 class="title">MA at different doses</h5> <p>Ten trials compared different doses of MA.</p> <p> <ul id="CD004310-list-0011"> <li> <p><a href="./references#CD004310-bbs2-0002" title="BellerE , TattersallM . Improved quality of life with megestrol acetate in patients with endocrine‐insensitive advanced cancer: a randomised placebo‐controlled trial. Annals of Oncology1997;8:277‐83. ">Beller 1997</a>: MA 160 mg versus MA 480 mg </p> </li> <li> <p><a href="./references#CD004310-bbs2-0003" title="Casado HerráezA . Phase II randomized study of two dose levels of megestrol acetate versus placebo for the treatment of anorexia and cachexia in patients with locoregional advanced or metastatic cancer [Estudio de fase II randomizado de dos niveles posológicos de acetato de Megestrol versus placebo para el tratamiento de la anorexia y la caquexia en pacientes con cáncer locoregional avanzado o metastásico. (Tesis de Doctorado ‐ Universidad Complutense Madrid)]. Available from http://eprints.ucm.es/8119/1/T30450.pdf 2008 (accessed 24 December 2011). ">Casado 2008</a>: MA 160 mg versus MA 960 mg versus placebo </p> </li> <li> <p><a href="./references#CD004310-bbs2-0009" title="GebbiaV , TestaA . Prospective randomised trial of two dose levels of megestrol acetate in the management of anorexia‐cachexia syndrome in patients with metastatic cancer. British Journal of Cancer1996;73:1576‐80. ">Gebbia 1996</a>: MA 160 mg versus MA 320 mg </p> </li> <li> <p><a href="./references#CD004310-bbs2-0011" title="HeckmayrM , GatzemeierU . Treatment of cancer weight loss in patients with advanced lung cancer. Oncology1992;49(Suppl 2):32‐4. ">Heckmayr 1992</a>: MA 160 versus MA 480 mg </p> </li> <li> <p><a href="./references#CD004310-bbs2-0017" title="LoprinziCL , BernathAM . Phase III evaluation of 4 doses of megestrol acetate for patients with cancer anorexia and/or cachexia. Oncology1994;51:2‐7. LoprinziCL , MichalakJC , SchaidDJ , MailliardJA , AthmannLM , GoldbergRM , et al. Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia. Journal of Clinical Oncology1993;11:762‐7. [CN‐00092689] ">Loprinzi 1994</a>: MA 160 versus MA 480 mg versus MA 800 mg versus MA 1280 mg </p> </li> <li> <p><a href="./references#CD004310-bbs2-0025" title="Sancho‐CuestaJF . Megestrol acetate and weight loss in advanced cancer [Abstract no: 1141]. European Journal of Cancer1993;29A:S204. ">Sancho‐Cuesta 1993</a>: MA 160 versus MA 320 mg </p> </li> <li> <p><a href="./references#CD004310-bbs2-0026" title="SchmollE , WilkeH , TholeR , PreusserP ,  WildfangI ,  SchmollHJ . Megestrol acetate in cancer cachexia. Seminars in Oncology1991;18(1 Suppl 2):32‐4. [CN‐00072963] ">Schmoll 1991</a>: MA 480 mg versus MA 960 mg versus placebo </p> </li> <li> <p><a href="./references#CD004310-bbs2-0027" title="SchmollE . Risks and benefits of various therapies for cancer anorexia. Oncology1992;49:43‐5. ">Schmoll 1992</a>: MA 480 mg versus MA 960 mg versus placebo </p> </li> <li> <p><a href="./references#CD004310-bbs2-0031" title="UlutinHC , ArpaciF , PakY . Megestrol acetate for cachexia and anorexia in advanced non‐small cell lung cancer: a randomized study comparing two different doses. Tumori2002;88:277‐80. ">Ulutin 2002</a>: MA 160 mg versus MA 320 mg </p> </li> <li> <p><a href="./references#CD004310-bbs2-0032" title="SeguiMA , VadellC , Gimenez‐ArnauJM , MoralesS , CireraL , BestitI , et al. Double‐blind randomized trial for the treatment of cancer related cachexia: comparison of placebo vs two different doses of megestrol acetate [Abstract 99]. Proceedings of the American Society of Clinical Oncology1996;15:529. VadellC , SeguiMA . Anticachectic efficacy of megestrol acetate at different doses and versus placebo in patients with neoplastic cachexia. American Journal of Clinical Oncology1998;21:347‐51. ">Vadell 1998</a>: MA 160 mg versus MA 480 mg versus placebo </p> </li> <li> <p><a href="./references#CD004310-bbs2-0034" title="CillaDD , GutierrezJL , KristensenA , KramerLD . The safety of megestrol acetate concentrated suspension (MA‐CS) and megestrol acetate oral suspension (MA‐OS) in a pilot study in patients with HIV‐associated unintended weight loss (UWL) [Abstract]. Blood2006;108:43. WankeC , GutierrezJ , KristensenA , MacEarchern , L . Safety and efficacy of two preparations of megestrol acetate in HIV‐infected individuals with weight loss in Africa, India, and the United States. Journal of Applied Research2007;7:206‐16. ">Wanke 2007</a>: MA 575 mg versus MA 800 mg </p> </li> </ul> </p> <p>We categorised the included studies according to the healthcare problem of the patient ‐ see <a href="#CD004310-tbl-0002">Table 1</a> for a summary. </p> <div class="table" id="CD004310-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Patient condition and numbers recruited to each trial</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Lung cancer</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Gastrointestinal and pancreas</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Head and neck cancer</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Gynaecological cancer</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Other cancer</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>AIDS</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>COPD</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cystic fibrosis</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Elderly</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004310-bbs2-0001" title="BatterhamM , GarsiaR . Randomised prospective medium term comparison of megestrol acetate, nandrolone decanoate and dietary therapy alone for HIV associated weight loss [abstract]. Australasian Society for HIV Medicine1997;9:91. BatterhamMJ , GarsiaR . A comparison of megestrol acetate, nandrolone decanoate and dietary counselling for HIV associated weight loss. International Journal of Andrology2001;24(4):232‐40. ">Batterham 2001</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004310-bbs2-0002" title="BellerE , TattersallM . Improved quality of life with megestrol acetate in patients with endocrine‐insensitive advanced cancer: a randomised placebo‐controlled trial. Annals of Oncology1997;8:277‐83. ">Beller 1997</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>106</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004310-bbs2-0003" title="Casado HerráezA . Phase II randomized study of two dose levels of megestrol acetate versus placebo for the treatment of anorexia and cachexia in patients with locoregional advanced or metastatic cancer [Estudio de fase II randomizado de dos niveles posológicos de acetato de Megestrol versus placebo para el tratamiento de la anorexia y la caquexia en pacientes con cáncer locoregional avanzado o metastásico. (Tesis de Doctorado ‐ Universidad Complutense Madrid)]. Available from http://eprints.ucm.es/8119/1/T30450.pdf 2008 (accessed 24 December 2011). ">Casado 2008</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ­</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004310-bbs2-0004" title="DeConnoF , MartiniC . Megestrol acetate for anorexia in patients with far‐advanced cancer: a double‐blind controlled clinical trial. European Journal of Cancer1998;34:1705‐9. ">De Conno 1998</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004310-bbs2-0005" title="EubanksV , KoppersmithN . Effects of megestrol acetate on weight gain, body composition, and pulmonary function in patients with cystic fibrosis. Journal of Pediatrics2002;140:439‐44. ">Eubanks 2002</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004310-bbs2-0006" title="FeliuJ , Gonzalez‐BaronM . Usefulness of megestrol acetate in cancer cachexia and anorexia. A placebo controlled study. American Journal of Clinical Oncology1992;15:436‐40. Gonzalez BaronM , FeliuJ , ZamoraP , ArtalA , GarridoP , ChaconI . Usefulness of megestrol acetate on cancer cachexia: a double blind randomized study. Annals of Oncology1990;1:29‐31. ">Feliu 1992</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004310-bbs2-0007" title="FietkauR , RieplM . Supportive treatment with megestrol acetate during radio (chemo) therapy. A randomised trial. Strahlentherapie und Onkologie1996;172:162‐8. FietkauR , RieplM , KettnerH , HinkeA , SauerR . Supportive use of megestrol acetate in patients with head and neck cancer during radio(chemo)therapy. European Journal of Cancer1997;33:75‐9. [CN‐00137738] ">Fietkau 1996</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004310-bbs2-0008" title="GambardellaA , PesceL , BologninoP , LombardiG , BarbieriM , RinaldiC . Megestrol acetate prevents cachexia in elderly cancer patient. Annals of Oncology1998;9(Suppl 3):72. [CN‐00305911] GambardellaA , PesceL , LammardoAM , LombardiG , BarbagalloM , TirelliP , et al. New factors involvement in elderly cancer patients with anorexia/cachexia syndrome role of megestrol acetate. Annals of Oncology2000;9 Suppl 2:22. ">Gambardella 1998</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004310-bbs2-0009" title="GebbiaV , TestaA . Prospective randomised trial of two dose levels of megestrol acetate in the management of anorexia‐cachexia syndrome in patients with metastatic cancer. British Journal of Cancer1996;73:1576‐80. ">Gebbia 1996</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004310-bbs2-0010" title="GiacosaA , FrascioF , SukkarSG , CostantiniM , BaraccoG , CapelliM . Changes of nutritional and psychological status after megestrol acetate treatment of cancer cachexia. Rivista Italiana Di Nutrizione Parenterale Ed Enterale.1997;15:20‐3. ">Giacosa 1997</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004310-bbs2-0011" title="HeckmayrM , GatzemeierU . Treatment of cancer weight loss in patients with advanced lung cancer. Oncology1992;49(Suppl 2):32‐4. ">Heckmayr 1992</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004310-bbs2-0012" title="HerrejonA , CatalanP , PalopJ , InchaurragaI , BlanquerR , LopezA . Effect of 8‐week 320 mg megestrol acetate daily administration in severe COPD and weight loss [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181:A4484. HerrejonA , PalopJ , InchaurragaI , LopezA , BañulsC , HernandezA , et al. Low doses of megestrol acetate increase weight and improve nutrition status in patients with severe chronic obstructive pulmonary disease and weight loss. Medicina Clinica2011;137:193‐8. ">Herrejon 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ­</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004310-bbs2-0078" title="JatoiA , LoprinziCL . An update: cancer‐associated anorexia as a treatment target. Current Opinion in Clinical Nutrition and Metabolic Care2001;4(3):179‐82. ">Jatoi 2001</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>208</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>139</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004310-bbs2-0014" title="JatoiA , RowlandK , LoprinziCL , SloanJA , DakhilSR , MacDonaldN , et al. An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer‐associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort. Journal of Clinical Oncology2004;22:2469‐76. ">Jatoi 2004</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>166</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>141</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>114</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004310-bbs2-0015" title="LesserGJ , CaseD , SharpS , ChoksiJ , MillerA , AtkinsJ , et al. A phase III randomized study comparing the effects of oxandrolone (Ox) and megestrol acetate (Meg) on weight (wt), lean body mass (LBM) and quality of life (QOL) in solid tumor patients (pts) receiving chemotherapy (chemo). Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I2006;24(18S (June 20 Suppl)):18546. ">Lesser 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004310-bbs2-0016" title="LoprinziCL , EllisonNM . Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. Journal of the National Cancer Institute1990;82:1127‐32. ">Loprinzi 1990b</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004310-bbs2-0017" title="LoprinziCL , BernathAM . Phase III evaluation of 4 doses of megestrol acetate for patients with cancer anorexia and/or cachexia. Oncology1994;51:2‐7. LoprinziCL , MichalakJC , SchaidDJ , MailliardJA , AthmannLM , GoldbergRM , et al. Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia. Journal of Clinical Oncology1993;11:762‐7. [CN‐00092689] ">Loprinzi 1994</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>111</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004310-bbs2-0162" title="LoprinziCL , KuglerJW , SloanJA . Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. Journal of Clinical Oncology1999;17:3299‐306. ">Loprinzi 1999</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>192</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>171</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>114</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004310-bbs2-0023" title="MwamburiDM , GerriorJ , WilsonIB , ChangH , ScullyE , SabooriS , et al. Comparing megestrol acetate therapy with oxandrolone therapy for HIV‐related weight loss: similar results in 2 months. Clinical Infectious Diseases2004;38:895‐902. ">Mwamburi 2004</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ­</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004310-bbs2-0022" title="McMillanDC , SimpsonJM . Effect of megestrol acetate on weight loss, body composition and blood screen of gastrointestinal cancer patients. Clinical Nutrition1994;13:85‐9. ">McMillan 1994</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004310-bbs2-0020" title="MacbethFR , GrgeorA , Cott . A randomised study of megestrol acetate (MA) and prednisolone (P) for anorexia and weight loss in patients with lung cancer. Lung Cancer1994;1 Suppl 1:88. ">Macbeth 1994</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004310-bbs2-0021" title="MadedduC , DessìM , PanzoneF , SerpeR , AntoniG , CauMC , et al. Randomized phase III clinical trial of a combined treatment with carnitine + celecoxib ± megestrol acetate for patients with cancer‐related anorexia/cachexia syndrome. Clinical Nutrition2012;31:176‐82. ">Madeddu 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004310-bbs2-0024" title="OsterMH , EndersSR . Megestrol acetate in patients with AIDS and cachexia. Annals of Internal Medicine1994;121:400‐8. ">Oster 1994</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004310-bbs2-0025" title="Sancho‐CuestaJF . Megestrol acetate and weight loss in advanced cancer [Abstract no: 1141]. European Journal of Cancer1993;29A:S204. ">Sancho‐Cuesta 1993</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004310-bbs2-0026" title="SchmollE , WilkeH , TholeR , PreusserP ,  WildfangI ,  SchmollHJ . Megestrol acetate in cancer cachexia. Seminars in Oncology1991;18(1 Suppl 2):32‐4. [CN‐00072963] ">Schmoll 1991</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004310-bbs2-0027" title="SchmollE . Risks and benefits of various therapies for cancer anorexia. Oncology1992;49:43‐5. ">Schmoll 1992</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004310-bbs2-0029" title="TchekmedyianNS , HickmanM . Megestrol acetate in cancer anorexia and weight loss. Cancer1992;69:1268‐74. ">Tchekmedyian 1992</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004310-bbs2-0033" title="VonRoennJH , ArmstrongD . Megestrol acetate in patients with AIDS‐related cachexia. Annals of Internal Medicine1994;121:393‐9. ">Von Roenn 1994</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>270</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004310-bbs2-0031" title="UlutinHC , ArpaciF , PakY . Megestrol acetate for cachexia and anorexia in advanced non‐small cell lung cancer: a randomized study comparing two different doses. Tumori2002;88:277‐80. ">Ulutin 2002</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>119</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004310-bbs2-0030" title="TimponeJG , WrightDJ . The safety and pharmacokinetics of single‐agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome. AIDS Research and Human Retroviruses1997;13:305‐15. ">Timpone 1997</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004310-bbs2-0032" title="SeguiMA , VadellC , Gimenez‐ArnauJM , MoralesS , CireraL , BestitI , et al. Double‐blind randomized trial for the treatment of cancer related cachexia: comparison of placebo vs two different doses of megestrol acetate [Abstract 99]. Proceedings of the American Society of Clinical Oncology1996;15:529. VadellC , SeguiMA . Anticachectic efficacy of megestrol acetate at different doses and versus placebo in patients with neoplastic cachexia. American Journal of Clinical Oncology1998;21:347‐51. ">Vadell 1998</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004310-bbs2-0035" title="WeisbergJ , WangerJ . Megestrol acetate stimulates weight gain and ventilation in underweight COPD patients. Chest2002;121(4):1070‐8. ">Weisberg 2002</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>145</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004310-bbs2-0036" title="YehSS , LovittS , SchusterMW . Usage of megestrol acetate in the treatment of anorexia‐cachexia syndrome in the elderly. Journal of Nutrition, Health and Aging2009;13:448‐54. YehSS , WuSY . Improvement in quality of life measures and stimulation of weight gain after treatment with megestrol acetate oral suspension in geriatric cachexia: results of a double‐blind, placebo‐controlled study. Journal of the American Geriatrics Society2000;48(5):485‐92. YehSS , WuSY , LevineDM , ParkerTS , OlsonJS , StevensMR , et al. The correlation of cytokine levels with body weight after megestrol acetate treatment in geriatric patients. Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2001;56:M48‐54. ">Yeh 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>­</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>­</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>­</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>­</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>­</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>­</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>­</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>­</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1342</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>928</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>284</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>21</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>907</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>475</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>185</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>17</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>69</b> </p> </td> </tr> </tbody> </table> </div> </section> <section id="CD004310-sec-0059"> <h5 class="title">Patient characteristics</h5> <p>A total of 4234 patients were included in this update.</p> <section id="CD004310-sec-0060"> <h6 class="title">Patients with any cancer</h6> <p>Twenty‐three trials (3428 patients) (<a href="./references#CD004310-bbs2-0002" title="BellerE , TattersallM . Improved quality of life with megestrol acetate in patients with endocrine‐insensitive advanced cancer: a randomised placebo‐controlled trial. Annals of Oncology1997;8:277‐83. ">Beller 1997</a>; <a href="./references#CD004310-bbs2-0003" title="Casado HerráezA . Phase II randomized study of two dose levels of megestrol acetate versus placebo for the treatment of anorexia and cachexia in patients with locoregional advanced or metastatic cancer [Estudio de fase II randomizado de dos niveles posológicos de acetato de Megestrol versus placebo para el tratamiento de la anorexia y la caquexia en pacientes con cáncer locoregional avanzado o metastásico. (Tesis de Doctorado ‐ Universidad Complutense Madrid)]. Available from http://eprints.ucm.es/8119/1/T30450.pdf 2008 (accessed 24 December 2011). ">Casado 2008</a>; <a href="./references#CD004310-bbs2-0004" title="DeConnoF , MartiniC . Megestrol acetate for anorexia in patients with far‐advanced cancer: a double‐blind controlled clinical trial. European Journal of Cancer1998;34:1705‐9. ">De Conno 1998</a>; <a href="./references#CD004310-bbs2-0006" title="FeliuJ , Gonzalez‐BaronM . Usefulness of megestrol acetate in cancer cachexia and anorexia. A placebo controlled study. American Journal of Clinical Oncology1992;15:436‐40. Gonzalez BaronM , FeliuJ , ZamoraP , ArtalA , GarridoP , ChaconI . Usefulness of megestrol acetate on cancer cachexia: a double blind randomized study. Annals of Oncology1990;1:29‐31. ">Feliu 1992</a>; <a href="./references#CD004310-bbs2-0007" title="FietkauR , RieplM . Supportive treatment with megestrol acetate during radio (chemo) therapy. A randomised trial. Strahlentherapie und Onkologie1996;172:162‐8. FietkauR , RieplM , KettnerH , HinkeA , SauerR . Supportive use of megestrol acetate in patients with head and neck cancer during radio(chemo)therapy. European Journal of Cancer1997;33:75‐9. [CN‐00137738] ">Fietkau 1996</a>; <a href="./references#CD004310-bbs2-0008" title="GambardellaA , PesceL , BologninoP , LombardiG , BarbieriM , RinaldiC . Megestrol acetate prevents cachexia in elderly cancer patient. Annals of Oncology1998;9(Suppl 3):72. [CN‐00305911] GambardellaA , PesceL , LammardoAM , LombardiG , BarbagalloM , TirelliP , et al. New factors involvement in elderly cancer patients with anorexia/cachexia syndrome role of megestrol acetate. Annals of Oncology2000;9 Suppl 2:22. ">Gambardella 1998</a>; <a href="./references#CD004310-bbs2-0009" title="GebbiaV , TestaA . Prospective randomised trial of two dose levels of megestrol acetate in the management of anorexia‐cachexia syndrome in patients with metastatic cancer. British Journal of Cancer1996;73:1576‐80. ">Gebbia 1996</a>; <a href="./references#CD004310-bbs2-0010" title="GiacosaA , FrascioF , SukkarSG , CostantiniM , BaraccoG , CapelliM . Changes of nutritional and psychological status after megestrol acetate treatment of cancer cachexia. Rivista Italiana Di Nutrizione Parenterale Ed Enterale.1997;15:20‐3. ">Giacosa 1997</a>; <a href="./references#CD004310-bbs2-0011" title="HeckmayrM , GatzemeierU . Treatment of cancer weight loss in patients with advanced lung cancer. Oncology1992;49(Suppl 2):32‐4. ">Heckmayr 1992</a>; <a href="./references#CD004310-bbs2-0013" title="JatoiA , WindschitlHE . Dronabinol versus megestrol acetate versus combination for cancer‐associated anorexia: A North Central Cancer Treatment Group Study. Journal of Clinical Oncology2002;20:567‐73. ">Jatoi 2002</a>; <a href="./references#CD004310-bbs2-0014" title="JatoiA , RowlandK , LoprinziCL , SloanJA , DakhilSR , MacDonaldN , et al. An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer‐associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort. Journal of Clinical Oncology2004;22:2469‐76. ">Jatoi 2004</a>; <a href="./references#CD004310-bbs2-0015" title="LesserGJ , CaseD , SharpS , ChoksiJ , MillerA , AtkinsJ , et al. A phase III randomized study comparing the effects of oxandrolone (Ox) and megestrol acetate (Meg) on weight (wt), lean body mass (LBM) and quality of life (QOL) in solid tumor patients (pts) receiving chemotherapy (chemo). Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I2006;24(18S (June 20 Suppl)):18546. ">Lesser 2006</a><a href="./references#CD004310-bbs2-0016" title="LoprinziCL , EllisonNM . Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. Journal of the National Cancer Institute1990;82:1127‐32. ">Loprinzi 1990b</a>; <a href="./references#CD004310-bbs2-0017" title="LoprinziCL , BernathAM . Phase III evaluation of 4 doses of megestrol acetate for patients with cancer anorexia and/or cachexia. Oncology1994;51:2‐7. LoprinziCL , MichalakJC , SchaidDJ , MailliardJA , AthmannLM , GoldbergRM , et al. Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia. Journal of Clinical Oncology1993;11:762‐7. [CN‐00092689] ">Loprinzi 1994</a>; <a href="./references#CD004310-bbs2-0162" title="LoprinziCL , KuglerJW , SloanJA . Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. Journal of Clinical Oncology1999;17:3299‐306. ">Loprinzi 1999</a>; <a href="./references#CD004310-bbs2-0022" title="McMillanDC , SimpsonJM . Effect of megestrol acetate on weight loss, body composition and blood screen of gastrointestinal cancer patients. Clinical Nutrition1994;13:85‐9. ">McMillan 1994</a>; <a href="./references#CD004310-bbs2-0020" title="MacbethFR , GrgeorA , Cott . A randomised study of megestrol acetate (MA) and prednisolone (P) for anorexia and weight loss in patients with lung cancer. Lung Cancer1994;1 Suppl 1:88. ">Macbeth 1994</a>; <a href="./references#CD004310-bbs2-0021" title="MadedduC , DessìM , PanzoneF , SerpeR , AntoniG , CauMC , et al. Randomized phase III clinical trial of a combined treatment with carnitine + celecoxib ± megestrol acetate for patients with cancer‐related anorexia/cachexia syndrome. Clinical Nutrition2012;31:176‐82. ">Madeddu 2012</a>; <a href="./references#CD004310-bbs2-0025" title="Sancho‐CuestaJF . Megestrol acetate and weight loss in advanced cancer [Abstract no: 1141]. European Journal of Cancer1993;29A:S204. ">Sancho‐Cuesta 1993</a><a href="./references#CD004310-bbs2-0026" title="SchmollE , WilkeH , TholeR , PreusserP ,  WildfangI ,  SchmollHJ . Megestrol acetate in cancer cachexia. Seminars in Oncology1991;18(1 Suppl 2):32‐4. [CN‐00072963] ">Schmoll 1991</a>; <a href="./references#CD004310-bbs2-0027" title="SchmollE . Risks and benefits of various therapies for cancer anorexia. Oncology1992;49:43‐5. ">Schmoll 1992</a>; <a href="./references#CD004310-bbs2-0029" title="TchekmedyianNS , HickmanM . Megestrol acetate in cancer anorexia and weight loss. Cancer1992;69:1268‐74. ">Tchekmedyian 1992</a>; <a href="./references#CD004310-bbs2-0031" title="UlutinHC , ArpaciF , PakY . Megestrol acetate for cachexia and anorexia in advanced non‐small cell lung cancer: a randomized study comparing two different doses. Tumori2002;88:277‐80. ">Ulutin 2002</a><a href="./references#CD004310-bbs2-0032" title="SeguiMA , VadellC , Gimenez‐ArnauJM , MoralesS , CireraL , BestitI , et al. Double‐blind randomized trial for the treatment of cancer related cachexia: comparison of placebo vs two different doses of megestrol acetate [Abstract 99]. Proceedings of the American Society of Clinical Oncology1996;15:529. VadellC , SeguiMA . Anticachectic efficacy of megestrol acetate at different doses and versus placebo in patients with neoplastic cachexia. American Journal of Clinical Oncology1998;21:347‐51. ">Vadell 1998</a>) assessed the effectiveness/safety of MA for anorexia‐cachexia syndrome in cancer patients where the primary site was: </p> <p> <ul id="CD004310-list-0012"> <li> <p>lung cancer(1342 patients);</p> </li> <li> <p>gastrointestinal and pancreatic cancer(928 patients);</p> </li> <li> <p>head and neck cancer(284 patients);</p> </li> <li> <p>gynaecological cancer (21 patients);</p> </li> <li> <p>non‐specified sites(907 patients).</p> </li> </ul> </p> </section> <section id="CD004310-sec-0061"> <h6 class="title">Patients with AIDS</h6> <p>Five trials (475 patients) assessed the effectiveness of MA for anorexia‐cachexia syndrome in AIDS patients (<a href="./references#CD004310-bbs2-0001" title="BatterhamM , GarsiaR . Randomised prospective medium term comparison of megestrol acetate, nandrolone decanoate and dietary therapy alone for HIV associated weight loss [abstract]. Australasian Society for HIV Medicine1997;9:91. BatterhamMJ , GarsiaR . A comparison of megestrol acetate, nandrolone decanoate and dietary counselling for HIV associated weight loss. International Journal of Andrology2001;24(4):232‐40. ">Batterham 2001</a>; <a href="./references#CD004310-bbs2-0023" title="MwamburiDM , GerriorJ , WilsonIB , ChangH , ScullyE , SabooriS , et al. Comparing megestrol acetate therapy with oxandrolone therapy for HIV‐related weight loss: similar results in 2 months. Clinical Infectious Diseases2004;38:895‐902. ">Mwamburi 2004</a>; <a href="./references#CD004310-bbs2-0024" title="OsterMH , EndersSR . Megestrol acetate in patients with AIDS and cachexia. Annals of Internal Medicine1994;121:400‐8. ">Oster 1994</a>; <a href="./references#CD004310-bbs2-0030" title="TimponeJG , WrightDJ . The safety and pharmacokinetics of single‐agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome. AIDS Research and Human Retroviruses1997;13:305‐15. ">Timpone 1997</a>; <a href="./references#CD004310-bbs2-0033" title="VonRoennJH , ArmstrongD . Megestrol acetate in patients with AIDS‐related cachexia. Annals of Internal Medicine1994;121:393‐9. ">Von Roenn 1994</a>). </p> </section> <section id="CD004310-sec-0062"> <h6 class="title">Patients with other underlying conditions</h6> <p>Four trials (271 patients) assessed the effectiveness of MA for anorexia‐cachexia syndrome in patients with the following conditions: </p> <p> <ul id="CD004310-list-0013"> <li> <p>COPD: two trials with 185 patients (<a href="./references#CD004310-bbs2-0012" title="HerrejonA , CatalanP , PalopJ , InchaurragaI , BlanquerR , LopezA . Effect of 8‐week 320 mg megestrol acetate daily administration in severe COPD and weight loss [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181:A4484. HerrejonA , PalopJ , InchaurragaI , LopezA , BañulsC , HernandezA , et al. Low doses of megestrol acetate increase weight and improve nutrition status in patients with severe chronic obstructive pulmonary disease and weight loss. Medicina Clinica2011;137:193‐8. ">Herrejon 2011</a>; <a href="./references#CD004310-bbs2-0035" title="WeisbergJ , WangerJ . Megestrol acetate stimulates weight gain and ventilation in underweight COPD patients. Chest2002;121(4):1070‐8. ">Weisberg 2002</a>); </p> </li> <li> <p>cystic fibrosis: one trial with 17 patients (<a href="./references#CD004310-bbs2-0005" title="EubanksV , KoppersmithN . Effects of megestrol acetate on weight gain, body composition, and pulmonary function in patients with cystic fibrosis. Journal of Pediatrics2002;140:439‐44. ">Eubanks 2002</a>); </p> </li> <li> <p>elderly: one trial with 69 patients (<a href="./references#CD004310-bbs2-0036" title="YehSS , LovittS , SchusterMW . Usage of megestrol acetate in the treatment of anorexia‐cachexia syndrome in the elderly. Journal of Nutrition, Health and Aging2009;13:448‐54. YehSS , WuSY . Improvement in quality of life measures and stimulation of weight gain after treatment with megestrol acetate oral suspension in geriatric cachexia: results of a double‐blind, placebo‐controlled study. Journal of the American Geriatrics Society2000;48(5):485‐92. YehSS , WuSY , LevineDM , ParkerTS , OlsonJS , StevensMR , et al. The correlation of cytokine levels with body weight after megestrol acetate treatment in geriatric patients. Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2001;56:M48‐54. ">Yeh 2000</a>). </p> </li> </ul> </p> </section> </section> <section id="CD004310-sec-0063"> <h5 class="title">Dose</h5> <p>Across the studies, the dose of MA ranged from 100 mg per day to 1600 mg per day in at least one of the study arms. </p> <p>The doses of MA assessed were as follows:</p> <p> <ul id="CD004310-list-0014"> <li> <p><i>400 mg per day or less</i> </p> </li> </ul> </p> <p>Seventeen trials: (<a href="./references#CD004310-bbs2-0001" title="BatterhamM , GarsiaR . Randomised prospective medium term comparison of megestrol acetate, nandrolone decanoate and dietary therapy alone for HIV associated weight loss [abstract]. Australasian Society for HIV Medicine1997;9:91. BatterhamMJ , GarsiaR . A comparison of megestrol acetate, nandrolone decanoate and dietary counselling for HIV associated weight loss. International Journal of Andrology2001;24(4):232‐40. ">Batterham 2001</a> 400 mg per day; <a href="./references#CD004310-bbs2-0002" title="BellerE , TattersallM . Improved quality of life with megestrol acetate in patients with endocrine‐insensitive advanced cancer: a randomised placebo‐controlled trial. Annals of Oncology1997;8:277‐83. ">Beller 1997</a> 160 mg per day; <a href="./references#CD004310-bbs2-0004" title="DeConnoF , MartiniC . Megestrol acetate for anorexia in patients with far‐advanced cancer: a double‐blind controlled clinical trial. European Journal of Cancer1998;34:1705‐9. ">De Conno 1998</a> 320 mg per day; <a href="./references#CD004310-bbs2-0006" title="FeliuJ , Gonzalez‐BaronM . Usefulness of megestrol acetate in cancer cachexia and anorexia. A placebo controlled study. American Journal of Clinical Oncology1992;15:436‐40. Gonzalez BaronM , FeliuJ , ZamoraP , ArtalA , GarridoP , ChaconI . Usefulness of megestrol acetate on cancer cachexia: a double blind randomized study. Annals of Oncology1990;1:29‐31. ">Feliu 1992</a> 240 mg per day; <a href="./references#CD004310-bbs2-0007" title="FietkauR , RieplM . Supportive treatment with megestrol acetate during radio (chemo) therapy. A randomised trial. Strahlentherapie und Onkologie1996;172:162‐8. FietkauR , RieplM , KettnerH , HinkeA , SauerR . Supportive use of megestrol acetate in patients with head and neck cancer during radio(chemo)therapy. European Journal of Cancer1997;33:75‐9. [CN‐00137738] ">Fietkau 1996</a> 160 mg per day; <a href="./references#CD004310-bbs2-0009" title="GebbiaV , TestaA . Prospective randomised trial of two dose levels of megestrol acetate in the management of anorexia‐cachexia syndrome in patients with metastatic cancer. British Journal of Cancer1996;73:1576‐80. ">Gebbia 1996</a> 160 mg and 320 mg per day; <a href="./references#CD004310-bbs2-0010" title="GiacosaA , FrascioF , SukkarSG , CostantiniM , BaraccoG , CapelliM . Changes of nutritional and psychological status after megestrol acetate treatment of cancer cachexia. Rivista Italiana Di Nutrizione Parenterale Ed Enterale.1997;15:20‐3. ">Giacosa 1997</a> 320 mg per day; <a href="./references#CD004310-bbs2-0011" title="HeckmayrM , GatzemeierU . Treatment of cancer weight loss in patients with advanced lung cancer. Oncology1992;49(Suppl 2):32‐4. ">Heckmayr 1992</a> 160 mg per day; <a href="./references#CD004310-bbs2-0012" title="HerrejonA , CatalanP , PalopJ , InchaurragaI , BlanquerR , LopezA . Effect of 8‐week 320 mg megestrol acetate daily administration in severe COPD and weight loss [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181:A4484. HerrejonA , PalopJ , InchaurragaI , LopezA , BañulsC , HernandezA , et al. Low doses of megestrol acetate increase weight and improve nutrition status in patients with severe chronic obstructive pulmonary disease and weight loss. Medicina Clinica2011;137:193‐8. ">Herrejon 2011</a> 320 mg per day; <a href="./references#CD004310-bbs2-0017" title="LoprinziCL , BernathAM . Phase III evaluation of 4 doses of megestrol acetate for patients with cancer anorexia and/or cachexia. Oncology1994;51:2‐7. LoprinziCL , MichalakJC , SchaidDJ , MailliardJA , AthmannLM , GoldbergRM , et al. Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia. Journal of Clinical Oncology1993;11:762‐7. [CN‐00092689] ">Loprinzi 1994</a> 160 mg per day; <a href="./references#CD004310-bbs2-0021" title="MadedduC , DessìM , PanzoneF , SerpeR , AntoniG , CauMC , et al. Randomized phase III clinical trial of a combined treatment with carnitine + celecoxib ± megestrol acetate for patients with cancer‐related anorexia/cachexia syndrome. Clinical Nutrition2012;31:176‐82. ">Madeddu 2012</a> 320 mg/per day <a href="./references#CD004310-bbs2-0025" title="Sancho‐CuestaJF . Megestrol acetate and weight loss in advanced cancer [Abstract no: 1141]. European Journal of Cancer1993;29A:S204. ">Sancho‐Cuesta 1993</a> 160 mg per day; <a href="./references#CD004310-bbs2-0028" title="SummerbellCD , YouleM , McDonaldV , CatalanJ , GazzardBG . Megestrol acetate vs cyproheptadine in the treatment of weight loss associated with HIV infection. International Journal of STD and AIDS1992;3:278‐80. ">Summerbell 1992</a> 40 mg daily on alternate weeks to a maximum of 160 mg daily; <a href="./references#CD004310-bbs2-0030" title="TimponeJG , WrightDJ . The safety and pharmacokinetics of single‐agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome. AIDS Research and Human Retroviruses1997;13:305‐15. ">Timpone 1997</a> 250 mg per day; <a href="./references#CD004310-bbs2-0031" title="UlutinHC , ArpaciF , PakY . Megestrol acetate for cachexia and anorexia in advanced non‐small cell lung cancer: a randomized study comparing two different doses. Tumori2002;88:277‐80. ">Ulutin 2002</a> 160 mg and 320 mg per day; <a href="./references#CD004310-bbs2-0032" title="SeguiMA , VadellC , Gimenez‐ArnauJM , MoralesS , CireraL , BestitI , et al. Double‐blind randomized trial for the treatment of cancer related cachexia: comparison of placebo vs two different doses of megestrol acetate [Abstract 99]. Proceedings of the American Society of Clinical Oncology1996;15:529. VadellC , SeguiMA . Anticachectic efficacy of megestrol acetate at different doses and versus placebo in patients with neoplastic cachexia. American Journal of Clinical Oncology1998;21:347‐51. ">Vadell 1998</a> 160 mg per day; <a href="./references#CD004310-bbs2-0033" title="VonRoennJH , ArmstrongD . Megestrol acetate in patients with AIDS‐related cachexia. Annals of Internal Medicine1994;121:393‐9. ">Von Roenn 1994</a> 100 mg and 400 mg per day). </p> <p> <ul id="CD004310-list-0015"> <li> <p><i>480 mg per day</i> </p> </li> </ul> </p> <p>Seven trials: <a href="./references#CD004310-bbs2-0002" title="BellerE , TattersallM . Improved quality of life with megestrol acetate in patients with endocrine‐insensitive advanced cancer: a randomised placebo‐controlled trial. Annals of Oncology1997;8:277‐83. ">Beller 1997</a>; <a href="./references#CD004310-bbs2-0011" title="HeckmayrM , GatzemeierU . Treatment of cancer weight loss in patients with advanced lung cancer. Oncology1992;49(Suppl 2):32‐4. ">Heckmayr 1992</a>; <a href="./references#CD004310-bbs2-0017" title="LoprinziCL , BernathAM . Phase III evaluation of 4 doses of megestrol acetate for patients with cancer anorexia and/or cachexia. Oncology1994;51:2‐7. LoprinziCL , MichalakJC , SchaidDJ , MailliardJA , AthmannLM , GoldbergRM , et al. Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia. Journal of Clinical Oncology1993;11:762‐7. [CN‐00092689] ">Loprinzi 1994</a>; <a href="./references#CD004310-bbs2-0022" title="McMillanDC , SimpsonJM . Effect of megestrol acetate on weight loss, body composition and blood screen of gastrointestinal cancer patients. Clinical Nutrition1994;13:85‐9. ">McMillan 1994</a>; <a href="./references#CD004310-bbs2-0026" title="SchmollE , WilkeH , TholeR , PreusserP ,  WildfangI ,  SchmollHJ . Megestrol acetate in cancer cachexia. Seminars in Oncology1991;18(1 Suppl 2):32‐4. [CN‐00072963] ">Schmoll 1991</a>; <a href="./references#CD004310-bbs2-0027" title="SchmollE . Risks and benefits of various therapies for cancer anorexia. Oncology1992;49:43‐5. ">Schmoll 1992</a>; <a href="./references#CD004310-bbs2-0032" title="SeguiMA , VadellC , Gimenez‐ArnauJM , MoralesS , CireraL , BestitI , et al. Double‐blind randomized trial for the treatment of cancer related cachexia: comparison of placebo vs two different doses of megestrol acetate [Abstract 99]. Proceedings of the American Society of Clinical Oncology1996;15:529. VadellC , SeguiMA . Anticachectic efficacy of megestrol acetate at different doses and versus placebo in patients with neoplastic cachexia. American Journal of Clinical Oncology1998;21:347‐51. ">Vadell 1998</a>. </p> <p> <ul id="CD004310-list-0016"> <li> <p><i>575 to 600 mg per day</i> </p> </li> </ul> </p> <p>Two trials: (<a href="./references#CD004310-bbs2-0034" title="CillaDD , GutierrezJL , KristensenA , KramerLD . The safety of megestrol acetate concentrated suspension (MA‐CS) and megestrol acetate oral suspension (MA‐OS) in a pilot study in patients with HIV‐associated unintended weight loss (UWL) [Abstract]. Blood2006;108:43. WankeC , GutierrezJ , KristensenA , MacEarchern , L . Safety and efficacy of two preparations of megestrol acetate in HIV‐infected individuals with weight loss in Africa, India, and the United States. Journal of Applied Research2007;7:206‐16. ">Wanke 2007</a> 575 mg per day; <a href="./references#CD004310-bbs2-0014" title="JatoiA , RowlandK , LoprinziCL , SloanJA , DakhilSR , MacDonaldN , et al. An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer‐associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort. Journal of Clinical Oncology2004;22:2469‐76. ">Jatoi 2004</a> 600 mg per day). </p> <p> <ul id="CD004310-list-0017"> <li> <p><i>750 to 800 mg per day</i> </p> </li> </ul> </p> <p>Ten trials: (<a href="./references#CD004310-bbs2-0030" title="TimponeJG , WrightDJ . The safety and pharmacokinetics of single‐agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome. AIDS Research and Human Retroviruses1997;13:305‐15. ">Timpone 1997</a> 750 mg per day; <a href="./references#CD004310-bbs2-0013" title="JatoiA , WindschitlHE . Dronabinol versus megestrol acetate versus combination for cancer‐associated anorexia: A North Central Cancer Treatment Group Study. Journal of Clinical Oncology2002;20:567‐73. ">Jatoi 2002</a>; <a href="./references#CD004310-bbs2-0016" title="LoprinziCL , EllisonNM . Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. Journal of the National Cancer Institute1990;82:1127‐32. ">Loprinzi 1990b</a>; <a href="./references#CD004310-bbs2-0017" title="LoprinziCL , BernathAM . Phase III evaluation of 4 doses of megestrol acetate for patients with cancer anorexia and/or cachexia. Oncology1994;51:2‐7. LoprinziCL , MichalakJC , SchaidDJ , MailliardJA , AthmannLM , GoldbergRM , et al. Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia. Journal of Clinical Oncology1993;11:762‐7. [CN‐00092689] ">Loprinzi 1994</a>; <a href="./references#CD004310-bbs2-0162" title="LoprinziCL , KuglerJW , SloanJA . Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. Journal of Clinical Oncology1999;17:3299‐306. ">Loprinzi 1999</a>; <a href="./references#CD004310-bbs2-0023" title="MwamburiDM , GerriorJ , WilsonIB , ChangH , ScullyE , SabooriS , et al. Comparing megestrol acetate therapy with oxandrolone therapy for HIV‐related weight loss: similar results in 2 months. Clinical Infectious Diseases2004;38:895‐902. ">Mwamburi 2004</a>; <a href="./references#CD004310-bbs2-0024" title="OsterMH , EndersSR . Megestrol acetate in patients with AIDS and cachexia. Annals of Internal Medicine1994;121:400‐8. ">Oster 1994</a>; <a href="./references#CD004310-bbs2-0033" title="VonRoennJH , ArmstrongD . Megestrol acetate in patients with AIDS‐related cachexia. Annals of Internal Medicine1994;121:393‐9. ">Von Roenn 1994</a>; <a href="./references#CD004310-bbs2-0035" title="WeisbergJ , WangerJ . Megestrol acetate stimulates weight gain and ventilation in underweight COPD patients. Chest2002;121(4):1070‐8. ">Weisberg 2002</a>; <a href="./references#CD004310-bbs2-0036" title="YehSS , LovittS , SchusterMW . Usage of megestrol acetate in the treatment of anorexia‐cachexia syndrome in the elderly. Journal of Nutrition, Health and Aging2009;13:448‐54. YehSS , WuSY . Improvement in quality of life measures and stimulation of weight gain after treatment with megestrol acetate oral suspension in geriatric cachexia: results of a double‐blind, placebo‐controlled study. Journal of the American Geriatrics Society2000;48(5):485‐92. YehSS , WuSY , LevineDM , ParkerTS , OlsonJS , StevensMR , et al. The correlation of cytokine levels with body weight after megestrol acetate treatment in geriatric patients. Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2001;56:M48‐54. ">Yeh 2000</a> (all 800 mg per day)). </p> <p> <ul id="CD004310-list-0018"> <li> <p><i>1280 mg per day</i> </p> </li> </ul> </p> <p>One trial: <a href="./references#CD004310-bbs2-0017" title="LoprinziCL , BernathAM . Phase III evaluation of 4 doses of megestrol acetate for patients with cancer anorexia and/or cachexia. Oncology1994;51:2‐7. LoprinziCL , MichalakJC , SchaidDJ , MailliardJA , AthmannLM , GoldbergRM , et al. Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia. Journal of Clinical Oncology1993;11:762‐7. [CN‐00092689] ">Loprinzi 1994</a>. </p> <p> <ul id="CD004310-list-0019"> <li> <p><i>1600 mg per day</i> </p> </li> </ul> </p> <p>One trial: <a href="./references#CD004310-bbs2-0029" title="TchekmedyianNS , HickmanM . Megestrol acetate in cancer anorexia and weight loss. Cancer1992;69:1268‐74. ">Tchekmedyian 1992</a>. </p> <p> <ul id="CD004310-list-0020"> <li> <p>One trial in children with cystic fibrosis assessed MA at a dose of 10 mg/kg per day (<a href="./references#CD004310-bbs2-0005" title="EubanksV , KoppersmithN . Effects of megestrol acetate on weight gain, body composition, and pulmonary function in patients with cystic fibrosis. Journal of Pediatrics2002;140:439‐44. ">Eubanks 2002</a>). </p> </li> </ul> </p> </section> <section id="CD004310-sec-0064"> <h5 class="title">Study duration</h5> <p>The study duration ranged from two weeks to 24 weeks. The median trial duration time was eight weeks. Seventeen trials had a duration of 12 weeks or more. (See <a href="./references#CD004310-sec-0121" title="">Characteristics of included studies</a> table). </p> <p> <ul id="CD004310-list-0021"> <li> <p>Final assessment at two weeks (<a href="./references#CD004310-bbs2-0002" title="BellerE , TattersallM . Improved quality of life with megestrol acetate in patients with endocrine‐insensitive advanced cancer: a randomised placebo‐controlled trial. Annals of Oncology1997;8:277‐83. ">Beller 1997</a>; <a href="./references#CD004310-bbs2-0004" title="DeConnoF , MartiniC . Megestrol acetate for anorexia in patients with far‐advanced cancer: a double‐blind controlled clinical trial. European Journal of Cancer1998;34:1705‐9. ">De Conno 1998</a>). </p> </li> <li> <p>Assessment at four weeks/one month (<a href="./references#CD004310-bbs2-0009" title="GebbiaV , TestaA . Prospective randomised trial of two dose levels of megestrol acetate in the management of anorexia‐cachexia syndrome in patients with metastatic cancer. British Journal of Cancer1996;73:1576‐80. ">Gebbia 1996</a>; <a href="./references#CD004310-bbs2-0011" title="HeckmayrM , GatzemeierU . Treatment of cancer weight loss in patients with advanced lung cancer. Oncology1992;49(Suppl 2):32‐4. ">Heckmayr 1992</a>; <a href="./references#CD004310-bbs2-0016" title="LoprinziCL , EllisonNM . Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. Journal of the National Cancer Institute1990;82:1127‐32. ">Loprinzi 1990b</a>). </p> </li> <li> <p>Assessment at six weeks (<a href="./references#CD004310-bbs2-0007" title="FietkauR , RieplM . Supportive treatment with megestrol acetate during radio (chemo) therapy. A randomised trial. Strahlentherapie und Onkologie1996;172:162‐8. FietkauR , RieplM , KettnerH , HinkeA , SauerR . Supportive use of megestrol acetate in patients with head and neck cancer during radio(chemo)therapy. European Journal of Cancer1997;33:75‐9. [CN‐00137738] ">Fietkau 1996</a>; <a href="./references#CD004310-bbs2-0029" title="TchekmedyianNS , HickmanM . Megestrol acetate in cancer anorexia and weight loss. Cancer1992;69:1268‐74. ">Tchekmedyian 1992</a>). </p> </li> <li> <p>Assessment at eight weeks/two months (<a href="./references#CD004310-bbs2-0006" title="FeliuJ , Gonzalez‐BaronM . Usefulness of megestrol acetate in cancer cachexia and anorexia. A placebo controlled study. American Journal of Clinical Oncology1992;15:436‐40. Gonzalez BaronM , FeliuJ , ZamoraP , ArtalA , GarridoP , ChaconI . Usefulness of megestrol acetate on cancer cachexia: a double blind randomized study. Annals of Oncology1990;1:29‐31. ">Feliu 1992</a>; <a href="./references#CD004310-bbs2-0013" title="JatoiA , WindschitlHE . Dronabinol versus megestrol acetate versus combination for cancer‐associated anorexia: A North Central Cancer Treatment Group Study. Journal of Clinical Oncology2002;20:567‐73. ">Jatoi 2002</a>; <a href="./references#CD004310-bbs2-0012" title="HerrejonA , CatalanP , PalopJ , InchaurragaI , BlanquerR , LopezA . Effect of 8‐week 320 mg megestrol acetate daily administration in severe COPD and weight loss [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181:A4484. HerrejonA , PalopJ , InchaurragaI , LopezA , BañulsC , HernandezA , et al. Low doses of megestrol acetate increase weight and improve nutrition status in patients with severe chronic obstructive pulmonary disease and weight loss. Medicina Clinica2011;137:193‐8. ">Herrejon 2011</a>; <a href="./references#CD004310-bbs2-0020" title="MacbethFR , GrgeorA , Cott . A randomised study of megestrol acetate (MA) and prednisolone (P) for anorexia and weight loss in patients with lung cancer. Lung Cancer1994;1 Suppl 1:88. ">Macbeth 1994</a>; <a href="./references#CD004310-bbs2-0023" title="MwamburiDM , GerriorJ , WilsonIB , ChangH , ScullyE , SabooriS , et al. Comparing megestrol acetate therapy with oxandrolone therapy for HIV‐related weight loss: similar results in 2 months. Clinical Infectious Diseases2004;38:895‐902. ">Mwamburi 2004</a>; <a href="./references#CD004310-bbs2-0017" title="LoprinziCL , BernathAM . Phase III evaluation of 4 doses of megestrol acetate for patients with cancer anorexia and/or cachexia. Oncology1994;51:2‐7. LoprinziCL , MichalakJC , SchaidDJ , MailliardJA , AthmannLM , GoldbergRM , et al. Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia. Journal of Clinical Oncology1993;11:762‐7. [CN‐00092689] ">Loprinzi 1994</a>; <a href="./references#CD004310-bbs2-0019" title="LoprinziCL , KuglerJ , SloanJ , MailliardJ , KrookJ , WilwerdingM , et al. Phase III randomized comparison of megestrol acetate, dexamethasone, and fluoxymesterone for the treatment of cancer anorexia/cachexia [Meeting abstract no 167]. ASCO Annual Meeting. 1997. LoprinziCL , KuglerJW . Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. Journal of Clinical Oncology1999;17:3299‐306. ">Loprinzi 1999b</a>; <a href="./references#CD004310-bbs2-0026" title="SchmollE , WilkeH , TholeR , PreusserP ,  WildfangI ,  SchmollHJ . Megestrol acetate in cancer cachexia. Seminars in Oncology1991;18(1 Suppl 2):32‐4. [CN‐00072963] ">Schmoll 1991</a>; <a href="./references#CD004310-bbs2-0027" title="SchmollE . Risks and benefits of various therapies for cancer anorexia. Oncology1992;49:43‐5. ">Schmoll 1992</a>; <a href="./references#CD004310-bbs2-0035" title="WeisbergJ , WangerJ . Megestrol acetate stimulates weight gain and ventilation in underweight COPD patients. Chest2002;121(4):1070‐8. ">Weisberg 2002</a>). </p> </li> <li> <p>Assessment at 12 weeks/three months (<a href="./references#CD004310-bbs2-0001" title="BatterhamM , GarsiaR . Randomised prospective medium term comparison of megestrol acetate, nandrolone decanoate and dietary therapy alone for HIV associated weight loss [abstract]. Australasian Society for HIV Medicine1997;9:91. BatterhamMJ , GarsiaR . A comparison of megestrol acetate, nandrolone decanoate and dietary counselling for HIV associated weight loss. International Journal of Andrology2001;24(4):232‐40. ">Batterham 2001</a>; <a href="./references#CD004310-bbs2-0003" title="Casado HerráezA . Phase II randomized study of two dose levels of megestrol acetate versus placebo for the treatment of anorexia and cachexia in patients with locoregional advanced or metastatic cancer [Estudio de fase II randomizado de dos niveles posológicos de acetato de Megestrol versus placebo para el tratamiento de la anorexia y la caquexia en pacientes con cáncer locoregional avanzado o metastásico. (Tesis de Doctorado ‐ Universidad Complutense Madrid)]. Available from http://eprints.ucm.es/8119/1/T30450.pdf 2008 (accessed 24 December 2011). ">Casado 2008</a>; <a href="./references#CD004310-bbs2-0014" title="JatoiA , RowlandK , LoprinziCL , SloanJA , DakhilSR , MacDonaldN , et al. An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer‐associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort. Journal of Clinical Oncology2004;22:2469‐76. ">Jatoi 2004</a>; <a href="./references#CD004310-bbs2-0015" title="LesserGJ , CaseD , SharpS , ChoksiJ , MillerA , AtkinsJ , et al. A phase III randomized study comparing the effects of oxandrolone (Ox) and megestrol acetate (Meg) on weight (wt), lean body mass (LBM) and quality of life (QOL) in solid tumor patients (pts) receiving chemotherapy (chemo). Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I2006;24(18S (June 20 Suppl)):18546. ">Lesser 2006</a>; <a href="./references#CD004310-bbs2-0022" title="McMillanDC , SimpsonJM . Effect of megestrol acetate on weight loss, body composition and blood screen of gastrointestinal cancer patients. Clinical Nutrition1994;13:85‐9. ">McMillan 1994</a>; <a href="./references#CD004310-bbs2-0024" title="OsterMH , EndersSR . Megestrol acetate in patients with AIDS and cachexia. Annals of Internal Medicine1994;121:400‐8. ">Oster 1994</a>; <a href="./references#CD004310-bbs2-0030" title="TimponeJG , WrightDJ . The safety and pharmacokinetics of single‐agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome. AIDS Research and Human Retroviruses1997;13:305‐15. ">Timpone 1997</a>; <a href="./references#CD004310-bbs2-0031" title="UlutinHC , ArpaciF , PakY . Megestrol acetate for cachexia and anorexia in advanced non‐small cell lung cancer: a randomized study comparing two different doses. Tumori2002;88:277‐80. ">Ulutin 2002</a>; <a href="./references#CD004310-bbs2-0032" title="SeguiMA , VadellC , Gimenez‐ArnauJM , MoralesS , CireraL , BestitI , et al. Double‐blind randomized trial for the treatment of cancer related cachexia: comparison of placebo vs two different doses of megestrol acetate [Abstract 99]. Proceedings of the American Society of Clinical Oncology1996;15:529. VadellC , SeguiMA . Anticachectic efficacy of megestrol acetate at different doses and versus placebo in patients with neoplastic cachexia. American Journal of Clinical Oncology1998;21:347‐51. ">Vadell 1998</a>; <a href="./references#CD004310-bbs2-0033" title="VonRoennJH , ArmstrongD . Megestrol acetate in patients with AIDS‐related cachexia. Annals of Internal Medicine1994;121:393‐9. ">Von Roenn 1994</a>; <a href="./references#CD004310-bbs2-0034" title="CillaDD , GutierrezJL , KristensenA , KramerLD . The safety of megestrol acetate concentrated suspension (MA‐CS) and megestrol acetate oral suspension (MA‐OS) in a pilot study in patients with HIV‐associated unintended weight loss (UWL) [Abstract]. Blood2006;108:43. WankeC , GutierrezJ , KristensenA , MacEarchern , L . Safety and efficacy of two preparations of megestrol acetate in HIV‐infected individuals with weight loss in Africa, India, and the United States. Journal of Applied Research2007;7:206‐16. ">Wanke 2007</a>). </p> </li> <li> <p>Assessment at 13 to 16 weeks (<a href="./references#CD004310-bbs2-0021" title="MadedduC , DessìM , PanzoneF , SerpeR , AntoniG , CauMC , et al. Randomized phase III clinical trial of a combined treatment with carnitine + celecoxib ± megestrol acetate for patients with cancer‐related anorexia/cachexia syndrome. Clinical Nutrition2012;31:176‐82. ">Madeddu 2012</a>; <a href="./references#CD004310-bbs2-0028" title="SummerbellCD , YouleM , McDonaldV , CatalanJ , GazzardBG . Megestrol acetate vs cyproheptadine in the treatment of weight loss associated with HIV infection. International Journal of STD and AIDS1992;3:278‐80. ">Summerbell 1992</a>; <a href="./references#CD004310-bbs2-0036" title="YehSS , LovittS , SchusterMW . Usage of megestrol acetate in the treatment of anorexia‐cachexia syndrome in the elderly. Journal of Nutrition, Health and Aging2009;13:448‐54. YehSS , WuSY . Improvement in quality of life measures and stimulation of weight gain after treatment with megestrol acetate oral suspension in geriatric cachexia: results of a double‐blind, placebo‐controlled study. Journal of the American Geriatrics Society2000;48(5):485‐92. YehSS , WuSY , LevineDM , ParkerTS , OlsonJS , StevensMR , et al. The correlation of cytokine levels with body weight after megestrol acetate treatment in geriatric patients. Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2001;56:M48‐54. ">Yeh 2000</a>). </p> </li> <li> <p>Assessment at six months or more (<a href="./references#CD004310-bbs2-0005" title="EubanksV , KoppersmithN . Effects of megestrol acetate on weight gain, body composition, and pulmonary function in patients with cystic fibrosis. Journal of Pediatrics2002;140:439‐44. ">Eubanks 2002</a>; <a href="./references#CD004310-bbs2-0025" title="Sancho‐CuestaJF . Megestrol acetate and weight loss in advanced cancer [Abstract no: 1141]. European Journal of Cancer1993;29A:S204. ">Sancho‐Cuesta 1993</a>). </p> </li> </ul> </p> </section> </section> <section id="CD004310-sec-0065"> <h4 class="title">Excluded studies</h4> <p>We excluded a total of 110 studies.</p> <p>In the present update we excluded the following studies that had been included in the previous review: <a href="./references#CD004310-bbs2-0047" title="BrueraE , McMillanK . A controlled trial of megestrol acetate on appetite, caloric intake, nutritional status, and other symptoms in patients with advanced cancer. Cancer1990;66:1279‐82. ">Bruera 1990</a>(cross‐over study); <a href="./references#CD004310-bbs2-0049" title="BrueraE , ScottE . Effectiveness of megestrol acetate in patients with advanced cancer: a randomized, double‐blind, crossover study. Cancer Prevention and Control1998;2(2):74‐8. ">Bruera 1998</a>(cross‐over study); <a href="./references#CD004310-bbs2-0055" title="ChenHC ,  LeungSW ,  WangCJ ,  SunLM ,  FangFM ,  HsuJH . Effect of megestrol acetate and prepulsid on nutritional improvement in patients with head and neck cancers undergoing radiotherapy. Radiotherapy and Oncology1997;43:75‐9. ">Chen 1997</a> (a trial of patients with head and neck cancers but only 18% were underweight; moreover 11% were overweight); <a href="./references#CD004310-bbs2-0062" title="ErkurtE , ErkisiM , TunaliC . Supportive treatment in weight‐losing cancer patients due to the additive adverse effects of radiation treatment and/or chemotherapy. Journal of Experimental &amp; Clinical Cancer Research 2000;19:431‐9. ">Erkurt 2000</a> (this study included a proportion of patients without weight loss in the previous six months and in addition patients were not balanced in both arms, specifically while in the MA arm 27% of the patients received oral nutrition support, in the placebo group 72% of patients received it); <a href="./references#CD004310-bbs2-0084" title="LaiYL , FangFM , YehCY . Management of anorexic patients in radiotherapy: a prospective randomized comparison of megestrol and prednisolone. Journal of Pain and Symptom Management1994;9:265‐8. ">Lai 1994</a> (patients did not have cachexia or any weight loss); <a href="./references#CD004310-bbs2-0098" title="MarchandV , BakerSS . Randomized, double‐blind, placebo‐controlled pilot trial of megestrol acetate in malnourished children with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2000;31:264‐9. ">Marchand 2000</a> (cross‐over study); <a href="./references#CD004310-bbs2-0102" title="McQuellonRP , MooseDB , RussellGB , CaseLD , GrevenK , StevensM , et al. Supportive use of megestrol acetate (Megace) with head/neck and lung cancer patients receiving radiation therapy. International Journal of Radiation Oncology, Biology, Physics2002;52:1180‐5. ">McQuellon 2002</a> (patients were not described as patients with cachexia); <a href="./references#CD004310-bbs2-0117" title="RowlandKM , LoprinziCL . Randomized double‐blind placebo‐controlled trial of cisplatin and etoposide plus megestrol acetate/placebo in extensive‐stage small‐cell lung cancer: a North Central Cancer Treatment Group Study. Journal of Clinical Oncology1996;14:135‐41. ">Rowland 1996</a> (patients were not described as patients with cachexia and anorexia); and <a href="./references#CD004310-bbs2-0146" title="ZecaE , MartiniC , VenturinoP , TedeschiM , VentafridaV , DeConnoF . Efficacy of megestrol acetate on anorexia in patients with advanced non hormone‐related tumors: a double‐blind placebo controlled clinical trial. European Journal of Cancer1995;31A:S261‐2. [CN‐00519065] ">Zeca 1995</a> (a trial that included patients with cancer and anorexia, but cachexia was not needed as a inclusion criterion). </p> </section> </section> <section id="CD004310-sec-0066"> <h3 class="title">Risk of bias in included studies</h3> <p>We assessed the methodological quality of the included studies using the Oxford Quality Scale (<a href="./references#CD004310-bbs2-0157" title="JadadA , MooreRA , Carroll D ,  JenkinsonC ,  ReynoldsDJ ,  GavaghanDJ ,  etal . Assessing the quality of reports on randomized clinical trials: is blinding necessary?. Controlled Clinical Trials1996;170:1‐12. ">Jadad 1996</a>). The review authors scored each report independently for quality using the three‐item scale described in the <a href="#CD004310-sec-0029">Methods</a> section above and agreed a 'consensus' score. The scores for methodological quality are shown in <a href="./references#CD004310-sec-0121" title="">Characteristics of included studies</a> . </p> <p>Eighteen trials (51%) scored three or more out of a maximum of five: <a href="./references#CD004310-bbs2-0002" title="BellerE , TattersallM . Improved quality of life with megestrol acetate in patients with endocrine‐insensitive advanced cancer: a randomised placebo‐controlled trial. Annals of Oncology1997;8:277‐83. ">Beller 1997</a>; <a href="./references#CD004310-bbs2-0004" title="DeConnoF , MartiniC . Megestrol acetate for anorexia in patients with far‐advanced cancer: a double‐blind controlled clinical trial. European Journal of Cancer1998;34:1705‐9. ">De Conno 1998</a>; <a href="./references#CD004310-bbs2-0005" title="EubanksV , KoppersmithN . Effects of megestrol acetate on weight gain, body composition, and pulmonary function in patients with cystic fibrosis. Journal of Pediatrics2002;140:439‐44. ">Eubanks 2002</a>; <a href="./references#CD004310-bbs2-0006" title="FeliuJ , Gonzalez‐BaronM . Usefulness of megestrol acetate in cancer cachexia and anorexia. A placebo controlled study. American Journal of Clinical Oncology1992;15:436‐40. Gonzalez BaronM , FeliuJ , ZamoraP , ArtalA , GarridoP , ChaconI . Usefulness of megestrol acetate on cancer cachexia: a double blind randomized study. Annals of Oncology1990;1:29‐31. ">Feliu 1992</a>; <a href="./references#CD004310-bbs2-0007" title="FietkauR , RieplM . Supportive treatment with megestrol acetate during radio (chemo) therapy. A randomised trial. Strahlentherapie und Onkologie1996;172:162‐8. FietkauR , RieplM , KettnerH , HinkeA , SauerR . Supportive use of megestrol acetate in patients with head and neck cancer during radio(chemo)therapy. European Journal of Cancer1997;33:75‐9. [CN‐00137738] ">Fietkau 1996</a>; <a href="./references#CD004310-bbs2-0012" title="HerrejonA , CatalanP , PalopJ , InchaurragaI , BlanquerR , LopezA . Effect of 8‐week 320 mg megestrol acetate daily administration in severe COPD and weight loss [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181:A4484. HerrejonA , PalopJ , InchaurragaI , LopezA , BañulsC , HernandezA , et al. Low doses of megestrol acetate increase weight and improve nutrition status in patients with severe chronic obstructive pulmonary disease and weight loss. Medicina Clinica2011;137:193‐8. ">Herrejon 2011</a>; <a href="./references#CD004310-bbs2-0013" title="JatoiA , WindschitlHE . Dronabinol versus megestrol acetate versus combination for cancer‐associated anorexia: A North Central Cancer Treatment Group Study. Journal of Clinical Oncology2002;20:567‐73. ">Jatoi 2002</a>; <a href="./references#CD004310-bbs2-0014" title="JatoiA , RowlandK , LoprinziCL , SloanJA , DakhilSR , MacDonaldN , et al. An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer‐associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort. Journal of Clinical Oncology2004;22:2469‐76. ">Jatoi 2004</a>; <a href="./references#CD004310-bbs2-0016" title="LoprinziCL , EllisonNM . Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. Journal of the National Cancer Institute1990;82:1127‐32. ">Loprinzi 1990b</a>; <a href="./references#CD004310-bbs2-0022" title="McMillanDC , SimpsonJM . Effect of megestrol acetate on weight loss, body composition and blood screen of gastrointestinal cancer patients. Clinical Nutrition1994;13:85‐9. ">McMillan 1994</a>; <a href="./references#CD004310-bbs2-0023" title="MwamburiDM , GerriorJ , WilsonIB , ChangH , ScullyE , SabooriS , et al. Comparing megestrol acetate therapy with oxandrolone therapy for HIV‐related weight loss: similar results in 2 months. Clinical Infectious Diseases2004;38:895‐902. ">Mwamburi 2004</a>; <a href="./references#CD004310-bbs2-0024" title="OsterMH , EndersSR . Megestrol acetate in patients with AIDS and cachexia. Annals of Internal Medicine1994;121:400‐8. ">Oster 1994</a>; <a href="./references#CD004310-bbs2-0029" title="TchekmedyianNS , HickmanM . Megestrol acetate in cancer anorexia and weight loss. Cancer1992;69:1268‐74. ">Tchekmedyian 1992</a>; <a href="./references#CD004310-bbs2-0030" title="TimponeJG , WrightDJ . The safety and pharmacokinetics of single‐agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome. AIDS Research and Human Retroviruses1997;13:305‐15. ">Timpone 1997</a>; <a href="./references#CD004310-bbs2-0032" title="SeguiMA , VadellC , Gimenez‐ArnauJM , MoralesS , CireraL , BestitI , et al. Double‐blind randomized trial for the treatment of cancer related cachexia: comparison of placebo vs two different doses of megestrol acetate [Abstract 99]. Proceedings of the American Society of Clinical Oncology1996;15:529. VadellC , SeguiMA . Anticachectic efficacy of megestrol acetate at different doses and versus placebo in patients with neoplastic cachexia. American Journal of Clinical Oncology1998;21:347‐51. ">Vadell 1998</a>; <a href="./references#CD004310-bbs2-0034" title="CillaDD , GutierrezJL , KristensenA , KramerLD . The safety of megestrol acetate concentrated suspension (MA‐CS) and megestrol acetate oral suspension (MA‐OS) in a pilot study in patients with HIV‐associated unintended weight loss (UWL) [Abstract]. Blood2006;108:43. WankeC , GutierrezJ , KristensenA , MacEarchern , L . Safety and efficacy of two preparations of megestrol acetate in HIV‐infected individuals with weight loss in Africa, India, and the United States. Journal of Applied Research2007;7:206‐16. ">Wanke 2007</a>; <a href="./references#CD004310-bbs2-0035" title="WeisbergJ , WangerJ . Megestrol acetate stimulates weight gain and ventilation in underweight COPD patients. Chest2002;121(4):1070‐8. ">Weisberg 2002</a>; <a href="./references#CD004310-bbs2-0036" title="YehSS , LovittS , SchusterMW . Usage of megestrol acetate in the treatment of anorexia‐cachexia syndrome in the elderly. Journal of Nutrition, Health and Aging2009;13:448‐54. YehSS , WuSY . Improvement in quality of life measures and stimulation of weight gain after treatment with megestrol acetate oral suspension in geriatric cachexia: results of a double‐blind, placebo‐controlled study. Journal of the American Geriatrics Society2000;48(5):485‐92. YehSS , WuSY , LevineDM , ParkerTS , OlsonJS , StevensMR , et al. The correlation of cytokine levels with body weight after megestrol acetate treatment in geriatric patients. Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2001;56:M48‐54. ">Yeh 2000</a>. </p> <p>Seventeen trials 49% achieved a low score (two points or lower): <a href="./references#CD004310-bbs2-0001" title="BatterhamM , GarsiaR . Randomised prospective medium term comparison of megestrol acetate, nandrolone decanoate and dietary therapy alone for HIV associated weight loss [abstract]. Australasian Society for HIV Medicine1997;9:91. BatterhamMJ , GarsiaR . A comparison of megestrol acetate, nandrolone decanoate and dietary counselling for HIV associated weight loss. International Journal of Andrology2001;24(4):232‐40. ">Batterham 2001</a>; <a href="./references#CD004310-bbs2-0003" title="Casado HerráezA . Phase II randomized study of two dose levels of megestrol acetate versus placebo for the treatment of anorexia and cachexia in patients with locoregional advanced or metastatic cancer [Estudio de fase II randomizado de dos niveles posológicos de acetato de Megestrol versus placebo para el tratamiento de la anorexia y la caquexia en pacientes con cáncer locoregional avanzado o metastásico. (Tesis de Doctorado ‐ Universidad Complutense Madrid)]. Available from http://eprints.ucm.es/8119/1/T30450.pdf 2008 (accessed 24 December 2011). ">Casado 2008</a>; <a href="./references#CD004310-bbs2-0008" title="GambardellaA , PesceL , BologninoP , LombardiG , BarbieriM , RinaldiC . Megestrol acetate prevents cachexia in elderly cancer patient. Annals of Oncology1998;9(Suppl 3):72. [CN‐00305911] GambardellaA , PesceL , LammardoAM , LombardiG , BarbagalloM , TirelliP , et al. New factors involvement in elderly cancer patients with anorexia/cachexia syndrome role of megestrol acetate. Annals of Oncology2000;9 Suppl 2:22. ">Gambardella 1998</a>; <a href="./references#CD004310-bbs2-0009" title="GebbiaV , TestaA . Prospective randomised trial of two dose levels of megestrol acetate in the management of anorexia‐cachexia syndrome in patients with metastatic cancer. British Journal of Cancer1996;73:1576‐80. ">Gebbia 1996</a>; <a href="./references#CD004310-bbs2-0010" title="GiacosaA , FrascioF , SukkarSG , CostantiniM , BaraccoG , CapelliM . Changes of nutritional and psychological status after megestrol acetate treatment of cancer cachexia. Rivista Italiana Di Nutrizione Parenterale Ed Enterale.1997;15:20‐3. ">Giacosa 1997</a>; <a href="./references#CD004310-bbs2-0011" title="HeckmayrM , GatzemeierU . Treatment of cancer weight loss in patients with advanced lung cancer. Oncology1992;49(Suppl 2):32‐4. ">Heckmayr 1992</a>; <a href="./references#CD004310-bbs2-0015" title="LesserGJ , CaseD , SharpS , ChoksiJ , MillerA , AtkinsJ , et al. A phase III randomized study comparing the effects of oxandrolone (Ox) and megestrol acetate (Meg) on weight (wt), lean body mass (LBM) and quality of life (QOL) in solid tumor patients (pts) receiving chemotherapy (chemo). Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I2006;24(18S (June 20 Suppl)):18546. ">Lesser 2006</a>; <a href="./references#CD004310-bbs2-0017" title="LoprinziCL , BernathAM . Phase III evaluation of 4 doses of megestrol acetate for patients with cancer anorexia and/or cachexia. Oncology1994;51:2‐7. LoprinziCL , MichalakJC , SchaidDJ , MailliardJA , AthmannLM , GoldbergRM , et al. Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia. Journal of Clinical Oncology1993;11:762‐7. [CN‐00092689] ">Loprinzi 1994</a>; <a href="./references#CD004310-bbs2-0018" title="LoprinziCL , KuglerJ , SloanJ , MailliardJ , KrookJ , WilwerdingM , et al. Phase III randomized comparison of megestrol acetate, dexamethasone, and fluoxymesterone for the treatment of cancer anorexia/cachexia [Meeting abstract no 167]. ASCO Annual Meeting. 1997. LoprinziCL , KuglerJW . Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. Journal of Clinical Oncology1999;17:3299‐306. ">Loprinzi 1999a</a>; <a href="./references#CD004310-bbs2-0020" title="MacbethFR , GrgeorA , Cott . A randomised study of megestrol acetate (MA) and prednisolone (P) for anorexia and weight loss in patients with lung cancer. Lung Cancer1994;1 Suppl 1:88. ">Macbeth 1994</a>; <a href="./references#CD004310-bbs2-0021" title="MadedduC , DessìM , PanzoneF , SerpeR , AntoniG , CauMC , et al. Randomized phase III clinical trial of a combined treatment with carnitine + celecoxib ± megestrol acetate for patients with cancer‐related anorexia/cachexia syndrome. Clinical Nutrition2012;31:176‐82. ">Madeddu 2012</a>; <a href="./references#CD004310-bbs2-0025" title="Sancho‐CuestaJF . Megestrol acetate and weight loss in advanced cancer [Abstract no: 1141]. European Journal of Cancer1993;29A:S204. ">Sancho‐Cuesta 1993</a>; <a href="./references#CD004310-bbs2-0026" title="SchmollE , WilkeH , TholeR , PreusserP ,  WildfangI ,  SchmollHJ . Megestrol acetate in cancer cachexia. Seminars in Oncology1991;18(1 Suppl 2):32‐4. [CN‐00072963] ">Schmoll 1991</a>; <a href="./references#CD004310-bbs2-0027" title="SchmollE . Risks and benefits of various therapies for cancer anorexia. Oncology1992;49:43‐5. ">Schmoll 1992</a>; <a href="./references#CD004310-bbs2-0028" title="SummerbellCD , YouleM , McDonaldV , CatalanJ , GazzardBG . Megestrol acetate vs cyproheptadine in the treatment of weight loss associated with HIV infection. International Journal of STD and AIDS1992;3:278‐80. ">Summerbell 1992</a>; <a href="./references#CD004310-bbs2-0031" title="UlutinHC , ArpaciF , PakY . Megestrol acetate for cachexia and anorexia in advanced non‐small cell lung cancer: a randomized study comparing two different doses. Tumori2002;88:277‐80. ">Ulutin 2002</a>; <a href="./references#CD004310-bbs2-0033" title="VonRoennJH , ArmstrongD . Megestrol acetate in patients with AIDS‐related cachexia. Annals of Internal Medicine1994;121:393‐9. ">Von Roenn 1994</a>. </p> <p>The scores of risk of bias are shown in <a href="#CD004310-fig-0002">Figure 2</a> </p> <div class="figure" id="CD004310-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias" data-id="CD004310-fig-0002" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias</p> </div> </div> </div> <section id="CD004310-sec-0067"> <h4 class="title">Allocation</h4> <p><a href="./references#CD004310-bbs2-0002" title="BellerE , TattersallM . Improved quality of life with megestrol acetate in patients with endocrine‐insensitive advanced cancer: a randomised placebo‐controlled trial. Annals of Oncology1997;8:277‐83. ">Beller 1997</a>; <a href="./references#CD004310-bbs2-0012" title="HerrejonA , CatalanP , PalopJ , InchaurragaI , BlanquerR , LopezA . Effect of 8‐week 320 mg megestrol acetate daily administration in severe COPD and weight loss [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181:A4484. HerrejonA , PalopJ , InchaurragaI , LopezA , BañulsC , HernandezA , et al. Low doses of megestrol acetate increase weight and improve nutrition status in patients with severe chronic obstructive pulmonary disease and weight loss. Medicina Clinica2011;137:193‐8. ">Herrejon 2011</a>; <a href="./references#CD004310-bbs2-0029" title="TchekmedyianNS , HickmanM . Megestrol acetate in cancer anorexia and weight loss. Cancer1992;69:1268‐74. ">Tchekmedyian 1992</a>; <a href="./references#CD004310-bbs2-0030" title="TimponeJG , WrightDJ . The safety and pharmacokinetics of single‐agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome. AIDS Research and Human Retroviruses1997;13:305‐15. ">Timpone 1997</a> and <a href="./references#CD004310-bbs2-0034" title="CillaDD , GutierrezJL , KristensenA , KramerLD . The safety of megestrol acetate concentrated suspension (MA‐CS) and megestrol acetate oral suspension (MA‐OS) in a pilot study in patients with HIV‐associated unintended weight loss (UWL) [Abstract]. Blood2006;108:43. WankeC , GutierrezJ , KristensenA , MacEarchern , L . Safety and efficacy of two preparations of megestrol acetate in HIV‐infected individuals with weight loss in Africa, India, and the United States. Journal of Applied Research2007;7:206‐16. ">Wanke 2007</a> adequately described the methods used to ensure that allocation of participants to treatment groups was concealed. The remaining studies did not report the method used. </p> </section> <section id="CD004310-sec-0068"> <h4 class="title">Blinding</h4> <p>Eleven studies were not blinded: <a href="./references#CD004310-bbs2-0001" title="BatterhamM , GarsiaR . Randomised prospective medium term comparison of megestrol acetate, nandrolone decanoate and dietary therapy alone for HIV associated weight loss [abstract]. Australasian Society for HIV Medicine1997;9:91. BatterhamMJ , GarsiaR . A comparison of megestrol acetate, nandrolone decanoate and dietary counselling for HIV associated weight loss. International Journal of Andrology2001;24(4):232‐40. ">Batterham 2001</a>; <a href="./references#CD004310-bbs2-0003" title="Casado HerráezA . Phase II randomized study of two dose levels of megestrol acetate versus placebo for the treatment of anorexia and cachexia in patients with locoregional advanced or metastatic cancer [Estudio de fase II randomizado de dos niveles posológicos de acetato de Megestrol versus placebo para el tratamiento de la anorexia y la caquexia en pacientes con cáncer locoregional avanzado o metastásico. (Tesis de Doctorado ‐ Universidad Complutense Madrid)]. Available from http://eprints.ucm.es/8119/1/T30450.pdf 2008 (accessed 24 December 2011). ">Casado 2008</a>; <a href="./references#CD004310-bbs2-0009" title="GebbiaV , TestaA . Prospective randomised trial of two dose levels of megestrol acetate in the management of anorexia‐cachexia syndrome in patients with metastatic cancer. British Journal of Cancer1996;73:1576‐80. ">Gebbia 1996</a>; <a href="./references#CD004310-bbs2-0010" title="GiacosaA , FrascioF , SukkarSG , CostantiniM , BaraccoG , CapelliM . Changes of nutritional and psychological status after megestrol acetate treatment of cancer cachexia. Rivista Italiana Di Nutrizione Parenterale Ed Enterale.1997;15:20‐3. ">Giacosa 1997</a>; <a href="./references#CD004310-bbs2-0011" title="HeckmayrM , GatzemeierU . Treatment of cancer weight loss in patients with advanced lung cancer. Oncology1992;49(Suppl 2):32‐4. ">Heckmayr 1992</a>; <a href="./references#CD004310-bbs2-0015" title="LesserGJ , CaseD , SharpS , ChoksiJ , MillerA , AtkinsJ , et al. A phase III randomized study comparing the effects of oxandrolone (Ox) and megestrol acetate (Meg) on weight (wt), lean body mass (LBM) and quality of life (QOL) in solid tumor patients (pts) receiving chemotherapy (chemo). Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I2006;24(18S (June 20 Suppl)):18546. ">Lesser 2006</a>; <a href="./references#CD004310-bbs2-0018" title="LoprinziCL , KuglerJ , SloanJ , MailliardJ , KrookJ , WilwerdingM , et al. Phase III randomized comparison of megestrol acetate, dexamethasone, and fluoxymesterone for the treatment of cancer anorexia/cachexia [Meeting abstract no 167]. ASCO Annual Meeting. 1997. LoprinziCL , KuglerJW . Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. Journal of Clinical Oncology1999;17:3299‐306. ">Loprinzi 1999a</a>; <a href="./references#CD004310-bbs2-0019" title="LoprinziCL , KuglerJ , SloanJ , MailliardJ , KrookJ , WilwerdingM , et al. Phase III randomized comparison of megestrol acetate, dexamethasone, and fluoxymesterone for the treatment of cancer anorexia/cachexia [Meeting abstract no 167]. ASCO Annual Meeting. 1997. LoprinziCL , KuglerJW . Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. Journal of Clinical Oncology1999;17:3299‐306. ">Loprinzi 1999b</a>; <a href="./references#CD004310-bbs2-0020" title="MacbethFR , GrgeorA , Cott . A randomised study of megestrol acetate (MA) and prednisolone (P) for anorexia and weight loss in patients with lung cancer. Lung Cancer1994;1 Suppl 1:88. ">Macbeth 1994</a>;<a href="./references#CD004310-bbs2-0021" title="MadedduC , DessìM , PanzoneF , SerpeR , AntoniG , CauMC , et al. Randomized phase III clinical trial of a combined treatment with carnitine + celecoxib ± megestrol acetate for patients with cancer‐related anorexia/cachexia syndrome. Clinical Nutrition2012;31:176‐82. ">Madeddu 2012</a>; <a href="./references#CD004310-bbs2-0031" title="UlutinHC , ArpaciF , PakY . Megestrol acetate for cachexia and anorexia in advanced non‐small cell lung cancer: a randomized study comparing two different doses. Tumori2002;88:277‐80. ">Ulutin 2002</a>; <a href="./references#CD004310-bbs2-0034" title="CillaDD , GutierrezJL , KristensenA , KramerLD . The safety of megestrol acetate concentrated suspension (MA‐CS) and megestrol acetate oral suspension (MA‐OS) in a pilot study in patients with HIV‐associated unintended weight loss (UWL) [Abstract]. Blood2006;108:43. WankeC , GutierrezJ , KristensenA , MacEarchern , L . Safety and efficacy of two preparations of megestrol acetate in HIV‐infected individuals with weight loss in Africa, India, and the United States. Journal of Applied Research2007;7:206‐16. ">Wanke 2007</a>. </p> <p>Ten more studies were described as blinded but did not describe the methods used to ensure that participants and interacting investigators were unable to differentiate between the treatment and control tablets: <a href="./references#CD004310-bbs2-0002" title="BellerE , TattersallM . Improved quality of life with megestrol acetate in patients with endocrine‐insensitive advanced cancer: a randomised placebo‐controlled trial. Annals of Oncology1997;8:277‐83. ">Beller 1997</a>; <a href="./references#CD004310-bbs2-0004" title="DeConnoF , MartiniC . Megestrol acetate for anorexia in patients with far‐advanced cancer: a double‐blind controlled clinical trial. European Journal of Cancer1998;34:1705‐9. ">De Conno 1998</a>; <a href="./references#CD004310-bbs2-0007" title="FietkauR , RieplM . Supportive treatment with megestrol acetate during radio (chemo) therapy. A randomised trial. Strahlentherapie und Onkologie1996;172:162‐8. FietkauR , RieplM , KettnerH , HinkeA , SauerR . Supportive use of megestrol acetate in patients with head and neck cancer during radio(chemo)therapy. European Journal of Cancer1997;33:75‐9. [CN‐00137738] ">Fietkau 1996</a>; <a href="./references#CD004310-bbs2-0008" title="GambardellaA , PesceL , BologninoP , LombardiG , BarbieriM , RinaldiC . Megestrol acetate prevents cachexia in elderly cancer patient. Annals of Oncology1998;9(Suppl 3):72. [CN‐00305911] GambardellaA , PesceL , LammardoAM , LombardiG , BarbagalloM , TirelliP , et al. New factors involvement in elderly cancer patients with anorexia/cachexia syndrome role of megestrol acetate. Annals of Oncology2000;9 Suppl 2:22. ">Gambardella 1998</a>; <a href="./references#CD004310-bbs2-0017" title="LoprinziCL , BernathAM . Phase III evaluation of 4 doses of megestrol acetate for patients with cancer anorexia and/or cachexia. Oncology1994;51:2‐7. LoprinziCL , MichalakJC , SchaidDJ , MailliardJA , AthmannLM , GoldbergRM , et al. Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia. Journal of Clinical Oncology1993;11:762‐7. [CN‐00092689] ">Loprinzi 1994</a>; <a href="./references#CD004310-bbs2-0022" title="McMillanDC , SimpsonJM . Effect of megestrol acetate on weight loss, body composition and blood screen of gastrointestinal cancer patients. Clinical Nutrition1994;13:85‐9. ">McMillan 1994</a>; <a href="./references#CD004310-bbs2-0029" title="TchekmedyianNS , HickmanM . Megestrol acetate in cancer anorexia and weight loss. Cancer1992;69:1268‐74. ">Tchekmedyian 1992</a>; <a href="./references#CD004310-bbs2-0033" title="VonRoennJH , ArmstrongD . Megestrol acetate in patients with AIDS‐related cachexia. Annals of Internal Medicine1994;121:393‐9. ">Von Roenn 1994</a>; <a href="./references#CD004310-bbs2-0035" title="WeisbergJ , WangerJ . Megestrol acetate stimulates weight gain and ventilation in underweight COPD patients. Chest2002;121(4):1070‐8. ">Weisberg 2002</a>; <a href="./references#CD004310-bbs2-0036" title="YehSS , LovittS , SchusterMW . Usage of megestrol acetate in the treatment of anorexia‐cachexia syndrome in the elderly. Journal of Nutrition, Health and Aging2009;13:448‐54. YehSS , WuSY . Improvement in quality of life measures and stimulation of weight gain after treatment with megestrol acetate oral suspension in geriatric cachexia: results of a double‐blind, placebo‐controlled study. Journal of the American Geriatrics Society2000;48(5):485‐92. YehSS , WuSY , LevineDM , ParkerTS , OlsonJS , StevensMR , et al. The correlation of cytokine levels with body weight after megestrol acetate treatment in geriatric patients. Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2001;56:M48‐54. ">Yeh 2000</a>. </p> <p>The remaining seven studies were blinded and provided adequate information: <a href="./references#CD004310-bbs2-0005" title="EubanksV , KoppersmithN . Effects of megestrol acetate on weight gain, body composition, and pulmonary function in patients with cystic fibrosis. Journal of Pediatrics2002;140:439‐44. ">Eubanks 2002</a>; <a href="./references#CD004310-bbs2-0012" title="HerrejonA , CatalanP , PalopJ , InchaurragaI , BlanquerR , LopezA . Effect of 8‐week 320 mg megestrol acetate daily administration in severe COPD and weight loss [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181:A4484. HerrejonA , PalopJ , InchaurragaI , LopezA , BañulsC , HernandezA , et al. Low doses of megestrol acetate increase weight and improve nutrition status in patients with severe chronic obstructive pulmonary disease and weight loss. Medicina Clinica2011;137:193‐8. ">Herrejon 2011</a>; <a href="./references#CD004310-bbs2-0013" title="JatoiA , WindschitlHE . Dronabinol versus megestrol acetate versus combination for cancer‐associated anorexia: A North Central Cancer Treatment Group Study. Journal of Clinical Oncology2002;20:567‐73. ">Jatoi 2002</a>; <a href="./references#CD004310-bbs2-0014" title="JatoiA , RowlandK , LoprinziCL , SloanJA , DakhilSR , MacDonaldN , et al. An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer‐associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort. Journal of Clinical Oncology2004;22:2469‐76. ">Jatoi 2004</a>; <a href="./references#CD004310-bbs2-0016" title="LoprinziCL , EllisonNM . Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. Journal of the National Cancer Institute1990;82:1127‐32. ">Loprinzi 1990b</a>; <a href="./references#CD004310-bbs2-0024" title="OsterMH , EndersSR . Megestrol acetate in patients with AIDS and cachexia. Annals of Internal Medicine1994;121:400‐8. ">Oster 1994</a>; <a href="./references#CD004310-bbs2-0032" title="SeguiMA , VadellC , Gimenez‐ArnauJM , MoralesS , CireraL , BestitI , et al. Double‐blind randomized trial for the treatment of cancer related cachexia: comparison of placebo vs two different doses of megestrol acetate [Abstract 99]. Proceedings of the American Society of Clinical Oncology1996;15:529. VadellC , SeguiMA . Anticachectic efficacy of megestrol acetate at different doses and versus placebo in patients with neoplastic cachexia. American Journal of Clinical Oncology1998;21:347‐51. ">Vadell 1998</a>. </p> <p>We have rated trials that were not blinded as follows: when the main outcome was weight, we decided that this outcome was not likely to the influenced for patients or researchers, so we rated the risk of bias as 'low'. When the main outcome was appetite, we decided that this could be influenced by patients and researchers, and we rated risk of bias as 'high'. </p> </section> <section id="CD004310-sec-0069"> <h4 class="title">Incomplete outcome data</h4> <p>In <a href="./references#CD004310-bbs2-0027" title="SchmollE . Risks and benefits of various therapies for cancer anorexia. Oncology1992;49:43‐5. ">Schmoll 1992</a>, withdrawals were higher in the placebo group (44%) than in both MA groups (30%) and explanations were not provided. In <a href="./references#CD004310-bbs2-0032" title="SeguiMA , VadellC , Gimenez‐ArnauJM , MoralesS , CireraL , BestitI , et al. Double‐blind randomized trial for the treatment of cancer related cachexia: comparison of placebo vs two different doses of megestrol acetate [Abstract 99]. Proceedings of the American Society of Clinical Oncology1996;15:529. VadellC , SeguiMA . Anticachectic efficacy of megestrol acetate at different doses and versus placebo in patients with neoplastic cachexia. American Journal of Clinical Oncology1998;21:347‐51. ">Vadell 1998</a>, the rate of withdrawals was very high (only 64 out of 152 initial patients remained in the study after 12 weeks). In both cases we rated risk of bias as 'high'. We rated the remaining studies as low risk, either because of lack of drop‐outs or losses in the follow‐up or because the number of drop‐outs was low and equitably balanced between intervention groups. </p> </section> <section id="CD004310-sec-0070"> <h4 class="title">Selective reporting</h4> <p>The protocols for the studies were not available (except for <a href="./references#CD004310-bbs2-0012" title="HerrejonA , CatalanP , PalopJ , InchaurragaI , BlanquerR , LopezA . Effect of 8‐week 320 mg megestrol acetate daily administration in severe COPD and weight loss [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181:A4484. HerrejonA , PalopJ , InchaurragaI , LopezA , BañulsC , HernandezA , et al. Low doses of megestrol acetate increase weight and improve nutrition status in patients with severe chronic obstructive pulmonary disease and weight loss. Medicina Clinica2011;137:193‐8. ">Herrejon 2011</a>), which we rated low risk of bias. In view of the fact that the authors only reported data at 12 weeks and not at 24 weeks we rated this a high risk bias in <a href="./references#CD004310-bbs2-0001" title="BatterhamM , GarsiaR . Randomised prospective medium term comparison of megestrol acetate, nandrolone decanoate and dietary therapy alone for HIV associated weight loss [abstract]. Australasian Society for HIV Medicine1997;9:91. BatterhamMJ , GarsiaR . A comparison of megestrol acetate, nandrolone decanoate and dietary counselling for HIV associated weight loss. International Journal of Andrology2001;24(4):232‐40. ">Batterham 2001</a>. We rated the rest of the studies as unclear risk of bias because all the predefined outcomes were available. </p> </section> <section id="CD004310-sec-0071"> <h4 class="title">Other potential sources of bias</h4> <p>Studies with small group sizes and poor quality (allocation sequence, concealment of allocation or adequate blinding) tend to overestimate efficacy (<a href="./references#CD004310-bbs2-0158" title="KjaergardLL , VillumsenJ , GluudC . Reported methodologic quality and discrepancies between large and small randomized trials in meta‐analyses. Annals of Internal Medicine2001;135:982‐9. ">Kjaergard 2001</a>; <a href="./references#CD004310-bbs2-0165" title="NüeschE , TrelleS , ReichenbachS , RutjesAW , TschannenB , AltmanDG , et al. Small study effects in meta‐analyses of osteoarthritis trials: meta‐epidemiological study. BMJ2010;341:c3515. ">Nüesch 2010</a>). In this review, 18 out of 34 trials had a sample size of less than 100 and poor quality; in particular the following: <a href="./references#CD004310-bbs2-0001" title="BatterhamM , GarsiaR . Randomised prospective medium term comparison of megestrol acetate, nandrolone decanoate and dietary therapy alone for HIV associated weight loss [abstract]. Australasian Society for HIV Medicine1997;9:91. BatterhamMJ , GarsiaR . A comparison of megestrol acetate, nandrolone decanoate and dietary counselling for HIV associated weight loss. International Journal of Andrology2001;24(4):232‐40. ">Batterham 2001</a> (15 patients); <a href="./references#CD004310-bbs2-0004" title="DeConnoF , MartiniC . Megestrol acetate for anorexia in patients with far‐advanced cancer: a double‐blind controlled clinical trial. European Journal of Cancer1998;34:1705‐9. ">De Conno 1998</a> (48 patients); <a href="./references#CD004310-bbs2-0005" title="EubanksV , KoppersmithN . Effects of megestrol acetate on weight gain, body composition, and pulmonary function in patients with cystic fibrosis. Journal of Pediatrics2002;140:439‐44. ">Eubanks 2002</a> (17 patients); <a href="./references#CD004310-bbs2-0007" title="FietkauR , RieplM . Supportive treatment with megestrol acetate during radio (chemo) therapy. A randomised trial. Strahlentherapie und Onkologie1996;172:162‐8. FietkauR , RieplM , KettnerH , HinkeA , SauerR . Supportive use of megestrol acetate in patients with head and neck cancer during radio(chemo)therapy. European Journal of Cancer1997;33:75‐9. [CN‐00137738] ">Fietkau 1996</a> (61 patients); <a href="./references#CD004310-bbs2-0008" title="GambardellaA , PesceL , BologninoP , LombardiG , BarbieriM , RinaldiC . Megestrol acetate prevents cachexia in elderly cancer patient. Annals of Oncology1998;9(Suppl 3):72. [CN‐00305911] GambardellaA , PesceL , LammardoAM , LombardiG , BarbagalloM , TirelliP , et al. New factors involvement in elderly cancer patients with anorexia/cachexia syndrome role of megestrol acetate. Annals of Oncology2000;9 Suppl 2:22. ">Gambardella 1998</a> (30 patients); <a href="./references#CD004310-bbs2-0010" title="GiacosaA , FrascioF , SukkarSG , CostantiniM , BaraccoG , CapelliM . Changes of nutritional and psychological status after megestrol acetate treatment of cancer cachexia. Rivista Italiana Di Nutrizione Parenterale Ed Enterale.1997;15:20‐3. ">Giacosa 1997</a> (28 patients); <a href="./references#CD004310-bbs2-0011" title="HeckmayrM , GatzemeierU . Treatment of cancer weight loss in patients with advanced lung cancer. Oncology1992;49(Suppl 2):32‐4. ">Heckmayr 1992</a> (66 patients); <a href="./references#CD004310-bbs2-0015" title="LesserGJ , CaseD , SharpS , ChoksiJ , MillerA , AtkinsJ , et al. A phase III randomized study comparing the effects of oxandrolone (Ox) and megestrol acetate (Meg) on weight (wt), lean body mass (LBM) and quality of life (QOL) in solid tumor patients (pts) receiving chemotherapy (chemo). Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I2006;24(18S (June 20 Suppl)):18546. ">Lesser 2006</a> (74 patients); <a href="./references#CD004310-bbs2-0021" title="MadedduC , DessìM , PanzoneF , SerpeR , AntoniG , CauMC , et al. Randomized phase III clinical trial of a combined treatment with carnitine + celecoxib ± megestrol acetate for patients with cancer‐related anorexia/cachexia syndrome. Clinical Nutrition2012;31:176‐82. ">Madeddu 2012</a> (60 patients); <a href="./references#CD004310-bbs2-0020" title="MacbethFR , GrgeorA , Cott . A randomised study of megestrol acetate (MA) and prednisolone (P) for anorexia and weight loss in patients with lung cancer. Lung Cancer1994;1 Suppl 1:88. ">Macbeth 1994</a> (75 patients); <a href="./references#CD004310-bbs2-0022" title="McMillanDC , SimpsonJM . Effect of megestrol acetate on weight loss, body composition and blood screen of gastrointestinal cancer patients. Clinical Nutrition1994;13:85‐9. ">McMillan 1994</a> (38 patients); <a href="./references#CD004310-bbs2-0023" title="MwamburiDM , GerriorJ , WilsonIB , ChangH , ScullyE , SabooriS , et al. Comparing megestrol acetate therapy with oxandrolone therapy for HIV‐related weight loss: similar results in 2 months. Clinical Infectious Diseases2004;38:895‐902. ">Mwamburi 2004</a> (40 patients); <a href="./references#CD004310-bbs2-0026" title="SchmollE , WilkeH , TholeR , PreusserP ,  WildfangI ,  SchmollHJ . Megestrol acetate in cancer cachexia. Seminars in Oncology1991;18(1 Suppl 2):32‐4. [CN‐00072963] ">Schmoll 1991</a> (55 patients); <a href="./references#CD004310-bbs2-0027" title="SchmollE . Risks and benefits of various therapies for cancer anorexia. Oncology1992;49:43‐5. ">Schmoll 1992</a> (91 patients); <a href="./references#CD004310-bbs2-0028" title="SummerbellCD , YouleM , McDonaldV , CatalanJ , GazzardBG . Megestrol acetate vs cyproheptadine in the treatment of weight loss associated with HIV infection. International Journal of STD and AIDS1992;3:278‐80. ">Summerbell 1992</a> (14 patients); <a href="./references#CD004310-bbs2-0030" title="TimponeJG , WrightDJ . The safety and pharmacokinetics of single‐agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome. AIDS Research and Human Retroviruses1997;13:305‐15. ">Timpone 1997</a> (50 patients); <a href="./references#CD004310-bbs2-0034" title="CillaDD , GutierrezJL , KristensenA , KramerLD . The safety of megestrol acetate concentrated suspension (MA‐CS) and megestrol acetate oral suspension (MA‐OS) in a pilot study in patients with HIV‐associated unintended weight loss (UWL) [Abstract]. Blood2006;108:43. WankeC , GutierrezJ , KristensenA , MacEarchern , L . Safety and efficacy of two preparations of megestrol acetate in HIV‐infected individuals with weight loss in Africa, India, and the United States. Journal of Applied Research2007;7:206‐16. ">Wanke 2007</a> (63 patients); and <a href="./references#CD004310-bbs2-0036" title="YehSS , LovittS , SchusterMW . Usage of megestrol acetate in the treatment of anorexia‐cachexia syndrome in the elderly. Journal of Nutrition, Health and Aging2009;13:448‐54. YehSS , WuSY . Improvement in quality of life measures and stimulation of weight gain after treatment with megestrol acetate oral suspension in geriatric cachexia: results of a double‐blind, placebo‐controlled study. Journal of the American Geriatrics Society2000;48(5):485‐92. YehSS , WuSY , LevineDM , ParkerTS , OlsonJS , StevensMR , et al. The correlation of cytokine levels with body weight after megestrol acetate treatment in geriatric patients. Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2001;56:M48‐54. ">Yeh 2000</a> (69 patients). </p> <p>Additionally, we rated three trials as high risk of bias: <a href="./references#CD004310-bbs2-0020" title="MacbethFR , GrgeorA , Cott . A randomised study of megestrol acetate (MA) and prednisolone (P) for anorexia and weight loss in patients with lung cancer. Lung Cancer1994;1 Suppl 1:88. ">Macbeth 1994</a> (stopped early for safety); <a href="./references#CD004310-bbs2-0028" title="SummerbellCD , YouleM , McDonaldV , CatalanJ , GazzardBG . Megestrol acetate vs cyproheptadine in the treatment of weight loss associated with HIV infection. International Journal of STD and AIDS1992;3:278‐80. ">Summerbell 1992</a> (discontinued because the recruitment was too slow) and <a href="./references#CD004310-bbs2-0015" title="LesserGJ , CaseD , SharpS , ChoksiJ , MillerA , AtkinsJ , et al. A phase III randomized study comparing the effects of oxandrolone (Ox) and megestrol acetate (Meg) on weight (wt), lean body mass (LBM) and quality of life (QOL) in solid tumor patients (pts) receiving chemotherapy (chemo). Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I2006;24(18S (June 20 Suppl)):18546. ">Lesser 2006</a> (we only have a conference proceeding dated 2006; we have not found any paper with all the relevant data for this trial). </p> </section> </section> <section id="CD004310-sec-0072"> <h3 class="title" id="CD004310-sec-0072">Effects of interventions</h3> <p>See: <a href="./full#CD004310-tbl-0001"><b>Summary of findings for the main comparison</b> Megestrol acetate for cachexia anorexia syndrome</a> </p> <p>We meta‐analysed data from the included studies in three groups.</p> <p> <ul id="CD004310-list-0022"> <li> <p>Megestrol acetate (MA) versus placebo</p> </li> <li> <p>MA versus other active drug treatments</p> </li> <li> <p>MA at different doses</p> </li> </ul> </p> <p>We further categorised the studies as follows.</p> <p> <ul id="CD004310-list-0023"> <li> <p>Patients with cancer</p> </li> <li> <p>Patients with AIDS</p> </li> <li> <p>Patients with other underlying pathologies</p> </li> </ul> </p> <p>We used risk ratio (RR) to assess quality of life, weight and appetite and used mean difference (MD) for weight and appetite gain as continuous variables. When quality of life was described as a continuous variable we used standardised mean difference (SMD) because this item was reported using different scales (Karnofsky Index, linear analogue self assessment, etc.). </p> <section id="CD004310-sec-0073"> <h4 class="title">Megestrol acetate versus placebo</h4> <section id="CD004310-sec-0074"> <h5 class="title">Weight gain</h5> <p>The overall results show weight improvement for patients treated with MA (RR 1.51, 95% CI 1.08 to 2.11) (<a href="./references#CD004310-fig-0009" title="">Analysis 1.3</a>). Eight trials were studied. The result for the subcategory of cancer patients was RR 1.55 (95% CI 1.06 to 2.26) (<a href="./references#CD004310-fig-0009" title="">Analysis 1.3</a>). One trial was found for each of the subcategories AIDS and other underlying pathologies. No overall results for these subcategories could be achieved. The quality of the trials for this outcome is shown in <a href="#CD004310-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD004310-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="original image" data-id="CD004310-fig-0003" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> <p>For weight gain, the overall results show an improvement for patients treated with MA (MD 1.93, 95% CI 0.95 to 2.91) (<a href="./references#CD004310-fig-0010" title="">Analysis 1.4</a>). Both the subcategories cancer patients and patients with other underlying pathologies show improvement (MD 1.63, 95% CI 0.87 to 2.38 and MD 1.47, 95% CI 0.06 to 2.87, respectively) (<a href="./references#CD004310-fig-0010" title="">Analysis 1.4</a>). </p> <p>We explored heterogeneity between the trials using the Chi<sup>2</sup> test, with a 10% level of significance, and the I<sup>2</sup> statistic. When we explored weight improvement in the MA versus placebo comparison, we obtained an I<sup>2</sup> of 66 %. We applied the recommendations in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i>, which suggest that an I<sup>2</sup> value more than 60% may represent high heterogeneity (<a href="./references#CD004310-bbs2-0153" title="DeeksJ , HigginsJ , AltmanD . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. The Cochrane Collaboration, 2008. Available from: www.cochrane‐handbook.org. ">Deeks 2008</a>). When we analysed data without the trials of <a href="./references#CD004310-bbs2-0035" title="WeisbergJ , WangerJ . Megestrol acetate stimulates weight gain and ventilation in underweight COPD patients. Chest2002;121(4):1070‐8. ">Weisberg 2002</a>; <a href="./references#CD004310-bbs2-0036" title="YehSS , LovittS , SchusterMW . Usage of megestrol acetate in the treatment of anorexia‐cachexia syndrome in the elderly. Journal of Nutrition, Health and Aging2009;13:448‐54. YehSS , WuSY . Improvement in quality of life measures and stimulation of weight gain after treatment with megestrol acetate oral suspension in geriatric cachexia: results of a double‐blind, placebo‐controlled study. Journal of the American Geriatrics Society2000;48(5):485‐92. YehSS , WuSY , LevineDM , ParkerTS , OlsonJS , StevensMR , et al. The correlation of cytokine levels with body weight after megestrol acetate treatment in geriatric patients. Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2001;56:M48‐54. ">Yeh 2000</a> the I<sup>2</sup> became 2%. Those two trials with patients with COPD and geriatric cachexia could be quite different from the overall and could explain heterogeneity. </p> </section> <section id="CD004310-sec-0075"> <h5 class="title">Quality of life</h5> <p>The overall results show improvement in quality of life for patients treated with MA (RR 1.78, 95% CI 1.09 to 2.92) (<a href="./references#CD004310-fig-0011" title="">Analysis 1.5</a>). The overall results for the cancer and AIDS patients subcategories were RR 1.91 (95% CI 1.02 to 3.59) and RR 1.49 (95% CI 0.47 to 4.69), respectively (<a href="./references#CD004310-fig-0011" title="">Analysis 1.5</a>). However, quality of life as a continuous variable shows no improvement (SMD 0.50, 95% CI ‐0.13 to 1.13) (<a href="./references#CD004310-fig-0012" title="">Analysis 1.6</a>). </p> </section> <section id="CD004310-sec-0076"> <h5 class="title">Appetite</h5> <p>The overall results show appetite improvement for patients treated with MA (RR 2.19, 95% confidence interval (CI) 1.41 to 3.40)) (<a href="./references#CD004310-fig-0007" title="">Analysis 1.1</a>). The only subcategory that could be analysed was cancer patients and appetite improvement was detected (RR 2.57, 95% CI 1.48 to 4.49). We could not analyse the subcategories of AIDS patients and patients with other underlying pathologies because there was only one trial including AIDS patients. The quality of trials for this outcome is shown in <a href="#CD004310-fig-0004">Figure 4</a>. </p> <div class="figure" id="CD004310-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="original image" data-id="CD004310-fig-0004" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> <p>For appetite gain, we did not find trials with patients with cancer or AIDS and only one subcategory could be analysed. There were patients with other underlying pathologies, namely chronic obstructive pulmonary disease (COPD) and geriatric cachexia (<a href="./references#CD004310-bbs2-0012" title="HerrejonA , CatalanP , PalopJ , InchaurragaI , BlanquerR , LopezA . Effect of 8‐week 320 mg megestrol acetate daily administration in severe COPD and weight loss [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181:A4484. HerrejonA , PalopJ , InchaurragaI , LopezA , BañulsC , HernandezA , et al. Low doses of megestrol acetate increase weight and improve nutrition status in patients with severe chronic obstructive pulmonary disease and weight loss. Medicina Clinica2011;137:193‐8. ">Herrejon 2011</a>; <a href="./references#CD004310-bbs2-0036" title="YehSS , LovittS , SchusterMW . Usage of megestrol acetate in the treatment of anorexia‐cachexia syndrome in the elderly. Journal of Nutrition, Health and Aging2009;13:448‐54. YehSS , WuSY . Improvement in quality of life measures and stimulation of weight gain after treatment with megestrol acetate oral suspension in geriatric cachexia: results of a double‐blind, placebo‐controlled study. Journal of the American Geriatrics Society2000;48(5):485‐92. YehSS , WuSY , LevineDM , ParkerTS , OlsonJS , StevensMR , et al. The correlation of cytokine levels with body weight after megestrol acetate treatment in geriatric patients. Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2001;56:M48‐54. ">Yeh 2000</a>). The overall results show an improvement for patients treated with MA (SMD 0.91, 95% CI 0.43 to 1.39) (<a href="./references#CD004310-fig-0008" title="">Analysis 1.2</a>) </p> </section> <section id="CD004310-sec-0077"> <h5 class="title">Anthropometric values</h5> <p>Seven studies showed results for triceps skinfold thickness (TST). Only four of them had results which were statistically significant (<a href="./references#CD004310-bbs2-0012" title="HerrejonA , CatalanP , PalopJ , InchaurragaI , BlanquerR , LopezA . Effect of 8‐week 320 mg megestrol acetate daily administration in severe COPD and weight loss [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181:A4484. HerrejonA , PalopJ , InchaurragaI , LopezA , BañulsC , HernandezA , et al. Low doses of megestrol acetate increase weight and improve nutrition status in patients with severe chronic obstructive pulmonary disease and weight loss. Medicina Clinica2011;137:193‐8. ">Herrejon 2011</a>; <a href="./references#CD004310-bbs2-0032" title="SeguiMA , VadellC , Gimenez‐ArnauJM , MoralesS , CireraL , BestitI , et al. Double‐blind randomized trial for the treatment of cancer related cachexia: comparison of placebo vs two different doses of megestrol acetate [Abstract 99]. Proceedings of the American Society of Clinical Oncology1996;15:529. VadellC , SeguiMA . Anticachectic efficacy of megestrol acetate at different doses and versus placebo in patients with neoplastic cachexia. American Journal of Clinical Oncology1998;21:347‐51. ">Vadell 1998</a>; <a href="./references#CD004310-bbs2-0033" title="VonRoennJH , ArmstrongD . Megestrol acetate in patients with AIDS‐related cachexia. Annals of Internal Medicine1994;121:393‐9. ">Von Roenn 1994</a>; <a href="./references#CD004310-bbs2-0035" title="WeisbergJ , WangerJ . Megestrol acetate stimulates weight gain and ventilation in underweight COPD patients. Chest2002;121(4):1070‐8. ">Weisberg 2002</a>) and three did not show statistical significance (<a href="./references#CD004310-bbs2-0002" title="BellerE , TattersallM . Improved quality of life with megestrol acetate in patients with endocrine‐insensitive advanced cancer: a randomised placebo‐controlled trial. Annals of Oncology1997;8:277‐83. ">Beller 1997</a>; <a href="./references#CD004310-bbs2-0007" title="FietkauR , RieplM . Supportive treatment with megestrol acetate during radio (chemo) therapy. A randomised trial. Strahlentherapie und Onkologie1996;172:162‐8. FietkauR , RieplM , KettnerH , HinkeA , SauerR . Supportive use of megestrol acetate in patients with head and neck cancer during radio(chemo)therapy. European Journal of Cancer1997;33:75‐9. [CN‐00137738] ">Fietkau 1996</a>; <a href="./references#CD004310-bbs2-0029" title="TchekmedyianNS , HickmanM . Megestrol acetate in cancer anorexia and weight loss. Cancer1992;69:1268‐74. ">Tchekmedyian 1992</a>; ) </p> <p>Two studies showed results for mid‐arm circumference (MAC). Only one had results which were statistically significant (<a href="./references#CD004310-bbs2-0005" title="EubanksV , KoppersmithN . Effects of megestrol acetate on weight gain, body composition, and pulmonary function in patients with cystic fibrosis. Journal of Pediatrics2002;140:439‐44. ">Eubanks 2002</a>) and (<a href="./references#CD004310-bbs2-0029" title="TchekmedyianNS , HickmanM . Megestrol acetate in cancer anorexia and weight loss. Cancer1992;69:1268‐74. ">Tchekmedyian 1992</a>)did not show statistical significance. </p> <p>In <a href="./references#CD004310-bbs2-0002" title="BellerE , TattersallM . Improved quality of life with megestrol acetate in patients with endocrine‐insensitive advanced cancer: a randomised placebo‐controlled trial. Annals of Oncology1997;8:277‐83. ">Beller 1997</a> the average difference in TST in mm between baseline and subsequent weeks was ‐0.28, ‐0.70 and +0.15 (P = 0.72) for placebo, lower doses of MA and higher doses of MA, respectively. </p> <p>In <a href="./references#CD004310-bbs2-0005" title="EubanksV , KoppersmithN . Effects of megestrol acetate on weight gain, body composition, and pulmonary function in patients with cystic fibrosis. Journal of Pediatrics2002;140:439‐44. ">Eubanks 2002</a> TST and MAC measurements were also increased compared with baseline for the entire MA‐treated group at two, three and six months (P &lt; 0.001 at all time points). </p> <p>In <a href="./references#CD004310-bbs2-0007" title="FietkauR , RieplM . Supportive treatment with megestrol acetate during radio (chemo) therapy. A randomised trial. Strahlentherapie und Onkologie1996;172:162‐8. FietkauR , RieplM , KettnerH , HinkeA , SauerR . Supportive use of megestrol acetate in patients with head and neck cancer during radio(chemo)therapy. European Journal of Cancer1997;33:75‐9. [CN‐00137738] ">Fietkau 1996</a>, “There was no decrease or even a slight increase in the thickness of the triceps skinfold in MA group compared with a continuous decrease in the control group" and "No differences in upper arm muscle circumferences were observed between the groups”. </p> <p>In <a href="./references#CD004310-bbs2-0012" title="HerrejonA , CatalanP , PalopJ , InchaurragaI , BlanquerR , LopezA . Effect of 8‐week 320 mg megestrol acetate daily administration in severe COPD and weight loss [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181:A4484. HerrejonA , PalopJ , InchaurragaI , LopezA , BañulsC , HernandezA , et al. Low doses of megestrol acetate increase weight and improve nutrition status in patients with severe chronic obstructive pulmonary disease and weight loss. Medicina Clinica2011;137:193‐8. ">Herrejon 2011</a> the mean differences in TST at eight weeks were 0.8 versus ‐0.1 (P = 0.003) for the MA and placebo group, respectively. </p> <p>In <a href="./references#CD004310-bbs2-0032" title="SeguiMA , VadellC , Gimenez‐ArnauJM , MoralesS , CireraL , BestitI , et al. Double‐blind randomized trial for the treatment of cancer related cachexia: comparison of placebo vs two different doses of megestrol acetate [Abstract 99]. Proceedings of the American Society of Clinical Oncology1996;15:529. VadellC , SeguiMA . Anticachectic efficacy of megestrol acetate at different doses and versus placebo in patients with neoplastic cachexia. American Journal of Clinical Oncology1998;21:347‐51. ">Vadell 1998</a> a significant increase in TST was noted in patients receiving higher doses of MA after the second month of treatment. </p> <p>In <a href="./references#CD004310-bbs2-0138" title="VonRoennJH . Randomized trials of megestrol acetate for AIDS‐associated anorexia and cachexia. Oncology1994;51 Suppl 1:19‐24. ">Von Roenn 1994a</a> “MA treatment presented the decrease of TST in patients receiving placebo and resulted in an increase in all doses tested”. </p> <p>In <a href="./references#CD004310-bbs2-0035" title="WeisbergJ , WangerJ . Megestrol acetate stimulates weight gain and ventilation in underweight COPD patients. Chest2002;121(4):1070‐8. ">Weisberg 2002</a> the mean TST values in the MA group increased significantly when compared to the placebo group: 1.35 ± 2.38 (n = 72) versus 0.13 ± 2.24 (n = 73). Only Weisberg’s trial described mean difference and standard deviation (SD) </p> <p>In <a href="./references#CD004310-bbs2-0029" title="TchekmedyianNS , HickmanM . Megestrol acetate in cancer anorexia and weight loss. Cancer1992;69:1268‐74. ">Tchekmedyian 1992</a> there were no significant changes in MAC or TST in either group at one month. </p> </section> </section> <section id="CD004310-sec-0078"> <h4 class="title">Megestrol acetate versus other drugs</h4> <p>We found seven trials in this group: <a href="./references#CD004310-bbs2-0018" title="LoprinziCL , KuglerJ , SloanJ , MailliardJ , KrookJ , WilwerdingM , et al. Phase III randomized comparison of megestrol acetate, dexamethasone, and fluoxymesterone for the treatment of cancer anorexia/cachexia [Meeting abstract no 167]. ASCO Annual Meeting. 1997. LoprinziCL , KuglerJW . Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. Journal of Clinical Oncology1999;17:3299‐306. ">Loprinzi 1999a</a>; <a href="./references#CD004310-bbs2-0019" title="LoprinziCL , KuglerJ , SloanJ , MailliardJ , KrookJ , WilwerdingM , et al. Phase III randomized comparison of megestrol acetate, dexamethasone, and fluoxymesterone for the treatment of cancer anorexia/cachexia [Meeting abstract no 167]. ASCO Annual Meeting. 1997. LoprinziCL , KuglerJW . Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. Journal of Clinical Oncology1999;17:3299‐306. ">Loprinzi 1999b</a>; <a href="./references#CD004310-bbs2-0013" title="JatoiA , WindschitlHE . Dronabinol versus megestrol acetate versus combination for cancer‐associated anorexia: A North Central Cancer Treatment Group Study. Journal of Clinical Oncology2002;20:567‐73. ">Jatoi 2002</a>; <a href="./references#CD004310-bbs2-0014" title="JatoiA , RowlandK , LoprinziCL , SloanJA , DakhilSR , MacDonaldN , et al. An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer‐associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort. Journal of Clinical Oncology2004;22:2469‐76. ">Jatoi 2004</a> in the subcategory of cancer and <a href="./references#CD004310-bbs2-0001" title="BatterhamM , GarsiaR . Randomised prospective medium term comparison of megestrol acetate, nandrolone decanoate and dietary therapy alone for HIV associated weight loss [abstract]. Australasian Society for HIV Medicine1997;9:91. BatterhamMJ , GarsiaR . A comparison of megestrol acetate, nandrolone decanoate and dietary counselling for HIV associated weight loss. International Journal of Andrology2001;24(4):232‐40. ">Batterham 2001</a>; <a href="./references#CD004310-bbs2-0023" title="MwamburiDM , GerriorJ , WilsonIB , ChangH , ScullyE , SabooriS , et al. Comparing megestrol acetate therapy with oxandrolone therapy for HIV‐related weight loss: similar results in 2 months. Clinical Infectious Diseases2004;38:895‐902. ">Mwamburi 2004</a>; <a href="./references#CD004310-bbs2-0028" title="SummerbellCD , YouleM , McDonaldV , CatalanJ , GazzardBG . Megestrol acetate vs cyproheptadine in the treatment of weight loss associated with HIV infection. International Journal of STD and AIDS1992;3:278‐80. ">Summerbell 1992</a>; <a href="./references#CD004310-bbs2-0030" title="TimponeJG , WrightDJ . The safety and pharmacokinetics of single‐agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome. AIDS Research and Human Retroviruses1997;13:305‐15. ">Timpone 1997</a> in the subcategory of AIDS. Loprinzi 1999 (<a href="./references#CD004310-bbs2-0018" title="LoprinziCL , KuglerJ , SloanJ , MailliardJ , KrookJ , WilwerdingM , et al. Phase III randomized comparison of megestrol acetate, dexamethasone, and fluoxymesterone for the treatment of cancer anorexia/cachexia [Meeting abstract no 167]. ASCO Annual Meeting. 1997. LoprinziCL , KuglerJW . Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. Journal of Clinical Oncology1999;17:3299‐306. ">Loprinzi 1999a</a>; <a href="./references#CD004310-bbs2-0019" title="LoprinziCL , KuglerJ , SloanJ , MailliardJ , KrookJ , WilwerdingM , et al. Phase III randomized comparison of megestrol acetate, dexamethasone, and fluoxymesterone for the treatment of cancer anorexia/cachexia [Meeting abstract no 167]. ASCO Annual Meeting. 1997. LoprinziCL , KuglerJW . Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. Journal of Clinical Oncology1999;17:3299‐306. ">Loprinzi 1999b</a>) compared MA to fluoxymesterone and dexamethasone, respectively. The analysis of Loprinzi 1999 was carried out by dividing the total number of placebo patients by two. In other words, the number of placebo patients in each comparison was taken to be 79 instead of 158 </p> <section id="CD004310-sec-0079"> <h5 class="title">Weight gain</h5> <p>The overall results show weight improvement (RR 1.66, 95% CI 1.09 to 2.52) (<a href="./references#CD004310-fig-0015" title="">Analysis 2.3</a>). Three studies in the subcategory of cancer patients (<a href="./references#CD004310-bbs2-0013" title="JatoiA , WindschitlHE . Dronabinol versus megestrol acetate versus combination for cancer‐associated anorexia: A North Central Cancer Treatment Group Study. Journal of Clinical Oncology2002;20:567‐73. ">Jatoi 2002</a>; <a href="./references#CD004310-bbs2-0014" title="JatoiA , RowlandK , LoprinziCL , SloanJA , DakhilSR , MacDonaldN , et al. An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer‐associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort. Journal of Clinical Oncology2004;22:2469‐76. ">Jatoi 2004</a>; <a href="./references#CD004310-bbs2-0018" title="LoprinziCL , KuglerJ , SloanJ , MailliardJ , KrookJ , WilwerdingM , et al. Phase III randomized comparison of megestrol acetate, dexamethasone, and fluoxymesterone for the treatment of cancer anorexia/cachexia [Meeting abstract no 167]. ASCO Annual Meeting. 1997. LoprinziCL , KuglerJW . Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. Journal of Clinical Oncology1999;17:3299‐306. ">Loprinzi 1999a</a>; <a href="./references#CD004310-bbs2-0019" title="LoprinziCL , KuglerJ , SloanJ , MailliardJ , KrookJ , WilwerdingM , et al. Phase III randomized comparison of megestrol acetate, dexamethasone, and fluoxymesterone for the treatment of cancer anorexia/cachexia [Meeting abstract no 167]. ASCO Annual Meeting. 1997. LoprinziCL , KuglerJW . Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. Journal of Clinical Oncology1999;17:3299‐306. ">Loprinzi 1999b</a>) and two in the subcategory of AIDS patients (<a href="./references#CD004310-bbs2-0023" title="MwamburiDM , GerriorJ , WilsonIB , ChangH , ScullyE , SabooriS , et al. Comparing megestrol acetate therapy with oxandrolone therapy for HIV‐related weight loss: similar results in 2 months. Clinical Infectious Diseases2004;38:895‐902. ">Mwamburi 2004</a>; <a href="./references#CD004310-bbs2-0028" title="SummerbellCD , YouleM , McDonaldV , CatalanJ , GazzardBG . Megestrol acetate vs cyproheptadine in the treatment of weight loss associated with HIV infection. International Journal of STD and AIDS1992;3:278‐80. ">Summerbell 1992</a>) were considered. </p> <p>The overall results for the outcome weight gain show improvement (MD 2.50, 95% CI 0.37 to 4.64) (<a href="./references#CD004310-fig-0016" title="">Analysis 2.4</a>). However, the overall results for each subcategory show no weight gain either in cancer or in AIDS patients (MD 0.61, 95% CI ‐0.15 to 1.38 and MD 4.85, 95% CI ‐0.79 to 10.49, respectively) (<a href="./references#CD004310-fig-0016" title="">Analysis 2.4</a>). </p> </section> <section id="CD004310-sec-0080"> <h5 class="title">Quality of life</h5> <p>Two trials (<a href="./references#CD004310-bbs2-0013" title="JatoiA , WindschitlHE . Dronabinol versus megestrol acetate versus combination for cancer‐associated anorexia: A North Central Cancer Treatment Group Study. Journal of Clinical Oncology2002;20:567‐73. ">Jatoi 2002</a>; <a href="./references#CD004310-bbs2-0018" title="LoprinziCL , KuglerJ , SloanJ , MailliardJ , KrookJ , WilwerdingM , et al. Phase III randomized comparison of megestrol acetate, dexamethasone, and fluoxymesterone for the treatment of cancer anorexia/cachexia [Meeting abstract no 167]. ASCO Annual Meeting. 1997. LoprinziCL , KuglerJW . Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. Journal of Clinical Oncology1999;17:3299‐306. ">Loprinzi 1999a</a>) included in the analysis measured health‐related quality of life as an outcome using different instruments. Quality of life did not show any benefit (RR 1.05, 95% CI 0.77 to 1.44 and SMD 0.20, 95% CI ‐0.02 to 0.43, respectively). </p> </section> <section id="CD004310-sec-0081"> <h5 class="title">Appetite</h5> <p>When we looked at the overall results, MA did not show benefits in terms of appetite improvement in comparison with other drugs in any category (RR 1.03, 95% CI 0.64 to 1.67) (<a href="./references#CD004310-fig-0013" title="">Analysis 2.1</a>). The only trial available in this analysis was Loprinzi 1999. </p> <p>Appetite gain as a continuous variable could only be analysed in one trial (<a href="./references#CD004310-bbs2-0001" title="BatterhamM , GarsiaR . Randomised prospective medium term comparison of megestrol acetate, nandrolone decanoate and dietary therapy alone for HIV associated weight loss [abstract]. Australasian Society for HIV Medicine1997;9:91. BatterhamMJ , GarsiaR . A comparison of megestrol acetate, nandrolone decanoate and dietary counselling for HIV associated weight loss. International Journal of Andrology2001;24(4):232‐40. ">Batterham 2001</a>) and shows lack of efficacy (MD 1.60, 95% CI ‐1.28 to 4.48) (<a href="./references#CD004310-fig-0014" title="">Analysis 2.2</a>). </p> <p>The quality of trials for the outcomes appetite and weight improvement is shown in <a href="#CD004310-fig-0003">Figure 3</a> and <a href="#CD004310-fig-0005">Figure 5</a>. </p> <div class="figure" id="CD004310-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="original image" data-id="CD004310-fig-0005" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> </section> <section id="CD004310-sec-0082"> <h5 class="title">Anthropometric values</h5> <p>In <a href="./references#CD004310-bbs2-0020" title="MacbethFR , GrgeorA , Cott . A randomised study of megestrol acetate (MA) and prednisolone (P) for anorexia and weight loss in patients with lung cancer. Lung Cancer1994;1 Suppl 1:88. ">Macbeth 1994</a> there was no evidence of statistical significance in the median change in TST at 12 weeks in either group. </p> </section> </section> <section id="CD004310-sec-0083"> <h4 class="title">Different dose levels of megestrol acetate</h4> <p>We analysed low doses versus high doses of megestrol. However, the definitions of low dose and high dose were according to those used in each trial. Accordingly, in some trials (such as <a href="./references#CD004310-bbs2-0002" title="BellerE , TattersallM . Improved quality of life with megestrol acetate in patients with endocrine‐insensitive advanced cancer: a randomised placebo‐controlled trial. Annals of Oncology1997;8:277‐83. ">Beller 1997</a>) low doses of MA were described as 160 mg and high doses as 480 mg; while in <a href="./references#CD004310-bbs2-0034" title="CillaDD , GutierrezJL , KristensenA , KramerLD . The safety of megestrol acetate concentrated suspension (MA‐CS) and megestrol acetate oral suspension (MA‐OS) in a pilot study in patients with HIV‐associated unintended weight loss (UWL) [Abstract]. Blood2006;108:43. WankeC , GutierrezJ , KristensenA , MacEarchern , L . Safety and efficacy of two preparations of megestrol acetate in HIV‐infected individuals with weight loss in Africa, India, and the United States. Journal of Applied Research2007;7:206‐16. ">Wanke 2007</a> low doses were defined as 575 mg and high doses as 800 mg. </p> <section id="CD004310-sec-0084"> <h5 class="title">Weight gain</h5> <p>The overall results show weight improvement with high doses versus low doses (RR 0.77, 95% CI 0.64 to 0.93) (<a href="./references#CD004310-bbs2-0009" title="GebbiaV , TestaA . Prospective randomised trial of two dose levels of megestrol acetate in the management of anorexia‐cachexia syndrome in patients with metastatic cancer. British Journal of Cancer1996;73:1576‐80. ">Gebbia 1996</a>; <a href="./references#CD004310-bbs2-0011" title="HeckmayrM , GatzemeierU . Treatment of cancer weight loss in patients with advanced lung cancer. Oncology1992;49(Suppl 2):32‐4. ">Heckmayr 1992</a>; <a href="./references#CD004310-bbs2-0017" title="LoprinziCL , BernathAM . Phase III evaluation of 4 doses of megestrol acetate for patients with cancer anorexia and/or cachexia. Oncology1994;51:2‐7. LoprinziCL , MichalakJC , SchaidDJ , MailliardJA , AthmannLM , GoldbergRM , et al. Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia. Journal of Clinical Oncology1993;11:762‐7. [CN‐00092689] ">Loprinzi 1994</a>; <a href="./references#CD004310-bbs2-0025" title="Sancho‐CuestaJF . Megestrol acetate and weight loss in advanced cancer [Abstract no: 1141]. European Journal of Cancer1993;29A:S204. ">Sancho‐Cuesta 1993</a>; <a href="./references#CD004310-bbs2-0027" title="SchmollE . Risks and benefits of various therapies for cancer anorexia. Oncology1992;49:43‐5. ">Schmoll 1992</a>; <a href="./references#CD004310-bbs2-0031" title="UlutinHC , ArpaciF , PakY . Megestrol acetate for cachexia and anorexia in advanced non‐small cell lung cancer: a randomized study comparing two different doses. Tumori2002;88:277‐80. ">Ulutin 2002</a>) (<a href="./references#CD004310-fig-0020" title="">Analysis 3.2</a>). All these trials were in the subcategory of cancer patients. When we analysed 160 mg of MA versus higher doses, the results remained unchanged, i.e. higher doses showed weight improvement (RR 0.72, 95% CI 0.52 to 0.99) (<a href="./references#CD004310-fig-0021" title="">Analysis 3.3</a>). </p> <p>Only two trials were found for the outcome weight gain as a continuous variable and demonstrated no statistical significance (MD ‐0.94, 95% CI ‐3.33 to 1.45); both were in the subcategory of AIDS patients (<a href="./references#CD004310-fig-0022" title="">Analysis 3.4</a>). </p> </section> <section id="CD004310-sec-0085"> <h5 class="title">Quality of life</h5> <p>Two studies included in this analysis (<a href="./references#CD004310-bbs2-0033" title="VonRoennJH , ArmstrongD . Megestrol acetate in patients with AIDS‐related cachexia. Annals of Internal Medicine1994;121:393‐9. ">Von Roenn 1994</a>; <a href="./references#CD004310-bbs2-0034" title="CillaDD , GutierrezJL , KristensenA , KramerLD . The safety of megestrol acetate concentrated suspension (MA‐CS) and megestrol acetate oral suspension (MA‐OS) in a pilot study in patients with HIV‐associated unintended weight loss (UWL) [Abstract]. Blood2006;108:43. WankeC , GutierrezJ , KristensenA , MacEarchern , L . Safety and efficacy of two preparations of megestrol acetate in HIV‐infected individuals with weight loss in Africa, India, and the United States. Journal of Applied Research2007;7:206‐16. ">Wanke 2007</a>) measured health‐related quality of life as an outcome using different instruments. Quality of life did not show any benefit related to dose (RR 0.81, 95% CI 0.58 to 1.11and SMD 0.26, 95% CI ‐0.23 to 0.76) (<a href="./references#CD004310-fig-0023" title="">Analysis 3.5</a>; <a href="./references#CD004310-fig-0024" title="">Analysis 3.6</a>). </p> </section> <section id="CD004310-sec-0086"> <h5 class="title">Appetite</h5> <p>The overall results show no differences in appetite improvement between doses (high and low doses) (<a href="./references#CD004310-bbs2-0009" title="GebbiaV , TestaA . Prospective randomised trial of two dose levels of megestrol acetate in the management of anorexia‐cachexia syndrome in patients with metastatic cancer. British Journal of Cancer1996;73:1576‐80. ">Gebbia 1996</a>; <a href="./references#CD004310-bbs2-0027" title="SchmollE . Risks and benefits of various therapies for cancer anorexia. Oncology1992;49:43‐5. ">Schmoll 1992</a>; <a href="./references#CD004310-bbs2-0031" title="UlutinHC , ArpaciF , PakY . Megestrol acetate for cachexia and anorexia in advanced non‐small cell lung cancer: a randomized study comparing two different doses. Tumori2002;88:277‐80. ">Ulutin 2002</a>). All trials were in the subcategory of cancer patients. </p> </section> <section id="CD004310-sec-0087"> <h5 class="title">Anthropometric values</h5> <p>In <a href="./references#CD004310-bbs2-0034" title="CillaDD , GutierrezJL , KristensenA , KramerLD . The safety of megestrol acetate concentrated suspension (MA‐CS) and megestrol acetate oral suspension (MA‐OS) in a pilot study in patients with HIV‐associated unintended weight loss (UWL) [Abstract]. Blood2006;108:43. WankeC , GutierrezJ , KristensenA , MacEarchern , L . Safety and efficacy of two preparations of megestrol acetate in HIV‐infected individuals with weight loss in Africa, India, and the United States. Journal of Applied Research2007;7:206‐16. ">Wanke 2007</a> there were no significant changes in TST or MAC in either group. </p> </section> </section> <section id="CD004310-sec-0088"> <h4 class="title">Safety</h4> <p>More than 40 adverse events were studied, categorised into more and less than 800 mg of MA. </p> <p>Fifteen trials reported 'any adverse events' and show an increase in the risk of suffering some of them, independent of dose (RR 1.20, 95% CI 1.07 to 1.36) (<a href="./references#CD004310-fig-0027" title="">Analysis 4.3</a>). All studies except <a href="./references#CD004310-bbs2-0013" title="JatoiA , WindschitlHE . Dronabinol versus megestrol acetate versus combination for cancer‐associated anorexia: A North Central Cancer Treatment Group Study. Journal of Clinical Oncology2002;20:567‐73. ">Jatoi 2002</a> are shown in the forest plot because this study had more 'any adverse events' in both arms than there were patients: 186/159 and 155/152 in the MA and placebo arm respectively. Therefore, 458 'any adverse events' were detected in 830 patients in the MA arm and 358 in 722 patients in the control arm. However, the overall results were the same. </p> <p>The numbers of serious adverse events (SAE) were reported in four trials, but without further information. In these cases, SAEs seemed not to be related to MA (RR 2.10, 95% CI 0.98 to 4.47) (<a href="./references#CD004310-fig-0026" title="">Analysis 4.2</a>). Lower doses seemed to produce more SAEs (RR 4.65, 95% CI 1.33 to 16.29). </p> <p>Dyspnoea was reported in eight trials and was related to MA (RR 2.23, 95% CI 1.01 to 4.93) (<a href="./references#CD004310-fig-0035" title="">Analysis 4.11</a>). Lower doses seemed to produce more dyspnoea (RR 2.80, 95% CI 1.02 to 7.67). </p> <p>Deaths were reported in 11 trials and MA seemed to produce more deaths (RR 1.42, 95% CI 1.04 to 1.94) (<a href="./references#CD004310-fig-0037" title="">Analysis 4.13</a>). Higher doses seemed to produce more deaths (RR 1.66, 95% CI 1.08 to 2.57). </p> <p>Oedema was reported in 15 trials and could be related to MA (RR 1.36, 95% CI 1.07 to 1.72) (<a href="./references#CD004310-fig-0055" title="">Analysis 4.31</a>). Higher doses seemed to produce more oedema (RR 1.37, 95% CI 1.04 to 1.81). </p> <p>Impotence was reported in 13 trials and MA produced more impotence than placebo or other drugs (RR 2.58, 95% CI 1.78 to 3.75) (<a href="./references#CD004310-fig-0048" title="">Analysis 4.24</a>). Both lower and higher doses were related to this adverse event (RR 2.89, 95% CI 1.33 to 6.26 and RR 2.49, 95% CI 1.63 to 3.81, respectively). </p> <p>Nausea and vomiting were reported in 12 trials and MA produced less nausea and vomiting (RR 0.58, 95% CI 0.45 to 0.74) (<a href="./references#CD004310-fig-0053" title="">Analysis 4.29</a>). Both lower and higher doses were related to this adverse event (RR 0.51, 95% CI 0.37 to 0.72 and RR 0.68, 95% CI 0.46 to 1.00, respectively). </p> <p>Thromboembolic phenomena including thrombophlebitis were reported in 11 trials and MA produced an overall increased risk (RR 1.84, 95% CI 1.07 to 3.18) (<a href="./references#CD004310-fig-0066" title="">Analysis 4.42</a>). However, neither higher doses nor lower doses showed statistical significance (RR 2.35, 95% CI 0.93 to 5.94 and RR 1.62, 95% CI 0.82 to 3.18, respectively). </p> <p>Sixteen trials described withdrawals (RR 0.94, 95% CI 0.83 to 1.06) (<a href="./references#CD004310-fig-0068" title="">Analysis 4.44</a>). Neither higher doses nor low doses showed statistical significance in the MA group versus the placebo group (RR 0.92, 95% CI 0.80 to 1.06 and RR 0.98, 95% CI 0.75 to 1.28, respectively). </p> <p>The quality of trials for the outcome of death is shown in <a href="#CD004310-fig-0006">Figure 6</a>. </p> <div class="figure" id="CD004310-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="original image" data-id="CD004310-fig-0006" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> </section> <section id="CD004310-sec-0089"> <h4 class="title">Sensitivity analysis</h4> <p>This 2013 update of the review does not show any change with regard to the sensitivity analyses from the previous review (2006). </p> <p>We undertook sensitivity analysis with trials where patients received more than 12 weeks of MA versus any drugs or placebo for any condition (cancer patients, AIDS, other underlying pathology). We analysed three outcomes: appetite improvement, weight improvement and weight gain. </p> <p>One trial studied appetite at six weeks and did not show an increase in appetite compared to more than six weeks (<a href="./references#CD004310-fig-0069" title="">Analysis 5.1</a>). Appetite did not change with treatment for less or more than 12 weeks (RR 1.80, 95% CI 1.06 to 3.04 and RR 1.56, 95% CI 1.13 to 2.16, respectively) (<a href="./references#CD004310-fig-0070" title="">Analysis 5.2</a>). </p> <p>No differences were shown for weight improvement with less or more than 12 weeks of treatment (RR 1.40, 95% CI 0.90 to 2.18 and RR 1.46, 95% CI 0.92 to 2.31, respectively) (<a href="./references#CD004310-fig-0074" title="">Analysis 5.6</a>). </p> <p>Weight gain was related to treatment duration of less of 12 weeks, but not to more than 12 weeks (MD 1.96 , 95% CI 1.06 to 2.87 and MD 1.94, 95% CI ‐1.64 to 5.53, respectively) (<a href="./references#CD004310-fig-0076" title="">Analysis 5.8</a>). </p> <p>Although appetite is a subjective perception and could be related to blinding, we did not detect this association; on the contrary, we found that only blinded trials showed an increase in appetite (RR 1.96, 95% CI 1.17 to 3.27 and RR 1.53, 95% CI 0.82 to 2.87 for blinded and open‐label trials, respectively) (<a href="./references#CD004310-fig-0077" title="">Analysis 5.9</a>). </p> <p>Weight improvement only showed benefit in blinded trials (RR 1.63, 95% CI 1.15 to 2.32 and RR 1.14, 95% CI 0.53 to 2.47 for blinded and open‐label trials, respectively) (<a href="./references#CD004310-fig-0079" title="">Analysis 5.11</a>). </p> <p>We also analysed according to a more broad definition of quality, using the Jadad scale of high quality (3 to 5 points) or low quality (0 to 2 points). Appetite was not related to quality (high quality RR 2.31, 95% CI 0.93 to 5.72 and low quality RR 1.47, 95% CI 0.96 to 2.27) (<a href="./references#CD004310-fig-0081" title="">Analysis 5.13</a>). Weight improvement was not related to quality (high quality RR 1.50, 95% CI 1.07 to 2.10 and low quality RR 1.60, 95% CI 1.17 to 2.20) (<a href="./references#CD004310-fig-0082" title="">Analysis 5.14</a>). When we analysed weight gain according to quality, both the categories of high and low quality were favourable to MA (MD 1.90, 95% CI 0.89 to 2.91 and MD 2.30, 95% CI 0.25 to 4.35) (<a href="./references#CD004310-fig-0083" title="">Analysis 5.15</a>). </p> <p>We also analysed whether the number of patients in the trials could be related to results for the main outcomes. We analysed two groups with more and fewer than 100 patients. Neither appetite nor weight improvement were related (<a href="./references#CD004310-fig-0087" title="">Analysis 5.19</a> and <a href="./references#CD004310-fig-0080" title="">Analysis 5.12</a>, respectively). However, weight gain in studies with fewer than 100 patients showed a MD of 3.45 (95% CI 0.82 to 6.08) and a MD of 1.13 (95% CI 0.59 to 1.68) with more than 100 patients (<a href="./references#CD004310-fig-0088" title="">Analysis 5.20</a>). Consequently, small trial size may be related to weight gain. </p> <p>We explored the duration of trials with oedema as an adverse event. This seemed to be related to trials of shorter duration: one to four weeks (RR 1.81, 95% CI 1.07 to 3.08), five to eight weeks (RR 1.43, 95% CI 1.04 to 1.97) versus 9 to 12 weeks (RR 1.10, 95% CI 0.82 to 1.46) (<a href="./references#CD004310-fig-0084" title="">Analysis 5.16</a>). When we explored trials with thromboembolic phenomena the shortest trials, with less than 12 weeks of follow‐up, showed a RR of 2.59(95% CI 1.16 to 5.76) whereas trials with follow‐up of 12 or more weeks did not show statistical significance (RR 1.45, 95% CI 0.71 to 2.94) (<a href="./references#CD004310-fig-0085" title="">Analysis 5.17</a>). </p> <p>We carried out two sensitivity analyses to study death. In the first one, we explored duration of exposure to MA and this suggested a link (<a href="./references#CD004310-fig-0093" title="">Analysis 5.25</a>). When deaths and pathology were explored, the association was not significant, but cancer and AIDS patients were more likely to suffer death as an adverse event (<a href="./references#CD004310-fig-0094" title="">Analysis 5.26</a>). The explanation could be thromboembolic phenomena, although pulmonary embolism was not detected in the trials (only two trials reported this). It is known that pulmonary embolism is frequently unreported in 'real life'. We need to emphasise that the mortality results are sensitive to the trial of <a href="./references#CD004310-bbs2-0013" title="JatoiA , WindschitlHE . Dronabinol versus megestrol acetate versus combination for cancer‐associated anorexia: A North Central Cancer Treatment Group Study. Journal of Clinical Oncology2002;20:567‐73. ">Jatoi 2002</a>, so this result needs to be interpreted with caution. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD004310-sec-0090" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD004310-sec-0090"></div> <section id="CD004310-sec-0091"> <h3 class="title" id="CD004310-sec-0091">Summary of main results</h3> <p>The aim of the present update of the review was to assess the efficacy, effectiveness and safety of megestrol acetate (MA) for the management of anorexia‐cachexia syndrome, a common clinical problem that substantially impacts upon the quality of life and survival of affected patients. </p> <p>Our search strategy allowed us to identify all relevant studies. We tried to include more data by requesting this from authors but unfortunately very few new data were introduced in this update. </p> <p>Our systematic review suggests that patients with cachexia‐anorexia syndrome treated with MA improve their weight and appetite (mean difference (MD) for weight gain 1.96 kg (95% confidence interval (CI) 1.11 kg to 2.81 kg) (<a href="./references#CD004310-fig-0083" title="">Analysis 5.15</a>); risk ratio (RR) for appetite improvement for any condition at six or more weeks of follow‐up 1.70 (95% CI 1.14 to 2.54) (<a href="./references#CD004310-fig-0069" title="">Analysis 5.1</a>)). This overall result was obtained from trials with a duration of 14 to 180 days. Most of the trials had a follow‐up of around 56 to 84 days. </p> <p>Appetite and weight improvement was seen in the subcategories of cancer and AIDS patients when comparing MA with placebo. When MA was compared with other drugs, weight improvement was only seen in cancer patients. Quality of life improvement was seen in both subcategories of cancer and AIDS, when comparing MA‐treated patients with placebo, but not against other drugs. However, no clear benefits were detected for quality of life gain (standardised mean difference (SMD) 0.32, 95% CI ‐0.02 to 0.65). </p> <p>More adverse events were related to MA than placebo ('any adverse event') (RR 1.20, 95% CI 1.07 to 1.36). Serious adverse events were related to lower doses (&lt; 800 mg/day RR 4.65, 95% CI 1.33 to 16.29). Dyspnoea seemed to be related to lower doses of MA (RR 2.23, 95% CI 1.01 to 4.93). Oedema and thromboembolic phenomena were common adverse events (RR 1.36, 95% CI 1.07 to 1.72 and RR 1.91, 95% CI 1.13 to 3.23, respectively). Deaths seemed to be increased (RR 1.43, 95% CI 1.05 to 1.96), especially with higher doses (RR 1.66, 95% CI 1.08 to 2.57). We could not pool data for anthropometrics values, but all results from the included trials are shown in <a href="#CD004310-sec-0072">Effects of interventions</a>. </p> </section> <section id="CD004310-sec-0092"> <h3 class="title" id="CD004310-sec-0092">Overall completeness and applicability of evidence</h3> <p>All the planned outcomes have been analysed. Unfortunately, a large proportion of data available in the included trials could not be pooled because the authors did not provide enough information or data were not complete. This review has focused on the patients that were selected in the initial design of the review. Cancer and AIDS patients were the most common disease categories; the elderly and patients with chronic obstructive pulmonary disease (COPD) were new subcategories included in this review. </p> <p>The mortality associated with cachexia‐anorexia syndrome was high and the review failed to show any improvement with MA; in fact mortality was increased. This conclusion should be taken with caution, however, because the severity of illness in these patients is high and they have a high risk of death. Increased death was related only to higher doses in all trials except <a href="./references#CD004310-bbs2-0036" title="YehSS , LovittS , SchusterMW . Usage of megestrol acetate in the treatment of anorexia‐cachexia syndrome in the elderly. Journal of Nutrition, Health and Aging2009;13:448‐54. YehSS , WuSY . Improvement in quality of life measures and stimulation of weight gain after treatment with megestrol acetate oral suspension in geriatric cachexia: results of a double‐blind, placebo‐controlled study. Journal of the American Geriatrics Society2000;48(5):485‐92. YehSS , WuSY , LevineDM , ParkerTS , OlsonJS , StevensMR , et al. The correlation of cytokine levels with body weight after megestrol acetate treatment in geriatric patients. Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2001;56:M48‐54. ">Yeh 2000</a>. It must also be stressed that these results are sensitive to the removal of the trial with most weight (<a href="./references#CD004310-bbs2-0013" title="JatoiA , WindschitlHE . Dronabinol versus megestrol acetate versus combination for cancer‐associated anorexia: A North Central Cancer Treatment Group Study. Journal of Clinical Oncology2002;20:567‐73. ">Jatoi 2002</a>) (RR 2.69, 95% CI 0.93 to 7.78), so must be taken with caution. However, none of the trials included in the review were designed to investigate mortality as primary endpoint and duration of follow‐up was very short in most, so this unexpected result requires serious additional research in the form of clinical trials with longer follow‐up and survival as a main outcome. </p> <p>Most trials defined weight loss as a loss of more than 5% of previous weight. Appetite and weight gain showed benefits, however, in most of the trials this weight gain did not result in the recovery of the initial weight. In particular, the benefits of weight gain compared with placebo were in the range of 2 kg. The likelihood of oedema and thromboembolic phenomena means that patients should be informed of these adverse events. </p> <p>The included trials did not have long‐term follow‐up. Since MA can be prescribed for several months in the treatment of cachexia‐anorexia syndrome, adverse events could be more relevant than those described in the present review. </p> </section> <section id="CD004310-sec-0093"> <h3 class="title" id="CD004310-sec-0093">Quality of the evidence</h3> <p>The main results are shown in <a href="./full#CD004310-tbl-0001">summary of findings Table for the main comparison</a> and we rated the quality from low to high using the GRADE system. We have calculated numbers needed to treat for an additional beneficial outcome (NNTB) from the risk ratio according to the formula NNT or NNH = 1/ACR*(1‐RR), where ACR = assumed control risk and RR = risk ratio. </p> <p> <ol id="CD004310-list-0024"> <li> <p>Appetite improvement versus placebo (<a href="#CD004310-fig-0004">Figure 4</a>). There is an improvement in appetite but the quality of the evidence is downgraded to <b>very low</b> because the risk bias for sequence generation was low only in <a href="./references#CD004310-bbs2-0006" title="FeliuJ , Gonzalez‐BaronM . Usefulness of megestrol acetate in cancer cachexia and anorexia. A placebo controlled study. American Journal of Clinical Oncology1992;15:436‐40. Gonzalez BaronM , FeliuJ , ZamoraP , ArtalA , GarridoP , ChaconI . Usefulness of megestrol acetate on cancer cachexia: a double blind randomized study. Annals of Oncology1990;1:29‐31. ">Feliu 1992</a>. Moreover, allocation concealment was unclear in all trials and in three out of five trials we rated the outcome appetite as high risk of bias because it could be sensitive to lack of blinding. The statistical test for heterogeneity was moderate (P &lt; 0.04 and I<sup>2</sup> = 59%; NNTB = 4, 95% CI 2 to 11). Doses of MA compared with placebo were very different, ranging from 160 mg to 960 mg in each subgroup. </p> </li> <li> <p>Weight improvement versus placebo (<a href="#CD004310-fig-0003">Figure 3</a>). We rated eight out of 10 trials as unclear regarding adequate sequence generation; we rated only one trial as low risk for allocation concealment. We rated all studies as low risk of bias for blinding. We rated <a href="./references#CD004310-bbs2-0026" title="SchmollE , WilkeH , TholeR , PreusserP ,  WildfangI ,  SchmollHJ . Megestrol acetate in cancer cachexia. Seminars in Oncology1991;18(1 Suppl 2):32‐4. [CN‐00072963] ">Schmoll 1991</a>; <a href="./references#CD004310-bbs2-0027" title="SchmollE . Risks and benefits of various therapies for cancer anorexia. Oncology1992;49:43‐5. ">Schmoll 1992</a> and <a href="./references#CD004310-bbs2-0033" title="VonRoennJH , ArmstrongD . Megestrol acetate in patients with AIDS‐related cachexia. Annals of Internal Medicine1994;121:393‐9. ">Von Roenn 1994</a> as low risk because lack of blinding is not related to weight. We rated only one study as high risk of bias due to incomplete outcome data addressed. We rated all trials as unclear with respect to 'other bias'. The results were quite similar and CI values overlapped for most of the trials. However, two studies (<a href="./references#CD004310-bbs2-0006" title="FeliuJ , Gonzalez‐BaronM . Usefulness of megestrol acetate in cancer cachexia and anorexia. A placebo controlled study. American Journal of Clinical Oncology1992;15:436‐40. Gonzalez BaronM , FeliuJ , ZamoraP , ArtalA , GarridoP , ChaconI . Usefulness of megestrol acetate on cancer cachexia: a double blind randomized study. Annals of Oncology1990;1:29‐31. ">Feliu 1992</a>; <a href="./references#CD004310-bbs2-0026" title="SchmollE , WilkeH , TholeR , PreusserP ,  WildfangI ,  SchmollHJ . Megestrol acetate in cancer cachexia. Seminars in Oncology1991;18(1 Suppl 2):32‐4. [CN‐00072963] ">Schmoll 1991</a>) showed higher effects and the CI was quite wide. The statistical test for heterogeneity was moderate (P = 0.02 and I<sup>2</sup> = 53%). The quality of the evidence is <b>very low</b> and the NNTB = 12 (95% CI 6 to 69). </p> </li> <li> <p>Appetite improvement versus other drugs (Figure not shown). Only one trial showed improvement but there was an unclear risk of bias for sequence generation and allocation concealment and a high risk of bias for blinding. The quality of the evidence was low and the NNTB was not statistically significant. </p> </li> <li> <p>Weight improvement versus other drugs (<a href="#CD004310-fig-0005">Figure 5</a>). We rated all studies except <a href="./references#CD004310-bbs2-0023" title="MwamburiDM , GerriorJ , WilsonIB , ChangH , ScullyE , SabooriS , et al. Comparing megestrol acetate therapy with oxandrolone therapy for HIV‐related weight loss: similar results in 2 months. Clinical Infectious Diseases2004;38:895‐902. ">Mwamburi 2004</a> as unclear risk of bias for adequate sequence generation and allocation concealment. The statistical test for heterogeneity was moderate (P = 0.05 and I<sup>2</sup> = 51%). The CI values overlapped for most of the studies. Cancer patients showed a better response in terms of weight. The quality of the evidence was <b>very low</b> and the NNTB = 22 (95% CI 9 to 159). </p> </li> <li> <p>Deaths (<a href="#CD004310-fig-0006">Figure 6</a>). We rated only two trials out of 11 as low risk of bias for adequate sequence generation and blinding. Allocation concealment was unclear in all trials. The CI values did not overlap. There was no large variation in the effect. The statistical test for heterogeneity was low (P &lt; 0.05 and I<sup>2</sup> = 0%). Follow‐up for this outcome was very short (up to 15 weeks) and we cannot disregard the possibility that in 'real life' very sick patients taking MA for a longer time, the number of deaths could increase. The quality of the evidence was <b>very low</b> and the number needed to treat for an additional harmful outcome (NNTH) = 23 (95% CI 10 to 200). </p> </li> <li> <p>Thromboembolic phenomena (Figure not shown). We rated adequate sequence generation as low risk in three out of 10 trials, and rated allocation concealment as low risk only in two out of 10 trials. The statistical test for heterogeneity was low (P &lt; 0.9 and I<sup>2</sup> = 0%). Thrombosis is a common complication in cancer patients and venous thromboembolism (VTE) is found at autopsy in at least 50% of cancer patients (<a href="./references#CD004310-bbs2-0170" title="ThompsonCM , RodgersRL . Analysis of the autopsy records of 157 cases of carcinoma of the pancreas with particular reference to the incidence of thromboembolism. American Journal of the Medical Sciences1952;223:469‐76. ">Thompson 1952</a>). However, assessment of the true incidence of VTE in cancer patients is difficult because most of these patients receive chemotherapy or hormonal therapy which could precipitate VTE. In addition, many cancer patients have indwelling central venous lines, which can also initiate thrombotic events in relation to the catheter (<a href="./references#CD004310-bbs2-0173" title="VersoM , AgnelliG . Venous thromboembolism associated with long‐term use of central venous catheters in cancer patients. Journal of Clinical Oncology2003;21:3665‐75. ">Verso 2003</a>). Consequently, we have calculated the NNTH assuming different basal risks from those obtained in the trials, namely 0.02, 0.10 and 0.50 in cancer patients. The resulting NNTH values were NNTH = 55 (95% CI 22 to 385), NNTH = 11 (95% CI 4 to 77) and NNTH = 2 (95% CI 1 to 15), respectively. The quality of the evidence was <b>very low</b>. </p> </li> <li> <p>Oedema (Figure not shown). We rated only three out of 11 trials as low risk regarding adequate sequence generation. We rated only two out of 11 trials as low risk for allocation concealment. We rated incomplete outcome data as low risk in eight out of 11 trials. The statistical test for heterogeneity was low (P = 0.76 and I<sup>2</sup> = 0%). The quality of the evidence was rated as <b>very low</b> (NNTH = 28, 95% CI 4 to 143). </p> </li> </ol> </p> </section> <section id="CD004310-sec-0094"> <h3 class="title" id="CD004310-sec-0094">Potential biases in the review process</h3> <p>We have estimated that the potential bias in this review is low. Objectivity during the review process cannot be assessed, but the evaluation of trials to be included was done in pairs. We detected one trial that was unpublished due to early stopping because of increased mortality. Despite the fact that this trial was removed, mortality remained unchanged. We created funnels plot for all outcomes with more than 10 trials and these did not suggest publication bias. (These figures are not shown). The authors of this review do not have any conflicts of interest regarding MA. </p> </section> <section id="CD004310-sec-0095"> <h3 class="title" id="CD004310-sec-0095">Agreements and disagreements with other studies or reviews</h3> <p>Previous systematic reviews have shown similar results despite the fact that they did not include the same trials. <a href="./references#CD004310-bbs2-0118" title="Ruiz‐GarciaV , JuanO , Perez HoyosS , PeiroR , RamonN , RoseroMA , et al. Megestrol acetate: a systematic review usefulness about the weight gain in neoplastic patients with cachexia. Medicina Clinica2002;119:166‐70. ">Ruiz‐Garcia 2002</a> found weight gain (MD 0.448 kg, CI 95% 0.02 to 0.87) only with low MA doses (≤ 240 mg). <a href="./references#CD004310-bbs2-0113" title="Pascual LopezA , FigulsM , Urrutia CuchiG , BerensteinEG , Almenar PasiesB , Balcells AlegreM , et al. Systematic review of megestrol acetate in the treatment of anorexia‐cachexia syndrome. Journal of Pain and Symptom Management2004;27:360‐9. ">Pascual 2004</a> concluded that MA improved appetite (RR 2.31, 95% CI 1.52 to 3.59), led to weight gain (RR 1.88, 95% CI 1.43 to 2.47) and improved health‐related quality of life (RR 1.52, 95% CI 1.00 to 2.30). <a href="./references#CD004310-bbs2-0086" title="LesniakW , BalaM , JaeschkeR , KrzakowskiM . Effects of megestrol acetate in patients with cancer anorexia‐cachexia syndrome‐‐a systematic review and meta‐analysis. Polskie Archiwum Medycyny Wewnętrznej2008;118:636‐44. ">Lesniak 2008</a> concluded, as in the present review, that MA increases appetite (RR 3.00, 95% CI 1.86 to 4.84, NNT = 3) and leads to weight gain (RR 1.71, 95% CI 1.24 to 2.36, NNT = 8). None of the reviews mentioned showed an increase in mortality in MA arm. Additionally, they either did not explicitly analyse adverse events or did not include them in their protocols. </p> <p>In palliative medicine, quality of life means not only the control of physical symptoms, functioning in daily life and psychological and social well being; quality of life also implies care of the patient's spiritual and existential concerns and also the perception by members of the patient's family of the quality of their care. It is our opinion that improving appetite and slight weight gain is not enough to improve quality of life in these patients. </p> <p>Prevalence of cachexia in AIDS patients is high (from 18% to 38% in cohort studies) despite antiretroviral therapy (<a href="./references#CD004310-bbs2-0152" title="CampaA , YangZ , LaiS , XueL , PhillipsJC , SalesS , et al. HIV‐related wasting in HIV‐infected drug users in the era of highly active antiretroviral therapy. Clinical Infectious Diseases2005;41:1179‐85. ">Campa 2005</a>; <a href="./references#CD004310-bbs2-0169" title="TangAM , JacobsonDL , SpiegelmanD , KnoxTA , WankeCA . Increasing risk of 5% or greater unintentional weight loss in a cohort of HIV‐infected patients, 1995 to 2003. Journal of Acquired Immune Deficiency Syndromes2005;40:70‐6. ">Tang 2005</a>). The prevalence of weight loss and wasting has not changed over time; it is as frequent now as it was in 1997 (<a href="./references#CD004310-bbs2-0169" title="TangAM , JacobsonDL , SpiegelmanD , KnoxTA , WankeCA . Increasing risk of 5% or greater unintentional weight loss in a cohort of HIV‐infected patients, 1995 to 2003. Journal of Acquired Immune Deficiency Syndromes2005;40:70‐6. ">Tang 2005</a>). The conclusion of the present review is in line with the statement of <a href="./references#CD004310-bbs2-0163" title="MangiliA , MurmanDH , ZampiniAM , WankeCA . Nutrition and HIV infection: review of weight loss and wasting in the era of highly active antiretroviral therapy from the nutrition for healthy living cohort. Clinical Infectious Diseases2006;42:836‐42. ">Mangili 2006</a>, "Although there has been the presumption that, if weight loss is associated with morbidity and mortality in HIV infection, then improvements in weight would lead to improved QoL, there has been little data that support this”. The conclusions of this review regarding geriatric patients are in line with the guidelines of the American Geriatrics Society (<a href="./references#CD004310-bbs2-0155" title="FickD , SemlaT , BeizerJ , BrandtN , DombrowskiR , DuBeauCE , et al. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society2012;60(4):616‐31. ">Fick 2012</a>) which state “Rationale: minimal effect on weight; increases risk of thrombotic events and possibly risk of death in older.. Recomendation: Avoid; Quality of evidence: moderate; Strenght of recommendation: Strong". </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD004310-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD004310-fig-0001" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/full#CD004310-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias" data-id="CD004310-fig-0002" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/full#CD004310-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD004310-fig-0003" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/full#CD004310-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD004310-fig-0004" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/full#CD004310-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD004310-fig-0005" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/full#CD004310-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD004310-fig-0006" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/full#CD004310-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Megestrol acetate versus placebo (ITT), Outcome 1 Appetite improvement." data-id="CD004310-fig-0007" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Megestrol acetate versus placebo (ITT), Outcome 1 Appetite improvement.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Megestrol acetate versus placebo (ITT), Outcome 2 Appetite gain." data-id="CD004310-fig-0008" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Megestrol acetate versus placebo (ITT), Outcome 2 Appetite gain.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Megestrol acetate versus placebo (ITT), Outcome 3 Weight improvement." data-id="CD004310-fig-0009" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Megestrol acetate versus placebo (ITT), Outcome 3 Weight improvement.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Megestrol acetate versus placebo (ITT), Outcome 4 Weight gain." data-id="CD004310-fig-0010" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Megestrol acetate versus placebo (ITT), Outcome 4 Weight gain.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Megestrol acetate versus placebo (ITT), Outcome 5 Quality of life improvement." data-id="CD004310-fig-0011" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Megestrol acetate versus placebo (ITT), Outcome 5 Quality of life improvement.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Megestrol acetate versus placebo (ITT), Outcome 6 Quality of life gain." data-id="CD004310-fig-0012" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Megestrol acetate versus placebo (ITT), Outcome 6 Quality of life gain.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Megestrol acetate versus other drugs (ITT), Outcome 1 Appetite improvement." data-id="CD004310-fig-0013" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Megestrol acetate versus other drugs (ITT), Outcome 1 Appetite improvement.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Megestrol acetate versus other drugs (ITT), Outcome 2 Appetite gain." data-id="CD004310-fig-0014" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Megestrol acetate versus other drugs (ITT), Outcome 2 Appetite gain.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Megestrol acetate versus other drugs (ITT), Outcome 3 Weight improvement." data-id="CD004310-fig-0015" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Megestrol acetate versus other drugs (ITT), Outcome 3 Weight improvement.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Megestrol acetate versus other drugs (ITT), Outcome 4 Weight gain." data-id="CD004310-fig-0016" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Megestrol acetate versus other drugs (ITT), Outcome 4 Weight gain.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Megestrol acetate versus other drugs (ITT), Outcome 5 Quality of life improvement." data-id="CD004310-fig-0017" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Megestrol acetate versus other drugs (ITT), Outcome 5 Quality of life improvement. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Megestrol acetate versus other drugs (ITT), Outcome 6 Quality of life gain." data-id="CD004310-fig-0018" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Megestrol acetate versus other drugs (ITT), Outcome 6 Quality of life gain. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Megestrol acetate versus megestrol acetate (ITT), Outcome 1 Appetite improvement." data-id="CD004310-fig-0019" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Megestrol acetate versus megestrol acetate (ITT), Outcome 1 Appetite improvement. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Megestrol acetate versus megestrol acetate (ITT), Outcome 2 Weight improvement." data-id="CD004310-fig-0020" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Megestrol acetate versus megestrol acetate (ITT), Outcome 2 Weight improvement.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Megestrol acetate versus megestrol acetate (ITT), Outcome 3 Weight improvement 160 mg versus other higher doses." data-id="CD004310-fig-0021" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Megestrol acetate versus megestrol acetate (ITT), Outcome 3 Weight improvement 160 mg versus other higher doses. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Megestrol acetate versus megestrol acetate (ITT), Outcome 4 Weight gain." data-id="CD004310-fig-0022" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Megestrol acetate versus megestrol acetate (ITT), Outcome 4 Weight gain.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Megestrol acetate versus megestrol acetate (ITT), Outcome 5 Quality of life improvement." data-id="CD004310-fig-0023" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Megestrol acetate versus megestrol acetate (ITT), Outcome 5 Quality of life improvement. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Megestrol acetate versus megestrol acetate (ITT), Outcome 6 Quality of life gain." data-id="CD004310-fig-0024" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 Megestrol acetate versus megestrol acetate (ITT), Outcome 6 Quality of life gain. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Safety, Outcome 1 Acute decompensation of COPD or pulmonary exacerbation." data-id="CD004310-fig-0025" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Safety, Outcome 1 Acute decompensation of COPD or pulmonary exacerbation.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Safety, Outcome 2 Serious adverse events (SAE)." data-id="CD004310-fig-0026" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Safety, Outcome 2 Serious adverse events (SAE).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Safety, Outcome 3 Any adverse event." data-id="CD004310-fig-0027" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Safety, Outcome 3 Any adverse event.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Safety, Outcome 4 Abdominal pain." data-id="CD004310-fig-0028" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Safety, Outcome 4 Abdominal pain.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-004-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-004-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Safety, Outcome 5 Abnormal appetite." data-id="CD004310-fig-0029" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4 Safety, Outcome 5 Abnormal appetite.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-004-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-004-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Safety, Outcome 6 Amenorrhoea/irregular menses." data-id="CD004310-fig-0030" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4 Safety, Outcome 6 Amenorrhoea/irregular menses.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-004-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-004-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Safety, Outcome 7 Bowel obstruction." data-id="CD004310-fig-0031" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4 Safety, Outcome 7 Bowel obstruction.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-004-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-004-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Safety, Outcome 8 Constipation." data-id="CD004310-fig-0032" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.8</div> <div class="figure-caption"> <p>Comparison 4 Safety, Outcome 8 Constipation.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-004-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-004-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Safety, Outcome 9 Chest pain." data-id="CD004310-fig-0033" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.9</div> <div class="figure-caption"> <p>Comparison 4 Safety, Outcome 9 Chest pain.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-004-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-004-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Safety, Outcome 10 Confusion." data-id="CD004310-fig-0034" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.10</div> <div class="figure-caption"> <p>Comparison 4 Safety, Outcome 10 Confusion.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-004-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-004-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Safety, Outcome 11 Dyspnoea." data-id="CD004310-fig-0035" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.11</div> <div class="figure-caption"> <p>Comparison 4 Safety, Outcome 11 Dyspnoea.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-004-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-004-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Safety, Outcome 12 Depression." data-id="CD004310-fig-0036" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.12</div> <div class="figure-caption"> <p>Comparison 4 Safety, Outcome 12 Depression.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-004-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-004-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Safety, Outcome 13 Deaths." data-id="CD004310-fig-0037" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.13</div> <div class="figure-caption"> <p>Comparison 4 Safety, Outcome 13 Deaths.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-004-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-004-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Safety, Outcome 14 Diarrhoea." data-id="CD004310-fig-0038" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.14</div> <div class="figure-caption"> <p>Comparison 4 Safety, Outcome 14 Diarrhoea.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-004-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-004-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Safety, Outcome 15 Drowsiness." data-id="CD004310-fig-0039" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.15</div> <div class="figure-caption"> <p>Comparison 4 Safety, Outcome 15 Drowsiness.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-004-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-004-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Safety, Outcome 16 Elevated transaminase levels." data-id="CD004310-fig-0040" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.16</div> <div class="figure-caption"> <p>Comparison 4 Safety, Outcome 16 Elevated transaminase levels.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-004-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-004-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Safety, Outcome 17 Glucose intolerance." data-id="CD004310-fig-0041" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.17</div> <div class="figure-caption"> <p>Comparison 4 Safety, Outcome 17 Glucose intolerance.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-004-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-004-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Safety, Outcome 18 Hallucinations/psychosis." data-id="CD004310-fig-0042" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.18</div> <div class="figure-caption"> <p>Comparison 4 Safety, Outcome 18 Hallucinations/psychosis.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-004-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-004-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Safety, Outcome 19 Headaches." data-id="CD004310-fig-0043" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.19</div> <div class="figure-caption"> <p>Comparison 4 Safety, Outcome 19 Headaches.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-004-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-004-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Safety, Outcome 20 Hyperphagia." data-id="CD004310-fig-0044" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.20</div> <div class="figure-caption"> <p>Comparison 4 Safety, Outcome 20 Hyperphagia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-004-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-004-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Safety, Outcome 21 Heart burn." data-id="CD004310-fig-0045" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.21</div> <div class="figure-caption"> <p>Comparison 4 Safety, Outcome 21 Heart burn.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-004-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-004-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Safety, Outcome 22 Heart failure." data-id="CD004310-fig-0046" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.22</div> <div class="figure-caption"> <p>Comparison 4 Safety, Outcome 22 Heart failure.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-004-23" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-004-23.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Safety, Outcome 23 Hypertension." data-id="CD004310-fig-0047" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-23.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.23</div> <div class="figure-caption"> <p>Comparison 4 Safety, Outcome 23 Hypertension.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-23.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-004-24" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-004-24.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Safety, Outcome 24 Impotence." data-id="CD004310-fig-0048" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-24.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.24</div> <div class="figure-caption"> <p>Comparison 4 Safety, Outcome 24 Impotence.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-24.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-004-25" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-004-25.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Safety, Outcome 25 Infections." data-id="CD004310-fig-0049" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-25.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.25</div> <div class="figure-caption"> <p>Comparison 4 Safety, Outcome 25 Infections.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-25.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-004-26" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-004-26.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Safety, Outcome 26 Inappropriate behaviour." data-id="CD004310-fig-0050" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-26.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.26</div> <div class="figure-caption"> <p>Comparison 4 Safety, Outcome 26 Inappropriate behaviour.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-26.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-004-27" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-004-27.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Safety, Outcome 27 Insomnia." data-id="CD004310-fig-0051" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-27.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.27</div> <div class="figure-caption"> <p>Comparison 4 Safety, Outcome 27 Insomnia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-27.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-004-28" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-004-28.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Safety, Outcome 28 Loss of co‐ordination." data-id="CD004310-fig-0052" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-28.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.28</div> <div class="figure-caption"> <p>Comparison 4 Safety, Outcome 28 Loss of co‐ordination.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-28.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-004-29" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-004-29.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Safety, Outcome 29 Nausea/vomiting." data-id="CD004310-fig-0053" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-29.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.29</div> <div class="figure-caption"> <p>Comparison 4 Safety, Outcome 29 Nausea/vomiting.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-29.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-004-30" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-004-30.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Safety, Outcome 30 Neoplasma." data-id="CD004310-fig-0054" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-30.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.30</div> <div class="figure-caption"> <p>Comparison 4 Safety, Outcome 30 Neoplasma.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-30.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-004-31" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-004-31.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Safety, Outcome 31 Oedema." data-id="CD004310-fig-0055" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-31.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.31</div> <div class="figure-caption"> <p>Comparison 4 Safety, Outcome 31 Oedema.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-31.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-004-32" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-004-32.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Safety, Outcome 32 Pneumonia." data-id="CD004310-fig-0056" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-32.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.32</div> <div class="figure-caption"> <p>Comparison 4 Safety, Outcome 32 Pneumonia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-32.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-004-33" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-004-33.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Safety, Outcome 33 Pruritus." data-id="CD004310-fig-0057" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-33.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.33</div> <div class="figure-caption"> <p>Comparison 4 Safety, Outcome 33 Pruritus.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-33.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-004-34" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-004-34.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Safety, Outcome 34 Pyrosis." data-id="CD004310-fig-0058" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-34.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.34</div> <div class="figure-caption"> <p>Comparison 4 Safety, Outcome 34 Pyrosis.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-34.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-004-35" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-004-35.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Safety, Outcome 35 Pulmonary embolism." data-id="CD004310-fig-0059" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-35.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.35</div> <div class="figure-caption"> <p>Comparison 4 Safety, Outcome 35 Pulmonary embolism.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-35.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-004-36" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-004-36.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Safety, Outcome 36 Respiratory failure." data-id="CD004310-fig-0060" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-36.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.36</div> <div class="figure-caption"> <p>Comparison 4 Safety, Outcome 36 Respiratory failure.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-36.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-004-37" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-004-37.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Safety, Outcome 37 Other adverse events." data-id="CD004310-fig-0061" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-37.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.37</div> <div class="figure-caption"> <p>Comparison 4 Safety, Outcome 37 Other adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-37.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-004-38" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-004-38.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Safety, Outcome 38 Skin disorder (includes vesiculobullous rash)." data-id="CD004310-fig-0062" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-38.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.38</div> <div class="figure-caption"> <p>Comparison 4 Safety, Outcome 38 Skin disorder (includes vesiculobullous rash).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-38.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-004-39" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-004-39.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Safety, Outcome 39 Sweating." data-id="CD004310-fig-0063" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-39.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.39</div> <div class="figure-caption"> <p>Comparison 4 Safety, Outcome 39 Sweating.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-39.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-004-40" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-004-40.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Safety, Outcome 40 Swelling legs or abdominal." data-id="CD004310-fig-0064" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-40.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.40</div> <div class="figure-caption"> <p>Comparison 4 Safety, Outcome 40 Swelling legs or abdominal.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-40.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-004-41" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-004-41.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Safety, Outcome 41 Stroke." data-id="CD004310-fig-0065" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-41.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.41</div> <div class="figure-caption"> <p>Comparison 4 Safety, Outcome 41 Stroke.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-41.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-004-42" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-004-42.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Safety, Outcome 42 Thromboembolic phenomena including thrombophlebitis." data-id="CD004310-fig-0066" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-42.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.42</div> <div class="figure-caption"> <p>Comparison 4 Safety, Outcome 42 Thromboembolic phenomena including thrombophlebitis.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-42.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-004-43" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-004-43.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Safety, Outcome 43 Testicular shrinkage." data-id="CD004310-fig-0067" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-43.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.43</div> <div class="figure-caption"> <p>Comparison 4 Safety, Outcome 43 Testicular shrinkage.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-43.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-004-44" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-004-44.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Safety, Outcome 44 Withdrawals." data-id="CD004310-fig-0068" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-44.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.44</div> <div class="figure-caption"> <p>Comparison 4 Safety, Outcome 44 Withdrawals.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-004-44.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Sensitivity analyses, Outcome 1 Appetite improvement treatment duration 6 weeks." data-id="CD004310-fig-0069" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Sensitivity analyses, Outcome 1 Appetite improvement treatment duration 6 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Sensitivity analyses, Outcome 2 Appetite improvement treatment duration 12 weeks." data-id="CD004310-fig-0070" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Sensitivity analyses, Outcome 2 Appetite improvement treatment duration 12 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-005-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-005-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Sensitivity analyses, Outcome 3 Appetite gain 12 weeks." data-id="CD004310-fig-0071" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-005-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 Sensitivity analyses, Outcome 3 Appetite gain 12 weeks.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-005-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-005-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-005-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Sensitivity analyses, Outcome 4 Weight improvement treatment duration 6 weeks." data-id="CD004310-fig-0072" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-005-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5 Sensitivity analyses, Outcome 4 Weight improvement treatment duration 6 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-005-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-005-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-005-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Sensitivity analyses, Outcome 5 Quality of life gain." data-id="CD004310-fig-0073" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-005-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5 Sensitivity analyses, Outcome 5 Quality of life gain.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-005-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-005-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-005-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Sensitivity analyses, Outcome 6 Weight improvement 12 weeks." data-id="CD004310-fig-0074" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-005-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5 Sensitivity analyses, Outcome 6 Weight improvement 12 weeks.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-005-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0075"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-005-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-005-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Sensitivity analyses, Outcome 7 Weight gain 6 weeks." data-id="CD004310-fig-0075" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-005-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.7</div> <div class="figure-caption"> <p>Comparison 5 Sensitivity analyses, Outcome 7 Weight gain 6 weeks.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0075">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-005-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0076"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-005-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-005-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Sensitivity analyses, Outcome 8 Weight gain 12 weeks." data-id="CD004310-fig-0076" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-005-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.8</div> <div class="figure-caption"> <p>Comparison 5 Sensitivity analyses, Outcome 8 Weight gain 12 weeks.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0076">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-005-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0077"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-005-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-005-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Sensitivity analyses, Outcome 9 Blinded versus open‐label appetite improvement." data-id="CD004310-fig-0077" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-005-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.9</div> <div class="figure-caption"> <p>Comparison 5 Sensitivity analyses, Outcome 9 Blinded versus open‐label appetite improvement.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0077">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-005-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0078"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-005-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-005-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Sensitivity analyses, Outcome 10 Blinded versus open‐label appetite gain." data-id="CD004310-fig-0078" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-005-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.10</div> <div class="figure-caption"> <p>Comparison 5 Sensitivity analyses, Outcome 10 Blinded versus open‐label appetite gain.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0078">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-005-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0079"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-005-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-005-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Sensitivity analyses, Outcome 11 Blinded versus open‐label weight Improvement." data-id="CD004310-fig-0079" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-005-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.11</div> <div class="figure-caption"> <p>Comparison 5 Sensitivity analyses, Outcome 11 Blinded versus open‐label weight Improvement.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0079">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-005-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0080"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-005-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-005-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Sensitivity analyses, Outcome 12 Sensitivity number patients weight improvement." data-id="CD004310-fig-0080" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-005-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.12</div> <div class="figure-caption"> <p>Comparison 5 Sensitivity analyses, Outcome 12 Sensitivity number patients weight improvement.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0080">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-005-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0081"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-005-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-005-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Sensitivity analyses, Outcome 13 Appetite improvement, study quality." data-id="CD004310-fig-0081" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-005-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.13</div> <div class="figure-caption"> <p>Comparison 5 Sensitivity analyses, Outcome 13 Appetite improvement, study quality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0081">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-005-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0082"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-005-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-005-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Sensitivity analyses, Outcome 14 Weight improvement, study quality." data-id="CD004310-fig-0082" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-005-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.14</div> <div class="figure-caption"> <p>Comparison 5 Sensitivity analyses, Outcome 14 Weight improvement, study quality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0082">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-005-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0083"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-005-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-005-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Sensitivity analyses, Outcome 15 Weight gain, study quality." data-id="CD004310-fig-0083" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-005-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.15</div> <div class="figure-caption"> <p>Comparison 5 Sensitivity analyses, Outcome 15 Weight gain, study quality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0083">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-005-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0084"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-005-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-005-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Sensitivity analyses, Outcome 16 Sensitivity duration oedema." data-id="CD004310-fig-0084" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-005-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.16</div> <div class="figure-caption"> <p>Comparison 5 Sensitivity analyses, Outcome 16 Sensitivity duration oedema.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0084">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-005-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0085"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-005-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-005-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Sensitivity analyses, Outcome 17 Sensitivity duration thromboembolic phenomena." data-id="CD004310-fig-0085" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-005-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.17</div> <div class="figure-caption"> <p>Comparison 5 Sensitivity analyses, Outcome 17 Sensitivity duration thromboembolic phenomena. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0085">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-005-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0086"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-005-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-005-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Sensitivity analyses, Outcome 18 Sensitivity blinded versus open‐label weight gain." data-id="CD004310-fig-0086" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-005-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.18</div> <div class="figure-caption"> <p>Comparison 5 Sensitivity analyses, Outcome 18 Sensitivity blinded versus open‐label weight gain. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0086">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-005-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0087"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-005-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-005-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Sensitivity analyses, Outcome 19 Sensitivity number of patients in trial appetite improvement." data-id="CD004310-fig-0087" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-005-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.19</div> <div class="figure-caption"> <p>Comparison 5 Sensitivity analyses, Outcome 19 Sensitivity number of patients in trial appetite improvement. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0087">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-005-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0088"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-005-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-005-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Sensitivity analyses, Outcome 20 Sensitivity number of patients weight gain." data-id="CD004310-fig-0088" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-005-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.20</div> <div class="figure-caption"> <p>Comparison 5 Sensitivity analyses, Outcome 20 Sensitivity number of patients weight gain. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0088">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-005-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0089"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-005-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-005-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Sensitivity analyses, Outcome 21 Sensitivity appetite improvement cancer." data-id="CD004310-fig-0089" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-005-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.21</div> <div class="figure-caption"> <p>Comparison 5 Sensitivity analyses, Outcome 21 Sensitivity appetite improvement cancer.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0089">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-005-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0090"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-005-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-005-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Sensitivity analyses, Outcome 22 Appetite improvement doses." data-id="CD004310-fig-0090" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-005-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.22</div> <div class="figure-caption"> <p>Comparison 5 Sensitivity analyses, Outcome 22 Appetite improvement doses.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0090">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-005-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0091"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-005-23" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-005-23.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Sensitivity analyses, Outcome 23 Weight improvement doses." data-id="CD004310-fig-0091" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-005-23.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.23</div> <div class="figure-caption"> <p>Comparison 5 Sensitivity analyses, Outcome 23 Weight improvement doses.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0091">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-005-23.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0092"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-005-24" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-005-24.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Sensitivity analyses, Outcome 24 Sensitivity (cancer/other patients) thromboembolic phenomena." data-id="CD004310-fig-0092" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-005-24.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.24</div> <div class="figure-caption"> <p>Comparison 5 Sensitivity analyses, Outcome 24 Sensitivity (cancer/other patients) thromboembolic phenomena. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0092">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-005-24.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0093"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-005-25" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-005-25.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Sensitivity analyses, Outcome 25 Deaths sensitivity 6 weeks." data-id="CD004310-fig-0093" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-005-25.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.25</div> <div class="figure-caption"> <p>Comparison 5 Sensitivity analyses, Outcome 25 Deaths sensitivity 6 weeks.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0093">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-005-25.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004310-fig-0094"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/urn:x-wiley:14651858:media:CD004310:CD004310-CMP-005-26" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_t/tCD004310-CMP-005-26.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Sensitivity analyses, Outcome 26 Deaths sensitivity/pathology." data-id="CD004310-fig-0094" src="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-005-26.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.26</div> <div class="figure-caption"> <p>Comparison 5 Sensitivity analyses, Outcome 26 Deaths sensitivity/pathology.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-fig-0094">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/media/CDSR/CD004310/image_n/nCD004310-CMP-005-26.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD004310-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Megestrol acetate for cachexia anorexia syndrome</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Megestrol acetate for cachexia anorexia syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> cachexia anorexia syndrome<br/> <b>Settings:</b> cancer patients, AIDS patients and patients with other underlying conditions<br/> <b>Intervention:</b> megestrol acetate </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Megestrol acetate </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Appetite improvement compared with placebo</b><br/> Subjective sense of appetite, responses to follow‐up questionnaire<br/> Follow‐up: mean 4 to 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 2.19</b> <br/> (1.41 to 3.4) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>699<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NNTB = 4 (95% CI 2 to 11)</p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>214 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>469 per 1000</b><br/> (302 to 728) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Weight improvement compared with placebo</b><br/> % of patients that improved their weight in kg<br/> Follow‐up: mean 4 to 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.51</b> <br/> (1.08 to 2.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1106<br/> (10 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>3,4,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>NNTB = 12 (95% CI 6 to 69)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>246 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>329 per 1000</b><br/> (260 to 408) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>233 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>312 per 1000</b><br/> (247 to 387) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Appetite improvement compared to other drugs</b><br/> Questionnaire of appetite rating<br/> Follow‐up: median 8 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.03</b> <br/> (0.64 to 1.67) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>475<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>6,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>NNTB = NS</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>325 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>335 per 1000</b><br/> (208 to 543) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>325 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>335 per 1000</b><br/> (208 to 543) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Weight improvement compared to other drugs</b><br/> % of patients that improved their weight in kg<br/> Follow‐up: mean 8 to 15 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.66</b> <br/> (1.09 to 2.52) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1131<br/> (7 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>3,8,9,10</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>NNTB = 22 (95% CI 9 to 159)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>72 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>119 per 1000</b><br/> (78 to 180) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>57 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>95 per 1000</b><br/> (62 to 144) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Deaths</b><br/> Follow‐up: mean 2 to 15 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 1.42</b> <br/> (1.04 to 1.94) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>1307<br/> (10 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>11,12,13,14</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>NNTH = 23 (95% CI 10 to 200)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>102 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>146 per 1000</b><br/> (107 to 200) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>48 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>69 per 1000</b><br/> (50 to 94) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Thromboembolic phenomena including thrombophlebitis</b><br/> Follow‐up: mean 4 to 16 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.84</b> <br/> (1.07 to 3.18) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1544<br/> (11 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>13,15,16</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>NNTH = 55 (95% CI 22 to 385)<br/> NNTH = 11 (95% CI 4 to 77)<br/> NNTH = 2 (95% CI 1 to 15) <sup>17</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>191 per 1000</b><br/> (113 to 323) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>500 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>955 per 1000</b><br/> (565 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Oedema</b><br/> Follow‐up: mean 2 to 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.36</b> <br/> (1.07 to 1.72) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2182<br/> (12 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>18,19</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>NNTH = 28 (95% CI 4 to 143)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>104 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>141 per 1000</b><br/> (111 to 179) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>109 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>148 per 1000</b><br/> (117 to 187) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval;<b>NNTB:</b> number needed to treat for an additional beneficial outcome; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Adequate sequence generation was low risk only in <a href="./references#CD004310-bbs2-0006" title="FeliuJ , Gonzalez‐BaronM . Usefulness of megestrol acetate in cancer cachexia and anorexia. A placebo controlled study. American Journal of Clinical Oncology1992;15:436‐40. Gonzalez BaronM , FeliuJ , ZamoraP , ArtalA , GarridoP , ChaconI . Usefulness of megestrol acetate on cancer cachexia: a double blind randomized study. Annals of Oncology1990;1:29‐31. ">Feliu 1992</a>. Allocation concealment was unclear in all studies. In three out of five studies appetite was rated as high risk of bias because it could be sensitive to lack of blinding.<br/> <sup>2</sup> The two different subcategories (cancer and AIDS patients) showed similar effects. Heterogeneity was moderate (I<sup>2</sup> = 59%) and is due to the study of <a href="./references#CD004310-bbs2-0026" title="SchmollE , WilkeH , TholeR , PreusserP ,  WildfangI ,  SchmollHJ . Megestrol acetate in cancer cachexia. Seminars in Oncology1991;18(1 Suppl 2):32‐4. [CN‐00072963] ">Schmoll 1991</a>. Heterogeneity without this study became low (I<sup>2</sup> = 39%). The confidence intervals of the studies overlap.<br/> <sup>3</sup> Doses of MA were very different (960 mg, 800 mg, 480 and 160 mg) compared with placebo.<br/> <sup>4</sup> Eight out of 10 studies were rated as unclear for adequate sequence generation; only one study was rated as low risk for allocation concealment. All studies were rated as low risk of bias for blinding. <a href="./references#CD004310-bbs2-0026" title="SchmollE , WilkeH , TholeR , PreusserP ,  WildfangI ,  SchmollHJ . Megestrol acetate in cancer cachexia. Seminars in Oncology1991;18(1 Suppl 2):32‐4. [CN‐00072963] ">Schmoll 1991</a>, <a href="./references#CD004310-bbs2-0027" title="SchmollE . Risks and benefits of various therapies for cancer anorexia. Oncology1992;49:43‐5. ">Schmoll 1992</a> and <a href="./references#CD004310-bbs2-0033" title="VonRoennJH , ArmstrongD . Megestrol acetate in patients with AIDS‐related cachexia. Annals of Internal Medicine1994;121:393‐9. ">Von Roenn 1994</a> were rated low risk because lack of blinding is not related to weight. Only one study was rated as high risk of bias for incomplete outcome data. All trials were rated unclear with respect to freedom from 'other bias'.<br/> <sup>5</sup> The effect is quite similar and CI values overlap for most of the studies. However, two studies (Feliu and Schmoll) showed greater effects and the CI was quite wide. The study of <a href="./references#CD004310-bbs2-0036" title="YehSS , LovittS , SchusterMW . Usage of megestrol acetate in the treatment of anorexia‐cachexia syndrome in the elderly. Journal of Nutrition, Health and Aging2009;13:448‐54. YehSS , WuSY . Improvement in quality of life measures and stimulation of weight gain after treatment with megestrol acetate oral suspension in geriatric cachexia: results of a double‐blind, placebo‐controlled study. Journal of the American Geriatrics Society2000;48(5):485‐92. YehSS , WuSY , LevineDM , ParkerTS , OlsonJS , StevensMR , et al. The correlation of cytokine levels with body weight after megestrol acetate treatment in geriatric patients. Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2001;56:M48‐54. ">Yeh 2000</a> showed different results in patients with geriatric cachexia to patients with neoplasia and AIDS. Heterogeneity was moderate (I<sup>2</sup> = 53%).<br/> <sup>6</sup> The only study found was rated as unclear risk of bias for adequate sequence generation and allocation concealment. It was not a blinded study and was rated as high risk of bias for the blinding item.<br/> <sup>7</sup> We pooled the results of two comparisons: MA versus dexamethasone and fluoxymesterone.<br/> <sup>8</sup> All studies except <a href="./references#CD004310-bbs2-0023" title="MwamburiDM , GerriorJ , WilsonIB , ChangH , ScullyE , SabooriS , et al. Comparing megestrol acetate therapy with oxandrolone therapy for HIV‐related weight loss: similar results in 2 months. Clinical Infectious Diseases2004;38:895‐902. ">Mwamburi 2004</a> were rated as unclear risk of bias for adequate sequence generation and allocation concealment study.<br/> <sup>9</sup> Heterogeneity was moderate (I<sup>2</sup> = 51%) but heterogeneity between subgroups was high. The effect seemed to be different in cancer and AIDS patients. The CI values overlapped for most of the studies. Cancer patients showed a better response for weight.<br/> <sup>10</sup> The CI interval (9 to 159) is too wide to establish a true effect.<br/> <sup>11</sup> Only one study out of seven was rated as low risk of bias for adequate sequence generation and allocation concealment.<br/> <sup>12</sup> Although the I<sup>2</sup> in both subgroups was 0% and the overall I<sup>2</sup> was low (6.4%), patients with cancer, AIDS and other pathologies were quite different. Moreover the comparator included placebo and other drugs.<br/> <sup>13</sup> Different doses of MA in each subgroup.<br/> <sup>14</sup> The CI interval for the NNT (10 to 200) is too wide to establish a true effect.<br/> <sup>15</sup> Adequate sequence generation was rated as low risk in three out of 10 trials and allocation concealment was rated low risk only in two out of 10.<br/> <sup>16</sup> Although the I<sup>2</sup> in both subgroups was 0% and the overall I<sup>2</sup> was low (0%), patients with cancer, AIDS and other pathologies were quite different. Moreover the comparator included placebo and other drugs.<br/> <sup>17</sup> The first NNTH was calculated with data of this Systematic Review. The second NNTH was calculated with an expected value of 0.10% and the last was calculated with an expected rate of 50%.<br/> <sup>18</sup> Only three out of 11 trials were rated as low risk for adequate sequence generation. Only two out of 11 trials were rated as low risk for allocation concealment.<br/> <sup>19</sup> Although the I<sup>2</sup> in both subgroups was 0% and the overall I<sup>2</sup> was low (0%), patients with cancer, AIDS and other pathologies such as COPD were quite different. Moreover the comparator included placebo and other drugs. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Megestrol acetate for cachexia anorexia syndrome</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/full#CD004310-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD004310-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Patient condition and numbers recruited to each trial</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Lung cancer</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Gastrointestinal and pancreas</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Head and neck cancer</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Gynaecological cancer</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Other cancer</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>AIDS</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>COPD</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cystic fibrosis</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Elderly</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004310-bbs2-0001" title="BatterhamM , GarsiaR . Randomised prospective medium term comparison of megestrol acetate, nandrolone decanoate and dietary therapy alone for HIV associated weight loss [abstract]. Australasian Society for HIV Medicine1997;9:91. BatterhamMJ , GarsiaR . A comparison of megestrol acetate, nandrolone decanoate and dietary counselling for HIV associated weight loss. International Journal of Andrology2001;24(4):232‐40. ">Batterham 2001</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004310-bbs2-0002" title="BellerE , TattersallM . Improved quality of life with megestrol acetate in patients with endocrine‐insensitive advanced cancer: a randomised placebo‐controlled trial. Annals of Oncology1997;8:277‐83. ">Beller 1997</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>106</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004310-bbs2-0003" title="Casado HerráezA . Phase II randomized study of two dose levels of megestrol acetate versus placebo for the treatment of anorexia and cachexia in patients with locoregional advanced or metastatic cancer [Estudio de fase II randomizado de dos niveles posológicos de acetato de Megestrol versus placebo para el tratamiento de la anorexia y la caquexia en pacientes con cáncer locoregional avanzado o metastásico. (Tesis de Doctorado ‐ Universidad Complutense Madrid)]. Available from http://eprints.ucm.es/8119/1/T30450.pdf 2008 (accessed 24 December 2011). ">Casado 2008</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ­</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004310-bbs2-0004" title="DeConnoF , MartiniC . Megestrol acetate for anorexia in patients with far‐advanced cancer: a double‐blind controlled clinical trial. European Journal of Cancer1998;34:1705‐9. ">De Conno 1998</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004310-bbs2-0005" title="EubanksV , KoppersmithN . Effects of megestrol acetate on weight gain, body composition, and pulmonary function in patients with cystic fibrosis. Journal of Pediatrics2002;140:439‐44. ">Eubanks 2002</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004310-bbs2-0006" title="FeliuJ , Gonzalez‐BaronM . Usefulness of megestrol acetate in cancer cachexia and anorexia. A placebo controlled study. American Journal of Clinical Oncology1992;15:436‐40. Gonzalez BaronM , FeliuJ , ZamoraP , ArtalA , GarridoP , ChaconI . Usefulness of megestrol acetate on cancer cachexia: a double blind randomized study. Annals of Oncology1990;1:29‐31. ">Feliu 1992</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004310-bbs2-0007" title="FietkauR , RieplM . Supportive treatment with megestrol acetate during radio (chemo) therapy. A randomised trial. Strahlentherapie und Onkologie1996;172:162‐8. FietkauR , RieplM , KettnerH , HinkeA , SauerR . Supportive use of megestrol acetate in patients with head and neck cancer during radio(chemo)therapy. European Journal of Cancer1997;33:75‐9. [CN‐00137738] ">Fietkau 1996</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004310-bbs2-0008" title="GambardellaA , PesceL , BologninoP , LombardiG , BarbieriM , RinaldiC . Megestrol acetate prevents cachexia in elderly cancer patient. Annals of Oncology1998;9(Suppl 3):72. [CN‐00305911] GambardellaA , PesceL , LammardoAM , LombardiG , BarbagalloM , TirelliP , et al. New factors involvement in elderly cancer patients with anorexia/cachexia syndrome role of megestrol acetate. Annals of Oncology2000;9 Suppl 2:22. ">Gambardella 1998</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004310-bbs2-0009" title="GebbiaV , TestaA . Prospective randomised trial of two dose levels of megestrol acetate in the management of anorexia‐cachexia syndrome in patients with metastatic cancer. British Journal of Cancer1996;73:1576‐80. ">Gebbia 1996</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004310-bbs2-0010" title="GiacosaA , FrascioF , SukkarSG , CostantiniM , BaraccoG , CapelliM . Changes of nutritional and psychological status after megestrol acetate treatment of cancer cachexia. Rivista Italiana Di Nutrizione Parenterale Ed Enterale.1997;15:20‐3. ">Giacosa 1997</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004310-bbs2-0011" title="HeckmayrM , GatzemeierU . Treatment of cancer weight loss in patients with advanced lung cancer. Oncology1992;49(Suppl 2):32‐4. ">Heckmayr 1992</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004310-bbs2-0012" title="HerrejonA , CatalanP , PalopJ , InchaurragaI , BlanquerR , LopezA . Effect of 8‐week 320 mg megestrol acetate daily administration in severe COPD and weight loss [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181:A4484. HerrejonA , PalopJ , InchaurragaI , LopezA , BañulsC , HernandezA , et al. Low doses of megestrol acetate increase weight and improve nutrition status in patients with severe chronic obstructive pulmonary disease and weight loss. Medicina Clinica2011;137:193‐8. ">Herrejon 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ­</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004310-bbs2-0078" title="JatoiA , LoprinziCL . An update: cancer‐associated anorexia as a treatment target. Current Opinion in Clinical Nutrition and Metabolic Care2001;4(3):179‐82. ">Jatoi 2001</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>208</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>139</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004310-bbs2-0014" title="JatoiA , RowlandK , LoprinziCL , SloanJA , DakhilSR , MacDonaldN , et al. An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer‐associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort. Journal of Clinical Oncology2004;22:2469‐76. ">Jatoi 2004</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>166</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>141</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>114</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004310-bbs2-0015" title="LesserGJ , CaseD , SharpS , ChoksiJ , MillerA , AtkinsJ , et al. A phase III randomized study comparing the effects of oxandrolone (Ox) and megestrol acetate (Meg) on weight (wt), lean body mass (LBM) and quality of life (QOL) in solid tumor patients (pts) receiving chemotherapy (chemo). Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I2006;24(18S (June 20 Suppl)):18546. ">Lesser 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004310-bbs2-0016" title="LoprinziCL , EllisonNM . Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. Journal of the National Cancer Institute1990;82:1127‐32. ">Loprinzi 1990b</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004310-bbs2-0017" title="LoprinziCL , BernathAM . Phase III evaluation of 4 doses of megestrol acetate for patients with cancer anorexia and/or cachexia. Oncology1994;51:2‐7. LoprinziCL , MichalakJC , SchaidDJ , MailliardJA , AthmannLM , GoldbergRM , et al. Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia. Journal of Clinical Oncology1993;11:762‐7. [CN‐00092689] ">Loprinzi 1994</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>111</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004310-bbs2-0162" title="LoprinziCL , KuglerJW , SloanJA . Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. Journal of Clinical Oncology1999;17:3299‐306. ">Loprinzi 1999</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>192</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>171</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>114</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004310-bbs2-0023" title="MwamburiDM , GerriorJ , WilsonIB , ChangH , ScullyE , SabooriS , et al. Comparing megestrol acetate therapy with oxandrolone therapy for HIV‐related weight loss: similar results in 2 months. Clinical Infectious Diseases2004;38:895‐902. ">Mwamburi 2004</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ­</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004310-bbs2-0022" title="McMillanDC , SimpsonJM . Effect of megestrol acetate on weight loss, body composition and blood screen of gastrointestinal cancer patients. Clinical Nutrition1994;13:85‐9. ">McMillan 1994</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004310-bbs2-0020" title="MacbethFR , GrgeorA , Cott . A randomised study of megestrol acetate (MA) and prednisolone (P) for anorexia and weight loss in patients with lung cancer. Lung Cancer1994;1 Suppl 1:88. ">Macbeth 1994</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004310-bbs2-0021" title="MadedduC , DessìM , PanzoneF , SerpeR , AntoniG , CauMC , et al. Randomized phase III clinical trial of a combined treatment with carnitine + celecoxib ± megestrol acetate for patients with cancer‐related anorexia/cachexia syndrome. Clinical Nutrition2012;31:176‐82. ">Madeddu 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004310-bbs2-0024" title="OsterMH , EndersSR . Megestrol acetate in patients with AIDS and cachexia. Annals of Internal Medicine1994;121:400‐8. ">Oster 1994</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004310-bbs2-0025" title="Sancho‐CuestaJF . Megestrol acetate and weight loss in advanced cancer [Abstract no: 1141]. European Journal of Cancer1993;29A:S204. ">Sancho‐Cuesta 1993</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004310-bbs2-0026" title="SchmollE , WilkeH , TholeR , PreusserP ,  WildfangI ,  SchmollHJ . Megestrol acetate in cancer cachexia. Seminars in Oncology1991;18(1 Suppl 2):32‐4. [CN‐00072963] ">Schmoll 1991</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004310-bbs2-0027" title="SchmollE . Risks and benefits of various therapies for cancer anorexia. Oncology1992;49:43‐5. ">Schmoll 1992</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004310-bbs2-0029" title="TchekmedyianNS , HickmanM . Megestrol acetate in cancer anorexia and weight loss. Cancer1992;69:1268‐74. ">Tchekmedyian 1992</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004310-bbs2-0033" title="VonRoennJH , ArmstrongD . Megestrol acetate in patients with AIDS‐related cachexia. Annals of Internal Medicine1994;121:393‐9. ">Von Roenn 1994</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>270</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004310-bbs2-0031" title="UlutinHC , ArpaciF , PakY . Megestrol acetate for cachexia and anorexia in advanced non‐small cell lung cancer: a randomized study comparing two different doses. Tumori2002;88:277‐80. ">Ulutin 2002</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>119</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004310-bbs2-0030" title="TimponeJG , WrightDJ . The safety and pharmacokinetics of single‐agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome. AIDS Research and Human Retroviruses1997;13:305‐15. ">Timpone 1997</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004310-bbs2-0032" title="SeguiMA , VadellC , Gimenez‐ArnauJM , MoralesS , CireraL , BestitI , et al. Double‐blind randomized trial for the treatment of cancer related cachexia: comparison of placebo vs two different doses of megestrol acetate [Abstract 99]. Proceedings of the American Society of Clinical Oncology1996;15:529. VadellC , SeguiMA . Anticachectic efficacy of megestrol acetate at different doses and versus placebo in patients with neoplastic cachexia. American Journal of Clinical Oncology1998;21:347‐51. ">Vadell 1998</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD004310-bbs2-0035" title="WeisbergJ , WangerJ . Megestrol acetate stimulates weight gain and ventilation in underweight COPD patients. Chest2002;121(4):1070‐8. ">Weisberg 2002</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>145</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>­</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004310-bbs2-0036" title="YehSS , LovittS , SchusterMW . Usage of megestrol acetate in the treatment of anorexia‐cachexia syndrome in the elderly. Journal of Nutrition, Health and Aging2009;13:448‐54. YehSS , WuSY . Improvement in quality of life measures and stimulation of weight gain after treatment with megestrol acetate oral suspension in geriatric cachexia: results of a double‐blind, placebo‐controlled study. Journal of the American Geriatrics Society2000;48(5):485‐92. YehSS , WuSY , LevineDM , ParkerTS , OlsonJS , StevensMR , et al. The correlation of cytokine levels with body weight after megestrol acetate treatment in geriatric patients. Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2001;56:M48‐54. ">Yeh 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>­</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>­</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>­</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>­</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>­</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>­</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>­</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>­</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1342</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>928</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>284</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>21</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>907</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>475</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>185</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>17</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>69</b> </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Patient condition and numbers recruited to each trial</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/full#CD004310-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004310-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Megestrol acetate versus placebo (ITT)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Appetite improvement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>699</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.19 [1.41, 3.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>429</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.57 [1.48, 4.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 AIDS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.56 [1.13, 2.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Other underlying pathology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Appetite gain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.43, 1.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 AIDS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Other underlying pathology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.43, 1.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Weight improvement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.51 [1.08, 2.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>767</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.55 [1.06, 2.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 AIDS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.15 [1.14, 4.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Other underlying pathology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.30, 1.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Weight gain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>552</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.93 [0.95, 2.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>227</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.63 [0.87, 2.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 AIDS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.26 [2.70, 5.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Other underlying pathology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>244</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.47 [0.06, 2.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Quality of life improvement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>670</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.78 [1.09, 2.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.91 [1.02, 3.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 AIDS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>370</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.49 [0.47, 4.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Other underlying pathology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Quality of life gain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [‐0.13, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [‐0.51, 0.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 AIDS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Other underlying pathology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.14, 1.50]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Megestrol acetate versus placebo (ITT)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004310-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Megestrol acetate versus other drugs (ITT)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Appetite improvement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>475</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.64, 1.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>475</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.64, 1.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 AIDS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Other underlying pathology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Appetite gain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.60 [‐1.28, 4.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 AIDS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.60 [‐1.28, 4.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Other underlying pathology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Weight improvement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.66 [1.09, 2.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1067</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.49 [1.54, 4.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 AIDS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.84, 1.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Other underlying pathology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Weight gain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>541</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.50 [0.37, 4.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>475</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [‐0.15, 1.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 AIDS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.85 [‐0.79, 10.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Other underlying pathology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Quality of life improvement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>475</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.77, 1.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>475</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.77, 1.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 AIDS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Other underlying pathology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Quality of life gain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>311</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [‐0.02, 0.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>311</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [‐0.02, 0.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 AIDS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Other underlying pathology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Megestrol acetate versus other drugs (ITT)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004310-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Megestrol acetate versus megestrol acetate (ITT)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Appetite improvement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>304</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.76, 1.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>304</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.76, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Weight improvement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>812</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.64, 0.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>812</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.64, 0.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Weight improvement 160 mg versus other higher doses <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>407</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.52, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>407</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.52, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Weight gain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>283</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.94 [‐3.33, 1.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 AIDS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>283</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.94 [‐3.33, 1.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Other underlying pathology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Quality of life improvement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>231</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.58, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 AIDS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>231</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.58, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Quality of life gain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [‐0.23, 0.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 AIDS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [‐0.23, 0.76]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Megestrol acetate versus megestrol acetate (ITT)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004310-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Safety</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Acute decompensation of COPD or pulmonary exacerbation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>271</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.34 [0.72, 2.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 High doses (=&gt; 800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>214</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.55 [0.41, 5.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Low doses (&lt; 800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.65, 2.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Serious adverse events (SAE) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>467</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.10 [0.98, 4.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 High doses (=&gt; 800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.31, 2.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Low doses (&lt; 800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>322</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.65 [1.33, 16.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Any adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1241</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [1.07, 1.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 High doses (=&gt; 800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>347</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [1.01, 1.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Low doses (&lt; 800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>894</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [1.01, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Abdominal pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>535</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.65 [0.89, 3.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 High doses (=&gt; 800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>475</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.69 [0.89, 3.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Low doses (&lt; 800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.07, 16.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Abnormal appetite <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.12, 3.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 High doses (=&gt; 800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Low doses (&lt; 800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.12, 3.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Amenorrhoea/irregular menses <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>504</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.45, 2.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 High doses (=&gt; 800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.75 [0.53, 5.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Low doses (&lt; 800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>338</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.22, 1.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Bowel obstruction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.13, 69.70]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 High doses (=&gt; 800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Low doses (&lt; 800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.13, 69.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Constipation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>167</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.85 [0.20, 16.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 High doses (=&gt; 800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Low doses (&lt; 800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>167</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.85 [0.20, 16.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Chest pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.13, 69.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 High doses (=&gt; 800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Low doses (&lt;800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.13, 69.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Confusion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>592</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.62, 1.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 High doses(=&gt; 800 mg /d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>311</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.58, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Low doses (&lt; 800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>281</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.46, 1.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Dyspnoea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>858</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.23 [1.01, 4.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 High doses (=&gt; 800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>379</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.38 [0.37, 5.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 Low doses (&lt; 800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>479</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.80 [1.02, 7.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Depression <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.45 [0.27, 22.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 High doses (=&gt; 800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.76 [0.12, 65.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 Low doses (&lt; 800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.18 [0.10, 46.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Deaths <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1367</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.42 [1.04, 1.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 High doses (=&gt; 800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>726</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.66 [1.08, 2.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 Low doses (&lt; 800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>641</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.77, 1.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Diarrhoea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>374</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.35, 3.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 High doses (=&gt; 800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.29, 5.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 Low doses (&lt; 800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>274</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.16, 4.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Drowsiness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>311</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.66, 1.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 High doses (=&gt; 800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>311</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.66, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 Low doses (&lt; 800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Elevated transaminase levels <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.07, 1.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 High doses (=&gt; 800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [0.01, 1.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2 Low doses (&lt; 800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.13, 67.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Glucose intolerance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.16, 4.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 High doses (=&gt; 800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.16, 4.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.2 Low doses (&lt; 800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Hallucinations/psychosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.08, 3.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1 High doses (=&gt; 800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.08, 3.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.2 Low doses (&lt; 800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Headaches <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.13, 69.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.1 High doses (=&gt; 800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.13, 69.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.2 Low doses (&lt; 800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Hyperphagia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.0 [0.42, 116.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.1 High doses (=&gt; 800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.2 Low doses (&lt; 800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.0 [0.42, 116.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 Heart burn <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>517</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.37, 1.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.1 High doses (=&gt; 800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>475</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.38, 1.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.2 Low doses (&lt; 800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 Heart failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.27 [0.01, 6.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.1 High doses (=&gt; 800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.27 [0.01, 6.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.2 Low doses (&lt;800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23 Hypertension <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.14, 2.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.1 High doses(=&gt; 800 mg /d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>240</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.14, 2.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.2 Low doses (&lt; 800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24 Impotence <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2071</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.58 [1.78, 3.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.1 High doses (=&gt; 800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1346</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.49 [1.63, 3.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.2 Low doses (&lt; 800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>725</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.89 [1.33, 6.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">25 Infections <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>885</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.64, 1.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.1 High doses (=&gt; 800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>669</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.60, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.2 Low doses (&lt; 800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>216</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.39, 2.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">26 Inappropriate behaviour <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>311</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.78 [0.56, 40.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.1 High doses (=&gt; 800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>311</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.78 [0.56, 40.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.2 Low doses (&lt; 800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">27 Insomnia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>492</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.71 [0.87, 15.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.1 High doses (=&gt; 800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>475</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.51 [0.58, 35.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.2 Low doses (&lt; 800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.8 [0.39, 20.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">28 Loss of co‐ordination <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>311</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.62, 1.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.1 High doses (=&gt; 800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>311</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.62, 1.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.2 Low doses (&lt; 800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">29 Nausea/vomiting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1645</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.45, 0.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>29.1 High doses (=&gt; 800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>997</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.37, 0.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>29.2 Low doses (&lt; 800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>648</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.46, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">30 Neoplasma <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.06, 14.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>30.1 High doses (=&gt; 800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.06, 14.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>30.2 Low doses (&lt; 800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">31 Oedema <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [1.07, 1.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>31.1 High doses (=&gt; 800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1285</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [1.04, 1.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>31.2 Low doses (&lt; 800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>897</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [0.84, 2.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">32 Pneumonia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>296</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.81 [0.51, 6.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>32.1 High doses (=&gt; 800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>214</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.34 [0.28, 6.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>32.2 Low doses (&lt; 800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.32, 27.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">33 Pruritus <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>272</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.14, 6.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>33.1 High doses (=&gt; 800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>33.2 Low doses (&lt; 800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>272</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.14, 6.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">34 Pyrosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.62 [0.40, 6.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>34.1 High doses (=&gt; 800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>34.2 Low doses (&lt; 800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.62 [0.40, 6.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">35 Pulmonary embolism <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>240</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.47 [0.12, 50.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>35.1 High doses (=&gt; 800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>35.2 Low doses (&lt; 800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>240</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.47 [0.12, 50.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">36 Respiratory failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>36.1 High doses (=&gt; 800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>36.2 Low doses (&lt; 800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">37 Other adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>254</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.51 [0.60, 3.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>37.1 High doses (=&gt; 800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>254</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.51 [0.60, 3.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>37.2 Low doses (&lt; 800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">38 Skin disorder (includes vesiculobullous rash) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>157</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.21, 3.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>38.1 High doses (=&gt; 800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.61 [0.22, 11.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>38.2 Low doses (&lt; 800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.04, 3.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">39 Sweating <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.15 [0.54, 18.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>39.1 High doses (=&gt; 800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.87 [0.31, 26.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>39.2 Low doses (&lt; 800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.64 [0.20, 65.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">40 Swelling legs or abdominal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>756</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.73, 1.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>40.1 High doses (=&gt; 800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>475</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.23, 1.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>40.2 Low doses (&lt; 800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>281</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.79, 1.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">41 Stroke <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.24, 5.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>41.1 High doses (=&gt; 800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.10, 5.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>41.2 Low doses (&lt; 800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.73 [0.14, 53.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">42 Thromboembolic phenomena including thrombophlebitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1604</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.84 [1.07, 3.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>42.1 High doses (=&gt; 800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>792</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.35 [0.93, 5.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>42.2 Low doses (&lt; 800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>812</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.62 [0.82, 3.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">43 Testicular shrinkage <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.2 [0.21, 83.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>43.1 High doses (=&gt; 800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>43.2 Low doses (&lt; 800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.2 [0.21, 83.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">44 Withdrawals <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1339</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.83, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>44.1 High doses (=&gt; 800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>818</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.80, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>44.2 Low doses (&lt; 800 mg/d)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>521</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.75, 1.28]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Safety</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004310-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Sensitivity analyses</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Appetite improvement treatment duration 6 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1174</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.70 [1.14, 2.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 &lt; 6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [0.87, 2.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 6 or more weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1041</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.78 [1.11, 2.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Appetite improvement treatment duration 12 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1174</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.70 [1.14, 2.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 0 to 11 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>904</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.80 [1.06, 3.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 12 or more weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.56 [1.13, 2.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Appetite gain 12 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [0.35, 2.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 &lt; 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.53 [0.89, 4.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 &gt; 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.32, 1.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Weight improvement treatment duration 6 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2237</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.55 [1.21, 1.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 &lt; 6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.69, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 6 or more weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.63 [1.27, 2.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Quality of life gain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>381</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [‐0.02, 0.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>344</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [‐0.01, 0.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Other underlying pathology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.14, 1.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Weight improvement 12 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2237</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [1.01, 1.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 &lt; 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1744</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [0.90, 2.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 &gt; 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>493</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.46 [0.92, 2.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Weight gain 6 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1093</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.96 [1.11, 2.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 &lt; 6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.46 [0.62, 2.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 6 or more weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>927</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.15 [1.09, 3.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Weight gain 12 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1093</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.96 [1.11, 2.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 &lt; 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1025</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.96 [1.06, 2.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 &gt; 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.94 [‐1.64, 5.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Blinded versus open‐label appetite improvement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1174</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.70 [1.14, 2.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Blinded studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>553</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.96 [1.17, 3.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Open‐label studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>621</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.53 [0.82, 2.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Blinded versus open‐label appetite gain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [0.35, 2.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Blinded studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.54 [‐0.01, 3.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Open‐label studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.60 [‐1.28, 4.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Blinded versus open‐label weight Improvement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2237</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [1.01, 1.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Blinded studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1552</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.63 [1.15, 2.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 Open‐label studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>685</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.53, 2.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Sensitivity number patients weight improvement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2237</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [1.01, 1.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 n &lt; 100 patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>467</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [0.98, 1.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 n &gt; 100 patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1770</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.53 [0.80, 2.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Appetite improvement, study quality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1174</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.70 [1.14, 2.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 Study quality (Jadad score 3, 4 or 5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>283</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.31 [0.93, 5.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 Study quality (Jadad score 2 or low)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>891</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.47 [0.96, 2.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Weight improvement, study quality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2237</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.55 [1.21, 1.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 Study quality (Jadad score 3,4 or 5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1322</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.50 [1.07, 2.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 Study quality (Jadad score 2 or low)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>915</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.60 [1.17, 2.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Weight gain, study quality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1093</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.96 [1.11, 2.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 Study quality (Jadad score 3,4 or 5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>528</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.90 [0.89, 2.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 Study quality (Jadad score 0 or low)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>565</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.30 [0.25, 4.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Sensitivity duration oedema <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2236</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.39 [1.12, 1.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 1 to 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>638</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.81 [1.07, 3.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2 &gt; 5 to 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.43 [1.04, 1.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.3 9 to 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>373</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.82, 1.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.4 &gt; 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Sensitivity duration thromboembolic phenomena <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1604</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.88 [1.11, 3.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 &lt; 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>934</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.59 [1.16, 5.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.2 &gt; 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>670</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [0.71, 2.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Sensitivity blinded versus open‐label weight gain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1214</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.42 [1.41, 3.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1 Blinded studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>673</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.69 [1.11, 2.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.2 Open‐label studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>541</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.15 [‐0.89, 7.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Sensitivity number of patients in trial appetite improvement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1174</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.70 [1.14, 2.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.1 n &lt; 100 patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.04 [1.52, 6.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.2 n &gt; 100 patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1028</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.50 [0.99, 2.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Sensitivity number of patients weight gain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1214</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.42 [1.41, 3.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.1 n &lt; 100 patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>252</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.45 [0.82, 6.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.2 n &gt; 100 patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>962</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.59, 1.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 Sensitivity appetite improvement cancer <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>904</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.80 [1.06, 3.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.1 Cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>904</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.80 [1.06, 3.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 Appetite improvement doses <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1174</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.70 [1.14, 2.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.1 ≤ 400 mg of MA/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>553</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.96 [1.17, 3.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.2 480 to 800 mg of MA/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.04 [1.52, 6.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.3 ≥ 800 mg of MA/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>475</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.64, 1.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23 Weight improvement doses <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2237</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.55 [1.21, 1.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.1 ≤ 400 mg MA/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>818</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.76 [1.19, 2.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.2 480 to 800 mg MA/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1330</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.46 [1.00, 2.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.3 ≥ 800 mg MA/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.38 [0.87, 2.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24 Sensitivity (cancer/other patients) thromboembolic phenomena <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1604</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.88 [1.11, 3.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.1 Cancer patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1491</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.89 [1.11, 3.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.2 Other patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.54 [0.06, 36.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">25 Deaths sensitivity 6 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1367</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.38 [1.01, 1.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.1 &lt; 6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>205</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [0.56, 2.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.2 &gt; 6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [1.00, 1.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">26 Deaths sensitivity/pathology <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1367</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.38 [1.01, 1.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.1 Cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>801</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.34 [0.97, 1.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.2 AIDS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>497</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.55 [0.63, 10.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.3 Other underlying pathology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.06, 14.07]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Sensitivity analyses</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004310.pub3/references#CD004310-tbl-0007">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD004310.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD004310-note-0002">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD004310-note-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD004310-note-0001">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004310\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004310\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004310\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004310\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004310\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004310\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004310\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004310\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004310\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004310\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004310\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004310\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004310\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004310\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004310\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004310\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004310\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004310\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=afU96cMv&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004310.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD004310.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD004310.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD004310.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004310.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740715713193"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD004310.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740715713197"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD004310.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d8dce6c04f55f',t:'MTc0MDcxNTcxMy4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 